Paratek Pharmaceuticals (PRTK) 10-K 29 Mar 21 2020 FY Annual report Financial data

Document and Entity Information

Document and Entity Information - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2020	Feb. 26, 2021	Jun. 30, 2020
Cover [Abstract]
Document Type	10-K
Amendment Flag	false
Document Period End Date	Dec. 31, 2020
Document Fiscal Year Focus	2020
Document Fiscal Period Focus	FY
Trading Symbol	PRTK
Entity Registrant Name	PARATEK PHARMACEUTICALS, INC.
Entity Central Index Key	0001178711
Current Fiscal Year End Date	--12-31
Entity Well-known Seasoned Issuer	No
Entity Current Reporting Status	Yes
Entity Voluntary Filers	No
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity File Number	001-36066
Entity Tax Identification Number	33-0960223
Entity Address, Address Line One	75 Park Plaza
Entity Address, City or Town	Boston
Entity Address, State or Province	MA
Entity Address, Postal Zip Code	02116
City Area Code	617
Local Phone Number	807-6600
Entity Common Stock, Shares Outstanding		46,892,728
Entity Interactive Data Current	Yes
Entity Public Float			$ 231,028,791
Title of 12(b) Security	Common Stock, par value $0.001 per share
Security Exchange Name	NASDAQ
Entity Incorporation, State or Country Code	DE
Document Annual Report	true
Document Transition Report	false
ICFR Auditor Attestation Flag	false
Documents Incorporated by Reference	Portions of the registrant’s definitive proxy statement for the registrant’s 2021 Annual Meeting of Stockholders to be filed pursuant to Regulation 14A within 120 days of the registrant’s year ended December 31, 2020 are incorporated herein by reference into Part III of this Annual Report on Form 10-K.

Consolidated Balance Sheets

Consolidated Balance Sheets - USD ($) $ in Thousands	Dec. 31, 2020	Dec. 31, 2019
Current assets
Cash and cash equivalents	$ 105,157	$ 102,302
Marketable securities	20,005	113,077
Restricted cash	891	324
Accounts receivable, net	11,878	8,475
Inventories, net	14,555	11,579
Other receivables	3,855	1,108
Prepaid and other current assets	7,776	6,489
Total current assets	164,117	243,354
Long-term restricted cash		3,007
Fixed assets, net	964	1,227
Goodwill	829	829
Right-of-use asset	2,010	2,514
Other long-term assets	8,933	148
Total assets	176,853	251,079
Current liabilities
Accounts payable	1,813	4,116
Accrued expenses	20,826	16,696
Other current liabilities	1,314	3,388
Total current liabilities	23,953	24,200
Long-term debt	250,474	260,728
Long-term lease liabilities	1,544	2,095
Other liabilities	3,142	3,703
Total liabilities	279,113	290,726
Commitments and contingencies (Note 18)
Stockholders’ deficit
Undesignated preferred stock: $0.001 par value; 5,000,000 authorized; no shares issued and outstanding
Common stock, $0.001 par value, 100,000,000 shares authorized, 46,516,567 and 39,827,749 issued and outstanding at December 31, 2020 and 2019, respectively	46	40
Additional paid-in capital	705,489	671,497
Accumulated other comprehensive income (loss)	4	74
Accumulated deficit	(807,799)	(711,258)
Total stockholders’ deficit	(102,260)	(39,647)
Total liabilities and stockholders’ deficit	$ 176,853	$ 251,079

Consolidated Balance Sheets (Pa

Consolidated Balance Sheets (Parenthetical) - $ / shares	Dec. 31, 2020	Dec. 31, 2019
Statement Of Financial Position [Abstract]
Undesignated preferred stock, par value	$ 0.001	$ 0.001
Undesignated preferred stock, shares authorized	5,000,000	5,000,000
Undesignated preferred stock, shares issued	0	0
Undesignated preferred stock, shares outstanding	0	0
Common stock, par value	$ 0.001	$ 0.001
Common stock, shares authorized	100,000,000	100,000,000
Common stock, shares issued	46,516,567	39,827,749
Common stock, shares outstanding	46,516,567	39,827,749

Consolidated Statements of Oper

Consolidated Statements of Operations and Comprehensive Loss - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019
Net revenue	$ 46,924	$ 16,544
Expenses:
Cost of product revenue	8,651	3,484
Research and development	23,922	39,554
Selling, general and administrative	89,855	89,135
Total operating expenses	122,428	132,173
Loss from operations	(75,504)	(115,629)
Other income and expenses:
Interest income	1,515	3,574
Interest expense	(20,240)	(16,403)
Loss on extinguishment of debt	(2,368)
Other gains (losses), net	56	(31)
Net loss before provision for income taxes	(96,541)	(128,489)
Provision for income taxes		301
Net loss	(96,541)	(128,790)
Other comprehensive loss
Unrealized gain (loss) on available-for-sale securities, net of tax	(70)	202
Other comprehensive gain (loss)	(70)	202
Comprehensive loss	$ (96,611)	$ (128,588)
Net loss per share:
Basic and diluted net loss per common share	$ (2.19)	$ (3.93)
Weighted average common shares outstanding Basic and diluted	44,174,765	32,791,934
Product Revenue, Net [Member]
Net revenue	$ 38,753	$ 11,517
Government Contract Service Revenue [Member]
Net revenue	3,299
Government Contract Grant Revenue [Member]
Net revenue	3,407
Collaboration and Royalty Revenue [Member]
Net revenue	$ 1,465	$ 5,027

Consolidated Statements of Stoc

Consolidated Statements of Stockholders' Equity (Deficit) - USD ($) $ in Thousands	Total	Common Stock [Member]	Additional Paid-in Capital [Member]	Accumulated Other Comprehensive Income (Loss) [Member]	Accumulated Deficit [Member]
Beginning balance at Dec. 31, 2018	$ 47,578	$ 32	$ 630,142	$ (128)	$ (582,468)
Beginning balance, shares at Dec. 31, 2018		32,259,363
Issuance of common stock, net of expenses	$ 26,559	$ 7	26,552
Issuance of common stock, net of expenses, shares		6,524,194
Exercise of stock options, shares	0
Vesting of restricted stock unit awards		$ 1	(1)
Vesting of restricted stock unit awards, shares		862,546
Issuance of stock under the employee stock purchase plan	$ 509		509
Issuance of stock under the employee stock purchase plan, shares		181,646
Employee stock purchase plan expense	101		101
Unrealized gain (loss) on available-for-sale securities, net of tax	202			202
Stock-based compensation expense	14,194		14,194
Net loss	(128,790)				(128,790)
Ending balance at Dec. 31, 2019	(39,647)	$ 40	671,497	74	(711,258)
Ending balance, shares at Dec. 31, 2019		39,827,749
Issuance of common stock, net of expenses	21,891	$ 5	21,886
Issuance of common stock, net of expenses, shares		5,176,000
Exercise of stock options	$ 170		170
Exercise of stock options, shares	39,479	39,479
Vesting of restricted stock unit awards		$ 1	(1)
Vesting of restricted stock unit awards, shares		1,281,968
Issuance of stock under the employee stock purchase plan	$ 562		562
Issuance of stock under the employee stock purchase plan, shares		191,371
Employee stock purchase plan expense	143		143
Unrealized gain (loss) on available-for-sale securities, net of tax	(70)			(70)
Stock-based compensation expense	10,105		10,105
Issuance of warrants for common stock	1,127		1,127
Net loss	(96,541)				(96,541)
Ending balance at Dec. 31, 2020	$ (102,260)	$ 46	$ 705,489	$ 4	$ (807,799)
Ending balance, shares at Dec. 31, 2020		46,516,567

Consolidated Statements of Cash

Consolidated Statements of Cash Flows - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019
Net loss	$ (96,541)	$ (128,790)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation, amortization and accretion	578	(1,292)
Stock-based compensation expense	10,248	14,295
Non-cash interest expense	1,518	3,480
Loss on extinguishment of debt	1,059
Changes in operating assets and liabilities
Accounts receivable, other receivables, prepaid, and other current assets	(7,459)	(11,467)
Inventories	(11,760)	(10,856)
Operating lease right-of-use asset	504	721
Accounts payable and accrued expenses	1,618	374
Long-term operating lease liability	(551)	(1,718)
Other liabilities and other assets	(2,638)	1,208
Net cash used in operating activities	(103,424)	(134,045)
Investing activities
Purchase of fixed assets	(376)	(239)
Purchase of marketable securities	(29,625)	(102,207)
Proceeds from maturities of marketable securities	122,500	237,000
Net cash provided by investing activities	92,499	134,554
Financing activities
Proceeds from employee stock purchase plan	562	509
Proceeds from exercise of stock options	170
Principal payments on long-term debt	(70,000)
Proceeds from issuance of common stock, net	21,891	26,559
Net cash provided by financing activities	11,340	57,622
Net increase in cash, cash equivalents and restricted cash	415	58,131
Cash, cash equivalents and restricted cash at the beginning of period	105,633	47,502
Cash, cash equivalents and restricted cash at end of period	106,048	105,633
SUPPLEMENTAL DISCLOSURES OF NONCASH FINANCING ACTIVITIES
Fair value of warrants issued	1,127
SUPPLEMENTAL DISCLOSURES OF CASH FLOW INFORMATION
Cash paid for interest	22,703	15,960
Debt issuance costs in accrued expenses	397
Purchases of equipment included in accrued expenses	152	339
Royalty Backed Loan Agreement [Member]
Financing activities
Proceeds from issuance of long-term debt, net of costs	$ 58,717	$ 30,554

Organization

Organization	12 Months Ended
	Dec. 31, 2020
Organization Consolidation And Presentation Of Financial Statements [Abstract]
Organization	1. Organization Paratek Pharmaceuticals, Inc., or the Company or Paratek, is a Delaware corporation with its corporate office in Boston, Massachusetts and an office in King of Prussia, Pennsylvania. The Company is a commercial-stage biopharmaceutical company focused on the development and commercialization of novel life-saving therapies for life-threatening diseases or other public health threats for civilian, government and military use. The Company’s United States, or U.S., Food and Drug Administration, or FDA, approved commercial product, NUZYRA ® ® The Company has incurred significant losses since inception in 1996. The Company has generated an accumulated deficit of $807.8 million through December 31, 2020 and may require substantial additional funding in connection with the Company’s continuing operations to support clinical development and commercialization activities associated with NUZYRA. Based upon the Company’s current operating plan, it anticipates that cash, cash equivalents, and available for sale marketable securities of $125.2 million as of December 31, 2020 will enable the Company to fund operating expenses and capital expenditure requirements through at least the next twelve months from the issuance of the financial statements included in this Annual Report on Form 10-K . The Company expects to finance future cash needs primarily through a combination of product sales, royalties, public or private equity offerings, debt or other structured financings, strategic collaborations, grant funding and government funding. The Company is subject to risks common to companies in the biopharmaceutical industry, including, but not limited to, risks of failure of preclinical studies and clinical trials, the need to obtain additional financing to fund the future development of the Company’s product candidates, the need to obtain compliant product from third-party manufacturers, the need to obtain marketing approval for the Company’s product candidates, the need to successfully commercialize and gain market acceptance of product candidates, the risks of manufacturing product with an external supply chain, dependence on key personnel, and compliance with government regulations.

Summary of Significant Accounti

Summary of Significant Accounting Policies	12 Months Ended
	Dec. 31, 2020
Accounting Policies [Abstract]
Summary of Significant Accounting Policies	2. Summary of Significant Accounting Policies Basis of Presentation The accompanying consolidated financial statements have been prepared in accordance with U.S. generally accepted accounting principles, or U.S. GAAP, as found in the Accounting Standards Codification, or ASC, and Accounting Standards Update, or ASU, of the Financial Accounting Standards Board, or FASB, and pursuant to the rules and regulations of the U.S. Securities and Exchange Commission, or the SEC. Beginning on January 1, 2020, purchase of prepaid interest - marketable securities, which totaled $0.2 million and was included as a line item in the December 31, 2019 consolidated statement of cash flows, has been reclassified into the accounts receivable, other receivables, prepaid, and other current assets line item to conform to the fiscal 2020 presentation. Principles of Consolidation The accompanying audited consolidated financial statements include the results of operations of Paratek Pharmaceuticals, Inc. and its wholly-owned subsidiaries, Paratek Pharma, LLC, Paratek Securities Corporation, Transcept Pharma, Inc., Paratek UK Limited, Paratek Ireland Limited, Paratek Royalty Corporation, Paratek Royalty Corporation II, PRTK SPV1 LLC and PRTK SPV2 LLC. All significant intercompany accounts and transactions have been eliminated in consolidation. Use of Estimates The preparation of consolidated financial statements in conformity with U.S. GAAP requires management of the Company to make certain estimates and assumptions that affect the reported amounts of assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. These estimates are based on management’s best knowledge of current events and actions the Company may undertake in the future. Management considers many factors in selecting appropriate financial accounting policies and controls, and in developing the estimates and assumptions that are used in the preparation of these financial statements. Management must apply significant judgment in this process. In addition, other factors may affect estimates, including expected business and operational changes, sensitivity and volatility associated with the assumptions used in developing estimates, and whether historical trends are expected to be representative of future trends. The estimation process often may yield a range of potentially reasonable estimates of the ultimate future outcomes and management must select an amount that falls within that range of reasonable estimates. This process may result in actual results differing materially from those estimated amounts used in the preparation of the financial statements. Estimates are used in accounting for, among other items, accounts receivable and related reserves, inventory and related reserves, goodwill, net product revenue, government contract service revenue, government contract grant revenue, collaboration and royalty revenue, leases, stock-based compensation arrangements, manufacturing and clinical accruals, useful lives for depreciation and valuation allowances on deferred tax assets. Actual results could differ from those estimates. The Company evaluates its estimates on an ongoing basis. Changes in estimates are reflected in reported results in the period in which they become known by the Company’s management. Cash and Cash Equivalents and Marketable Securities The Company considers all highly liquid investments purchased with original maturities of 90 days or less at acquisition to be cash equivalents. Cash and cash equivalents include cash held in banks and amounts held primarily in interest-bearing money market accounts. Cash equivalents are carried at cost, which approximates their fair market value. The Company determines the appropriate classification of marketable securities at the time of purchase and reevaluates such designation at each balance sheet date. The Company classified all of its marketable securities at December 31, 2020 as “available-for-sale” pursuant to ASC 320, Investments – Debt and Equity Securities. The Company reviews marketable securities for other-than-temporary impairment whenever the fair value of a marketable security is less than the amortized cost and evidence indicates that a marketable security’s carrying amount is not recoverable within a reasonable period of time. Other-than-temporary impairments of investments are recognized in the consolidated statements of operations and comprehensive loss if the Company has experienced a credit loss, has the intent to sell the marketable security, or if it is more likely than not that the Company will be required to sell the marketable security before recovery of the amortized cost basis. Evidence considered in this assessment includes reasons for the impairment, compliance with the Company’s investment policy, the severity and duration of the impairment and changes in value subsequent to the end of the period. There were no other-than-temporary impairments of investments recognized for the years ended December 31, 2020 and 2019. Fair Value of Financial Instruments The Company is required to disclose information on all assets and liabilities reported at fair value that enables an assessment of the inputs used in determining the reported fair values. FASB ASC 820, Fair Value Measurements and Disclosures Level 1—Valuations based on unadjusted quoted prices in active markets for identical assets or liabilities that the Company has the ability to access at the measurement date. Level 2—Valuations based on quoted prices for similar assets or liabilities in markets that are not active or for which all significant inputs are observable, either directly or indirectly. Level 3—Valuations that require inputs that reflect the Company’s own assumptions that are both significant to the fair value measurement and unobservable. To the extent that valuation is based on models or inputs that are less observable or unobservable in the market, the determination of fair value requires more judgment. Accordingly, the degree of judgment exercised by the Company in determining fair value is greatest for instruments categorized in Level 3. A financial instrument’s level within the fair value hierarchy is based on the lowest level of any input that is significant to the fair value measurement. Restricted Cash Cash accounts with any type of restriction are classified as restricted cash. If restrictions are expected to be lifted or to be used to pay a third party in the next twelve months, the restricted cash account is classified as current. Accounts Receivable, Net Accounts receivable as of December 31, 2020 is primarily comprised of trade accounts receivable of $10.1 million due from customers for sales of NUZYRA, net of prompt payment discounts, chargebacks, rebates and certain fees. The balance of accounts receivable as of December 31, 2020 incudes $0.6 million of government contract service revenue earned under the BARDA contract, $0.6 million of government contract grant revenue earned under the BARDA contract, and $0.5 million in estimated revenue from royalties earned on U.S. sales of SEYSARA under the Almirall Collaboration Agreement and U.S. sales of XERAVA under the Tetraphase License Agreement Government Contract Revenue License and Collaboration Agreements Concentration of Credit Risk Financial instruments that subject the Company to credit risk consist primarily of cash, restricted cash, and accounts receivable. The Company places its cash in an accredited financial institution and this balance is above federally insured amounts. The Company has no off-balance sheet concentrations of credit risk such as foreign currency exchange contracts, option contracts or other hedging arrangements. Fixed Assets Fixed assets, including leasehold improvements, are recorded at cost and depreciated when placed into service using the straight-line method, based on their estimated useful lives as follows: Estimated Useful Life In Years Laboratory equipment 5 Office equipment 5 Machinery and equipment 5 Computer equipment 3 Computer software 3 In addition, leasehold improvements are depreciated over the shorter of their estimated useful lives or the term of the respective lease on a straight-line basis. Costs for capital assets not yet placed into service have been capitalized as construction-in-progress and will be depreciated in accordance with the above guidelines once placed into service. The Company reviews its long-lived assets for impairment whenever events or changes in business circumstances indicate that the carrying amount of assets may not be fully recoverable or that the useful lives of these assets are no longer appropriate. Each impairment test is based on a comparison of the undiscounted cash flow to the recorded value of the asset. If impairment is indicated, the asset will be written down to its estimated fair value on a discounted cash flow basis. Upon sale or retirement, the asset cost and related accumulated depreciation are removed from the respective accounts, and any related gain or loss is reflected in results of operations. Repair and maintenance costs are expensed as incurred. Inventory Inventories are stated at the lower of cost or estimated net realizable value, on a first-in, first-out basis. Prior to the regulatory approval of its product candidates, the Company incurs expenses for the manufacture of drug product that could potentially be available to support the commercial launch of its products. Until the first reporting period when regulatory approval has been received or is otherwise considered probable, the Company records all such costs as research and development expense. Inventory used in clinical trials is also expensed as research and development expense, when selected for such use. The Company classifies inventory costs as long-term when the Company expects to utilize the inventory beyond its normal operating cycle. The Company performs an assessment of the recoverability of capitalized inventory during each reporting period and writes down any excess and obsolete inventory to its net realizable value in the period in which the impairment is first identified. Such impairment charges, should they occur, are recorded as a component of cost of product sales in the consolidated statements of operations and comprehensive loss. The determination of whether inventory costs will be realizable requires the use of estimates by management. If actual market conditions are less favorable than projected by management, additional write-downs of inventory may be required. Valuation of Goodwill Goodwill is not amortized but is evaluated for impairment within the Company’s single reporting unit on an annual basis, during the fourth quarter, or more frequently if an event occurs or circumstances change that would more-likely-than-not reduce the fair value of the Company’s reporting unit below its carrying amount. As discussed below, on January 1, 2020, the Company adopted ASU No. 2017-04, Simplifying the Test for Goodwill Impairment , or ASU 2017-04, which eliminates the second step of the goodwill impairment test. Under this ASU 2017-04, the Company will now perform a one-step quantitative test and record the amount of goodwill impairment, if any, as the excess of a reporting unit's carrying amount over its fair value, not to exceed the total amount of goodwill allocated to the reporting unit. The Company did not record an impairment charge relating to goodwill for the years ended December 31, 2020 and 2019. Accrued Expenses The Company’s process of determining accrued expense for a financial period-end involves reviewing open contracts and purchase orders, communicating with personnel to identify services that have been performed for the Company and estimating the level of service performed and the associated cost incurred for the service when the Company has not yet been invoiced or otherwise notified of the actual cost. The majority of the Company’s service providers invoice periodically in arrears for services performed or when contractual milestones are met. The Company estimates accrued expenses at a financial period-end based on facts and circumstances known at that time and may periodically confirm the accuracy of estimates with its service providers and make adjustments if necessary. Leases At the inception of an arrangement, the Company determines whether the arrangement is or contains a lease based on the unique facts and circumstances present in the arrangement including the use of a distinct identified asset(s) and the Company’s control over the use of that identified asset. Most leases are recognized on the balance sheet as right-of-use assets and lease liabilities, current and non-current, as applicable. The Company has elected not to recognize on the balance sheet leases with terms of 12 months or less. These lease costs will be expensed as incurred. The Company typically only includes an initial lease term in its assessment of a lease arrangement. Options to renew a lease are not included in the Company’s assessment unless there is reasonable certainty that the Company will renew. The Company monitors its plans to renew its material leases on a quarterly basis. Right-of-use assets and lease liabilities are recorded based on the present value of lease payments over the expected remaining lease term. Certain adjustments to the right-of-use asset may be required for items such as incentives received or initial direct costs. The interest rate implicit in lease contracts is typically not readily determinable. As a result, the Company utilizes its incremental borrowing rate, which reflects the fixed rate at which the Company could borrow on a collateralized basis the amount of the lease payments in the same currency, for a similar term, in a similar economic environment. In transition to ASU No. 2016-02, Leases In accordance with ASC 842, components of a lease should be split into three categories: lease components (e.g., land, building, etc.), non-lease components (e.g., common area maintenance, consumables, etc.), and non-components (e.g., property taxes, insurance, etc.). The fixed and in-substance fixed contract consideration (including any consideration related to non-components) must be allocated based on the respective relative fair values to the lease components and non-lease components. Although separation of lease and non-lease components is otherwise required, certain expedients are available. Entities may elect to not separate lease and non-lease components by class of underlying asset and account for each lease component and the related non-lease component together as a single component. For new and amended leases beginning in 2019 and after, the Company has elected to account for each lease component and related non-lease component as a single lease component and allocate all of the contract consideration to the lease component only. In contrast, the Company does not apply the practical expedient for embedded leases in manufacturing and supply agreements with certain of its contract manufacturing organizations and has instead allocated contract consideration between the lease and non-lease components based on their relative standalone price. Revenue Recognition Accounting Standards Codification, or ASC, Topic 606, Revenue from Contracts with Customers The Company enters into collaboration agreements for research, development, manufacturing and commercial services that are within the scope of ASC 606, under which it licenses certain rights to its product candidates to third parties. The terms of these arrangements typically include payment to the Company of one or more of the following: non-refundable, upfront license fees; reimbursement of certain costs; customer option exercise fees; development, regulatory and commercial milestone payments; and royalties on net sales of licensed products. The amount of variable consideration is constrained until it is probable that the revenue is not at a significant risk of reversal in a future period. The contracts into which the Company enters generally do not include significant financing components. As part of the accounting for these arrangements, the Company must use significant judgment to determine: (a) the transaction price under step (iii) above and (b) the timing of revenue recognition, including the appropriate measure of progress, in step (v) above. The Company uses judgment to determine whether milestones or other variable consideration, except for royalties, should be included in the transaction price, as described further below. The transaction price is allocated to each performance obligation on a relative stand-alone selling price basis, for which the Company recognizes revenue as or when the performance obligations under the contract are satisfied. If a milestone or other variable consideration relates specifically to the Company’s efforts to satisfy a single performance obligation or to a specific outcome from satisfying the performance obligation, the Company generally allocates the milestone amount entirely to that performance obligation once it is probable that a significant revenue reversal would not occur. Amounts received prior to revenue recognition are recorded as deferred revenue. Amounts expected to be recognized as revenue within the 12 months following the balance sheet date are classified as current portion of deferred revenue in the accompanying consolidated balance sheets. Amounts not expected to be recognized as revenue within the 12 months following the balance sheet date are classified as deferred revenue, net of current portion. Licenses of intellectual property In assessing whether a license is distinct from the other promises, the Company considers factors such as the research, development, manufacturing and commercialization capabilities of the collaboration partner and the availability of the associated expertise in the general marketplace. In addition, the Company considers whether the collaboration partner can benefit from a license for its intended purpose without the receipt of the remaining promise(s), whether the value of the license is dependent on the unsatisfied promise(s), whether there are other vendors that could provide the remaining promise(s), and whether it is separately identifiable from the remaining promise(s). For licenses that are combined with other promises, the Company utilizes judgment to assess the nature of the combined performance obligation to determine whether the combined performance obligation is satisfied over time or at a point in time and, if over time, the appropriate method of measuring progress for purposes of recognizing revenue. The Company evaluates the measure of progress each reporting period and, if necessary, adjusts the measure of performance and related revenue recognition. Customer options If an arrangement is determined to contain customer options that allow the customer to acquire additional goods or services, the goods and services underlying the customer options are not considered to be performance obligations at the outset of the arrangement, as they are contingent upon option exercise. The Company evaluates the customer options for material rights, or options to acquire additional goods or services for free or at a discount. If the customer options are determined to represent or include a material right, the material right is recognized as a separate performance obligation at the outset of the arrangement. The Company allocates the transaction price to material rights based on the relative standalone selling price, which is determined based on the identified discount and the probability that the customer will exercise. Amounts allocated to a material right are not recognized as revenue until, at the earliest, the option is exercised. Milestone payments At the inception of each arrangement that includes milestone payments, the Company evaluates whether the milestones are considered probable of being achieved and estimates the amount to be included in the transaction price using the most likely amount method. If it is probable that a significant reversal of cumulative revenue would not occur, the associated milestone value is included in the transaction price. Milestone payments that are not within the control of the Company or the licensee, such as regulatory approvals, are not considered probable of being achieved until those approvals are received. The Company evaluates factors such as the scientific, clinical, regulatory, commercial, and other risks that must be overcome to achieve the particular milestone in making this assessment. There is considerable judgment involved in determining whether it is probable that a significant reversal of cumulative revenue would not occur. At the end of each subsequent reporting period, the Company reevaluates the probability of achievement of all milestones subject to constraint and, if necessary, adjusts its estimate of the overall transaction price. Any such adjustments are recorded on a cumulative catch-up basis, which would affect revenues and earnings in the period of adjustment. Royalties For arrangements that include sales-based royalties, including milestone payments based on a level of sales, and the license is deemed to be the predominant item to which the royalties relate, the Company recognizes revenue at the later of (i) when the related sales occur, or (ii) when the performance obligation to which some or all the royalty has been allocated is satisfied (or partially satisfied). Contract costs The Company recognizes as an asset the incremental costs of obtaining a contract with a customer if the costs are expected to be recovered. As a practical expedient, the Company recognizes the incremental costs of obtaining a contract as an expense when incurred if the amortization period of the asset that the Company otherwise would have recognized is one year or less. To date, the Company has not incurred any incremental costs of obtaining a contract with a customer. The Company sells its product principally to a limited number of specialty distributors and specialty pharmacy providers in the U.S Revenues from product sales are recognized when the customer obtains control of the Company’s product, which typically occurs once the Company has transferred physical possession of the good to the customer. The transaction price that the Company recognizes as revenue reflects the amount it expects to be entitled to in connection with the sale and transfer of control of product to its customers. Variable consideration is only included in the transaction price to the extent that it is probable that a significant reversal in the amount of cumulative revenue recognized will not occur when the uncertainty associated with the variable consideration is subsequently resolved. At the time that the Company’s customers take control of the product, which is when the Company’s performance obligation under the sales contracts is complete, the Company records product revenues net of applicable reserves for various types of variable consideration based on the Company’s estimates of channel mix. The types of variable consideration in our product revenue are as follows: • Trade discounts and allowances • Product returns • Chargebacks and rebates • Government rebates • Commercial payer and other rebates • Voluntary patient assistance programs In determining the amounts of certain allowances and accruals, the Company must make significant judgments and estimates. For example, in determining these amounts, the Company estimates prescription demand from the specialty pharmacies, hospital demand, buying patterns by hospitals, hospital systems and/or group purchasing organizations and the levels of inventory held by specialty distributors and customers. Making these determinations involves analyzing third-party industry data to determine whether trends in historical channel distribution patterns will predict future product sales. The Company receives data periodically from its specialty distributors and customers on inventory levels and historical channel sales mix, and the Company considers this data when determining the amount of the allowances and accruals for variable consideration. The amount of variable consideration is estimated by using either of the following methods, depending on which method better predicts the amount of consideration to which the Company is entitled: a) The “expected value” is the sum of probability-weighted amounts in a range of possible consideration amounts. Under ASC 606, an expected value may be an appropriate estimate of the amount of variable consideration if the Company has many contracts with similar characteristics. b) The “most likely amount” is the single most likely amount in a range of possible consideration amounts (i.e., the single most likely outcome of the contract). Under ASC 606, the most likely amount may be an appropriate estimate of the amount of variable consideration if the contract has only two possible outcomes (i.e., either achieve or do not achieve a threshold specified in a contract). The method selected is applied consistently throughout the contract when estimating the effect of an uncertainty on an amount of variable consideration. In addition, the Company considers all the information (historical, current, and forecasted) that is reasonably available to the Company and shall identify a reasonable number of possible consideration amounts. The relevant factors used in this determination include, but are not limited to, current contractual and statutory requirements, specific known market events and trends, industry data, and forecasted customer buying and payment patterns. In assessing whether a constraint is necessary, the Company considers both the likelihood and the magnitude of the revenue reversal. Actual amounts of consideration ultimately received may differ from the Company’s estimates. If actual results in the future vary from the Company’s estimates, the Company adjusts these estimates, which would affect net product revenue and earnings in the period such variances become known. The specific considerations the Company uses in estimating these amounts related to variable consideration associated with the Company’s products are as follows: Trade Discounts and Allowances Product Returns At the end of each reporting period for any of our products, the Company may decide to constrain revenue for product returns based on information from various sources, including channel inventory levels and dating and sell-through data, the expiration dates of product currently being shipped, price changes of competitive products and introductions of generic products. Chargebacks U.S. Government Rebates – The Company is subject to discount obligations under state Medicaid programs and Medicare. The Company estimates our Medicaid and Medicare rebates based upon a range of possible outcomes that are probability-weighted for the estimated payer mix. These reserves are recorded in the same period the related product revenue is recognized, resulting in a reduction of product revenue and the establishment of a current liability that is included in accrued expenses on the consolidated balance sheet. For Medicare, the Company also estimate s the number of patients in the prescription drug coverage gap for whom it will owe an additional liability under the Medicare Part D program. The Company’s liability for these rebates consists of an estimate of claims for the current quarter and estimated future claims that will be made for product sales that have been recognized as revenue but remain in distribution channel inventory at period end. Commercial Payer and Other Rebates Patient Assistance At the end of each reporting period, the Company adjusts its allowances for cash discounts, product returns, chargebacks, and other rebates and discounts when the Company believes actual experience may differ from current estimates. Revenue Earned Under Government Contracts If the Company concludes that some or all aspects of its government contracts represent a transaction with a customer to obtain services or goods that are an output of its ordinary activities in exchange for consideration, it accounts for those aspects of the arrangement in accordance with ASC 606. Arrangements that are entirely in the scope of other guidance are accounted for under that guidance. The Company recognizes sales of NUZYRA under its government contracts as product revenue when control of NUZYRA is transferred, in accordance with ASC 606. It also recognizes government contract service revenue and government contract grant revenue as defined below. Government Contract Service Revenue Government contract service revenue is recognized as services are performed. Revenue and related reimbursable expenses are presented on a gross basis in the Company’s consolidated statements of operations. The related reimbursable expenses are expensed as incurred as research and development expense. Government Contract Grant Revenue The allocated consideration of government contract grant revenue is recognized as the related reimbursable expenses are incurred. The cost reimbursements that are reported as revenue is presented gross of the related reimbursable expenses in the Company’s consolidated statements of operations. The related reimbursable expenses are expensed as incurred as research and development expense. Cost of Product Revenue Cost of product revenue consists primarily of the manufacturing costs for NUZYRA and royalties owed on net sales of NUZYRA. All manufacturing costs incurred prior to NUZYRA’s approval in the U.S. Research and Development Expenses Research and development expenses are charged to expense as incurred. Research and development expenses consist of the costs incurred in performing research and development activities, including personnel-related costs, stock-based compensation, facilities, research-related overhead, clinical trial costs, contracted services, manufacturing, license fees and other external costs. Research and development expenses also include gross reimbursable costs incurred through research and development services performed for the treatment of pulmonary anthrax, services performed for U.S. manufacturing onshoring and security requirements, and services performed for FDA PMRs under the BARDA contract. The Company accounts for nonrefundable advance payments for goods and services that will be used in future research and development activities as expenses when the service has been performed or when the goods have been received rather than when the payment is made. Income Taxes The Company accounts for income taxes under the asset and liability method, which requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of events that have been included in the financial statements. Under this method, the Company determines deferred tax assets and liabilities on the basis of the differences between the financial statement and tax bases of assets and liabilities by using enacted tax rates in effect for the year in which the differences are expected to reverse. The effect of a change in tax rates on deferred tax assets and liabilities is recognized in income in the period that includes the enactment date. The Company recognizes deferred tax assets to the extent that the Company believes that these assets are more likely than not to be realized. In making such a determination, the Company considers all available positive and negative evidence, including future reversals of existing taxable temporary differences, projected future taxable income, tax-planning strategies, and results of recent operations. If the Company determines that the Company would be able to realize our deferred tax assets in the future in excess of their net recorded amount, the Company would make an adjustment to the deferred tax asset valuation allowance, which would reduce the provision for income taxes. The Company records uncertain tax positions in accordance with ASC 740, Income Taxes The Company recognizes interest and penalties related to unrecognized tax benefits on the income tax expense line in the accompanying consolidated statement of operations. The Company has not recorded interest and penalties Stock-Based Compensation The Company accounts for its stock-based awards in accordance with ASC 718, Compensation—Stock Compensation The measurement date for non-employee awards is the later of the adoption date of ASU No. 20

Product Revenue

Product Revenue	12 Months Ended
	Dec. 31, 2020
Revenue From Contract With Customer [Abstract]
Product Revenue	3. Product Revenue To date, the Company’s only source of product revenue has been from NUZYRA product sales beginning in February 2019 when NUZYRA launched in the United States . Chargebacks, discounts and fees Government and other rebates Returns Patient assistance Total Balance at December 31, 2018 $ — $ — $ — $ — $ — Provision related to current period sales 926 1,424 369 174 2,893 Adjustment related to prior period sales — — — — — Credit or payments made during the period (627 ) (729 ) — (45 ) (1,401 ) Balance at December 31, 2019 $ 299 $ 695 $ 369 $ 129 $ 1,492 Provision related to current period sales 3,160 6,091 337 371 9,959 Adjustment related to prior period sales (8 ) 19 — — 11 Credit or payments made during the period (2,824 ) (4,603 ) (320 ) (286 ) (8,033 ) Balance at December 31, 2020 $ 627 $ 2,202 $ 386 $ 214 $ 3,429

Net Loss Per Share

Net Loss Per Share	12 Months Ended
	Dec. 31, 2020
Earnings Per Share [Abstract]
Net Loss Per Share	4 . Net Loss Per Share Basic net loss per share is calculated by dividing the net loss by the weighted-average number of common stock outstanding during the period, without consideration for common stock equivalents. Diluted net loss per share is computed by dividing the net loss by the weighted-average number of common share equivalents outstanding for the period determined using the treasury-stock method or the if-converted method, as applicable. For purposes of this calculation, shares of common stock issuable upon conversion of convertible debt, stock options, restricted stock units, warrants to purchase common stock, and shares issuable under the employee stock purchase plan are considered to be common stock equivalents and are only included in the calculation of diluted net loss per share when their effect is dilutive. The following outstanding shares subject to stock options and restricted stock units, warrants to purchase shares of common stock, common stock issuable upon conversion of convertible debt and shares issuable under the employee stock purchase plan were antidilutive due to a net loss in the periods presented and, therefore, were excluded from the dilutive securities computation for the years ended December 31, 2020 and 2019 as indicated below: Year Ended December 31, 2020 2019 Excluded potentially dilutive securities (1) Common stock issuable under outstanding convertible notes 10,377,361 10,377,361 Shares subject to outstanding options to purchase common stock 1,986,442 3,236,073 Unvested restricted stock units 3,393,425 2,305,408 Shares subject to warrants to purchase common stock 479,002 104,455 Shares issuable under employee stock purchase plan 606,816 798,187 Totals 16,843,046 16,821,484 (1) The number of shares is based on the maximum number of shares issuable on exercise or conversion of the related securities as of the year end. Such amounts have not been adjusted for the treasury-stock method or weighted-average outstanding calculations as required if the securities were dilutive.

Government Contract Revenue

Government Contract Revenue	12 Months Ended
	Dec. 31, 2020
Organization Consolidation And Presentation Of Financial Statements [Abstract]
Government Contract Revenue	5 . Government Contract Revenue Biomedical Advanced Research and Development Authority On December 18, 2019, the Company entered into a five-year The BARDA contract could result in payments to the Company of up to approximately $284.7 million and consists of a five-year Under the terms of the agreement, BARDA awarded initial funding of approximately $59.4 million for the development of NUZYRA for the treatment of pulmonary anthrax and the purchase of an initial 2,500 treatment courses of NUZYRA to add to the current SNS. The contract provides for additional staged funding, including approximately $76.8 million for existing FDA PMR commitments and approximately $20.4 million for manufacturing-related requirements, both of which began in April 2020. BARDA exercised the options to award the initial funding in December 2019 and the additional staged funding in April 2020. The additional staged funding will support all FDA PMRs associated with the approval of NUZYRA, including CABP and pediatric studies as well as a five-year post-marketing bacterial surveillance study, and support the U.S. onshoring and security requirements of Paratek manufacturing activities for NUZYRA. The remaining option funding under the BARDA contract includes the potential for approximately $12.7 million to support the development of NUZYRA for the prophylaxis of anthrax and a maximum of approximately $115.4 million to provide for three additional purchases of NUZYRA treatment courses, each of which may be exercised at BARDA’s discretion upon development milestones related to the anthrax treatment development program. The BARDA contract contains a number of terms and conditions that are customary for government contracts of this nature, including provisions giving the government the right to terminate the contract at any time for its convenience. The Company evaluated the BARDA contract under ASC 606 and concluded that a portion of the arrangement represents a transaction with a customer. The Company identified five material promises under the BARDA contract: (i) research and development services performed for the treatment of pulmonary anthrax, (ii) the procurement of 2,500 treatment courses of NUZYRA, (iii) an option for services performed for the supplemental late-stage development of NUZYRA for treatment and prophylaxis of pulmonary anthrax, (iv) an option for services related to U.S. manufacturing onshoring and security requirements, which includes shelf-life stability extension work and regulatory activities that will benefit the manufacturing processes that support NUZYRA for the treatment of pulmonary anthrax and (v) options to procure up to three 2,500 treatment courses of NUZYRA. In December 2019, the Company determined material promises (i) and (ii) above were performance obligations since they were distinct within the context of the contract as the services are separately identifiable from other promises within the arrangement. The Company also determined that for (i) and (ii) the transaction price included within the BARDA contract was equivalent to the standalone selling price of the services and the cost of the procurement. The Company evaluated the material promises that contained option rights ((iii), (iv), and (v) above). The Company determined that (iii) and (iv) were not offered at a discount that is incremental to the range of discounts typically given for these goods and services, and therefore do not represent material rights. As such, options for additional services in (iii) and (iv) were not considered performance obligations at the outset of the arrangement. The Company also evaluated the future procurement option rights (v) and determined that those option rights represent a material right. As such, the optional additional NUZYRA procurements in (v) were considered performance obligations at the outset of the arrangement. The Company concluded that three performance obligations existed at the outset of the BARDA contract. As the BARDA contract is partially within the scope of ASC 606 and partially within the scope of other guidance, the Company applied the guidance of ASC 606 to initially measure the parts of the contract within ASC 606. The total transaction price of the parts of the BARDA contract that existed at the outset of the contract that fall under ASC 606 was determined to be $63.6 million, inclusive of $4.2 million in variable consideration and was allocated to each of the three performance obligations based on the performance obligation’s estimated relative stand-alone selling prices. As of December 31, 2020, the Company reevaluated the variable consideration of $4.2 million that is included in the transaction price and determined that the variable consideration should not be constrained as it is not probable that a significant reversal in the amount of the cumulative revenue recognized will occur in a future period. The transaction price was allocated as follows: $21.5 million to research and development services performed for the treatment of pulmonary anthrax in (i), which will be classified as government contract service revenue when recognized, $37.9 million to the procurement of 2,500 treatment courses of NUZYRA in (ii), which will be classified as product revenue when recognized, and a total of $4.2 million to the options to procure up to three 2,500 treatment courses of NUZYRA in (v), which would be included within product revenue when recognized upon exercise and transfer of control of related treatment courses. The Company estimated the stand-alone selling price of the research and development services performed for the treatment of pulmonary anthrax based on the Company’s projected cost of providing the services plus an applicable profit margin commensurate with observable market data for similar services. The Company estimated the stand-alone selling price of the procurement of 2,500 treatment courses of NUZYRA based on historical pricing of the Company’s commercial products to similar customers. The Company estimated the stand-alone selling price of the future procurement options based on the discount that the customer would obtain when exercising the option, adjusted for any discount that the customer could receive without entering into the contract, and the likelihood that the option will be exercised. The Company’s performance obligations are either satisfied over time as work progresses or at a point in time. The Company concluded that research and development services performed for the treatment of pulmonary anthrax in (i) would be recognized as government contract service revenue over time as the performance obligation is satisfied. Costs incurred represent work performed, which corresponds with, and thereby best depicts, the transfer of control to the customer. Types of contract costs include labor, material, and third-party services. The product procurement performance obligations ((ii) and, if any optional additional procurements are exercised from, (v) above), generate revenue at a point in time, which will be upon transfer of control of the product. As such, the related revenue for these performance obligations will be recognized at a point in time as product revenue within the Company’s consolidated statement of operations. As of December 31, 2020, no product procurement performance obligations have been completed and therefore no product revenue has been recognized. In April 2020, BARDA exercised its option to obtain manufacturing-related services under material promise (iv) and the Company is treating these services as a separate $20.4 million contract for accounting purposes since manufacturing-related services were determined at the contract outset to be optional services that did not represent a material right. The Company’s manufacturing-related services are satisfied over time as work progresses. The Company recognized $3.3 million of government contract service revenue during the year ended December 31 As of December 31 . The Company concluded that BARDA’s reimbursement for existing FDA PMRs associated with the initial NUZYRA approval was not within the scope of ASC 606 as BARDA is not receiving services as the Company’s customer. The Company estimated the consideration to be allocated to government contract grant revenue based on the consideration under the BARDA contract in excess of the estimated standalone selling prices for components of the BARDA contract accounted for under ASC 606. The Company recognizes the allocated consideration for BARDA’s reimbursement of existing FDA PMRs associated with the initial NUZYRA approval of $72.6 million as government contract grant revenue as the related reimbursable expenses are incurred. The Company recognized $3.4 million of government contract grant revenue under the BARDA contract during the year ended December 31 Contract Balances Contract assets (i.e. unbilled accounts receivable) and/or contract liabilities (i.e. customer advances and deposits) may exist at the end of each reporting period under the BARDA contract. When amounts are received prior to performance obligations being satisfied, the amounts allocated to those performance obligations are reflected as contract liabilities on the consolidated balance sheets, as deferred revenue, until the performance obligations are satisfied. As of December 31, 2020, $0.6 million of unbilled accounts receivable was recorded and is a component of accounts receivable, net on the Company’s consolidated balance sheet. As of December

License and Collaboration Agree

License and Collaboration Agreements	12 Months Ended
	Dec. 31, 2020
Text Block [Abstract]
License and Collaboration Agreements	6 . License and Collaboration Agreements Tetraphase Pharmaceuticals, Inc. On March 18, 2019, Paratek and Tetraphase Pharmaceuticals, Inc., or Tetraphase, which is now a subsidiary of La Jolla Pharmaceutical Company, entered into a License Agreement, or the Tetraphase License Agreement. Under the terms of the Tetraphase License Agreement, Paratek granted to Tetraphase a non-exclusive, worldwide, royalty-bearing license, with the right to grant sublicenses, under certain Paratek patents, to develop, make, have, use, import, offer for sale and sell the licensed product, or XERAVA, which is a drug for the treatment of complicated, intra-abdominal infections caused by bacteria, which was approved by the FDA in August 2018. The terms of the Tetraphase License Agreement provide for Tetraphase to pay Paratek royalties at a low single digit percent on net product revenues of the licensed product sold in the U.S. Tetraphase’s obligation to pay royalties with respect to the licensed product shall be retroactive to the date of the first commercial sale of the licensed product in the U.S., which occurred in February 2019. Tetraphase is currently selling XERAVA in the U.S. The Tetraphase License Agreement will continue until the expiration of and payment by Tetraphase of all its payment obligations, which is when there are no longer any valid claims of the licensed Paratek patents that would be infringed, in the absence of a license, by a manufacture, use, or sales of the licensed product. The principal licensed patent under the Tetraphase License Agreement is expected to expire in October 2023. The Company recognized $0.2 million of royalty revenue for the year ended December 31, 2020 under the Tetraphase License Agreement. Zai Lab (Shanghai) Co., Ltd. On April 21, 2017, Paratek Bermuda Ltd., a former wholly-owned subsidiary of Paratek Pharmaceuticals, Inc., and Zai Lab (Shanghai) Co., Ltd., or Zai, entered into a License and Collaboration Agreement, or the Zai Collaboration Agreement. On December 18, 2019 Paratek Bermuda Ltd. assigned its rights under the Agreement to Paratek Pharmaceuticals, Inc. Under the terms of the Zai Collaboration Agreement, Paratek granted Zai an exclusive license to develop, manufacture and commercialize omadacycline, or the licensed product, in the People’s Republic of China, Hong Kong, Macau and Taiwan, or the Zai territory, for all human therapeutic and preventative uses other than biodefense. Zai is responsible for the development, manufacturing and commercialization of the licensed product in the Zai territory, at its sole cost with certain assistance from Paratek. Under the terms of the Zai Collaboration Agreement, Paratek earned an upfront cash payment of $7.5 million in April 2017, $5.0 million upon approval by the FDA of a NDA submission in the CABP indication, in October 2018 and $3.0 million upon submission of the first regulatory approval application for a licensed product in the People’s Republic of China in December 2019. Paratek is eligible to receive $6.0 million upon regulatory approval for a licensed product in the People’s Republic of China the next being $6.0 million. The Zai Collaboration Agreement will continue, on a region-by-region basis, until the expiration of and payment by Zai of all Zai’s payment obligations, which is until the later of: (i) the abandonment, expiry or final determination of invalidity of the last valid claim within the Paratek patents that covers the licensed product in the region in the Zai territory in the manner that Zai or its affiliates or sublicensees exploit the licensed product or intend for the licensed product to be exploited; or (ii) the eleventh anniversary of the first commercial sale of such licensed product in such region. The Company evaluated the Zai Collaboration Agreement under ASC 606. The Company determined that there were six material promises under the Zai Collaboration Agreement: (i) an exclusive license to develop, manufacture and commercialize omadacycline in the Zai territory, (ii) the initial technology transfer (iii) a transfer of certain materials and materials know-how, (iv) optional manufacturing services, (v) optional regulatory support and (vi) optional commercialization support. The Company determined that the exclusive license and initial technology transfer were not distinct from one another, as the license has limited value without the transfer of the Company’s technology, which will allow Zai to develop the manufacturing process and commercialize omadacycline in the Zai territory in the timeline anticipated under the agreement. Without the technology transfer, Zai would incur additional costs to recreate the Company’s know-how. Therefore, the license and initial technology transfer are combined as a single performance obligation. The transfer of materials is a single distinct performance obligation. The Company evaluated the option rights for manufacturing services, regulatory support and commercialization support to determine whether they represent or include material rights to Zai and concluded that the options were not issued at a discount, and therefore do not represent material rights. As such, they are not considered performance obligations at the outset of the arrangement. Based on these assessments, the Company determined that two performance obligations existed at the outset of the Zai Collaboration Agreement: (i) the exclusive license combined with the initial technology transfer and (ii) the transfer of certain materials. At the outset of the Zai Collaboration Agreements and in prior years, the Company has recognized $12.5 million in milestone revenue. As submission of the first regulatory approval application for a licensed product in the People’s Republic of China, or the PRC, is not within the control of the Company and was not obtained until December 2019, the achievement of the milestone was not was not deemed probable and the risk of significant reversal of revenue was not resolved until that time. Upon submission, the uncertainty related to this milestone was resolved and a significant reversal of revenue would not occur in future periods. As such, the $3.0 million milestone payment was recognized as revenue at the time of the regulatory approval application submission in the fourth quarter of 2019. As regulatory approval in the PRC There was no deferred revenue as of December 31, 2020 and 2019 under the Zai Collaboration Agreement. Almirall, LLC In July 2007, the Company and Warner Chilcott Company, Inc. (which became a part of Allergan plc, or Allergan), entered into a collaborative research and license agreement under which the Company granted Allergan an exclusive license to research, develop, manufacture and commercialize tetracycline products for use in the U.S. for the treatment of acne and rosacea. In September 2018, Allergan assigned to Almirall, its rights under the collaboration agreement, or the Almirall Collaboration Agreement. Since Allergan did not exercise its development option with respect to the treatment of rosacea prior to initiation of a Phase 3 trial for the product, the license grant to Allergan, which was assigned to Almirall, converted to a non-exclusive license for the treatment of rosacea as of December 2014. Under the terms of the Almirall Collaboration Agreement, Almirall is responsible for and is obligated to use commercially reasonable efforts to develop and commercialize tetracycline compounds that are specified in the agreement for the treatment of acne. The Company has agreed during the term of the Almirall Collaboration Agreement not to directly or indirectly develop or commercialize any tetracycline compounds in the U.S. for the treatment of acne, and Almirall has agreed during the term of the Almirall Collaboration Agreement not to directly or indirectly develop or commercialize any tetracycline compound included as part of the agreement for any use other than as provided in the Almirall Collaboration Agreement. In February 2020, the Company finalized a license agreement with Almirall granting the Company exclusive rights to develop, manufacture and commercialize sarecycline outside of the U.S., including rights of reference to Almirall’s clinical data thus formalizing the Company’s rights to develop, manufacture and commercialize sarecycline in the rest of the world. In connection with that license, the Company then exclusively licensed Almirall pursuant to the Almirall China License Agreement, the rights to develop, manufacture and commercialize sarecycline in the greater China region. Almirall currently holds a nonexclusive license to develop and commercialize sarecycline for the treatment of rosacea in the U.S., and in the U.S., Paratek cannot grant rights on back-up compounds, lead candidate(s), or products licensed to Almirall for rosacea. The Almirall Collaboration Agreement contains two performance obligations: (i) an exclusive license to research, develop and commercialize tetracycline products for use in the U.S. for the treatment of acne and rosacea and (ii) research and development services. The performance obligation to deliver the license was satisfied upon execution of the Almirall Collaboration Agreement in July 2007. All research and development services were completed by December 2010. The options provided to Almirall for additional development services do not provide Almirall with a material right as these services will not be provided at a significant or incremental discount. As such, the option services are not performance obligations. As the performance obligation to deliver the license was satisfied in 2007 and research and development services were completed by December 2010, all subsequent milestone payments are recognized as revenue when the risk of significant reversal is resolved, generally when the milestone event occurs. The Company recognized all Almirall milestones in prior years. There are no milestones left to be recognized under the Almirall Collaboration Agreement. Royalty payments will be recognized when the sales occur. The Company recognized $1.3 million of royalty revenue recognized for sales of SEYSARA in the U.S. by Almirall for the year ended December 31, 2020 under the Almirall Collaboration Agreement. During the fourth quarter of 2020, royalty revenue recognized for sales of SEYSARA in the U.S. was estimated using third-party data and an approximation of discounts and allowances to calculate net product sales, to which the Company then applied the applicable royalty percentage specified in the Almirall Collaboration Agreement. Differences between actual and estimated royalty revenues will be adjusted for in the period in which they become known, which is expected to be the following quarter. Refer to Note 16, Long-Term Debt, for further details. In February 2020, we entered into (i) an ex-U.S. license agreement with Almirall, or the Ex-U.S. License, under which Almirall granted to us an exclusive license in and to certain technology owned or in-licensed by Almirall or its affiliates certain technology owned or in-licensed by us or our affiliates Under the terms of the China License, Almirall is responsible for and is obligated to use commercially reasonable efforts to develop and commercialize sarecycline for the treatment of acne, including requirements to (i) file an Investigational New Drug Application (or analogous foreign submission) for sarecycline for the treatment of acne in the greater China region in calendar year 2020, (ii) receive regulatory approval for sarecycline for the treatment of acne in the greater China region within seven years following such submission and (iii) commercialize sarecycline for the treatment of acne in the greater China region within eighteen months after obtaining regulatory approval. If Almirall does not satisfy the diligence requirements set forth in subclauses ii or iii above, we may terminate the China License. We have agreed during the term of the Ex-U.S. License to use commercially reasonable efforts to not, directly or indirectly, make sarecycline products commercialized by us, our affiliates or our sublicensees available for resale in U.S., and Almirall has agreed during the term of the Ex-U.S. License to use commercially reasonable efforts to not, directly or indirectly, make sarecycline products commercialized by Almirall, their affiliates or their sublicensees available for resale outside of the greater China region. Similarly, we have agreed during the term of the China License to use commercially reasonable efforts to not, directly or indirectly, make sarecycline products commercialized by us, our affiliates or our sublicensees available for resale in the greater China region, and Almirall has agreed during the term of the China License to use commercially reasonable efforts to not, directly or indirectly, make sarecycline products commercialized by Almirall, their affiliates or their sublicensees available for resale outside of the greater China region, other than as provided in the Almirall Collaboration Agreement. In connection with the Ex-U.S. License, we pay Almirall, on a country-by-country and product-by-product basis, (i) for eight years following the first commercial sale of a sarecycline product in a country, a royalty in the middle-single digits on our or our affiliates’ nets sales of sarecycline products outside of the U.S., subject to certain standard reductions, and (ii) for fifteen years following the first commercial sale of a sarecycline product in a country, a percentage of the consideration (e.g., milestones, royalties) we receive from sublicensees in connection with developing and commercializing sarecycline outside of the U.S., which ranges from one-fifth to one-half of such consideration, subject to certain standard reductions. In connection with the China License, for fifteen years following the first commercial sale of a sarecycline product in China, Almirall pays us a royalty in the high-single digits on their, their affiliates’ or their sublicensees’ net sales of sarecycline products in the greater China region, subject to certain standard reductions. Tufts University In February 1997, the Company and Tufts University, or Tufts, entered into a license agreement under which the Company acquired an exclusive license to certain patent applications and other intellectual property of Tufts related to the drug resistance field to develop and commercialize products for the treatment or prevention of bacterial or microbial diseases or medical conditions in humans or animals or for agriculture. The Company subsequently entered into eleven amendments to that agreement, collectively the Tufts License Agreement, to include patent applications filed after the effective date of the original license agreement, to exclusively license additional technology from Tufts, to expand the field of the agreement to include disinfectant applications, and to change the royalty rate and percentage of sublicense income paid by the Company to Tufts under sublicense agreements with specified sublicensees. The Company is obligated under the Tufts License Agreement to provide Tufts with annual diligence reports and a business plan and to meet certain other diligence milestones. The Company has the right to grant sublicenses of the licensed rights to third parties, which will be subject to the prior approval of Tufts unless the proposed sublicensee meets a certain net worth or market capitalization threshold. The Company is primarily responsible for the preparation, filing, prosecution and maintenance of all patent applications and patents covering the intellectual property licensed under the Tufts License Agreement at its sole expense. The Company has the first right, but not the obligation, to enforce the licensed intellectual property against infringement by third parties. The Company issued Tufts 1,024 shares of the Company’s common stock on the date of execution of the original license agreement, and the Company was required to make certain payments of up to $0.3 million to Tufts upon the achievement by products developed under the agreement of specified development and regulatory approval milestones. The Company made a payment of $50,000 to Tufts for achieving the first milestone following commencement of the Phase 3 clinical trial for omadacycline and a payment of $100,000 to Tufts for achieving the second milestone following its first marketing application submitted in the U.S. The third, and final, payment of $150,000 became due upon FDA approval of omadacycline in October 2018. The Company is also obligated to pay Tufts a minimum royalty payment in the amount of $25,000 per year. In addition, the Company is obligated to pay Tufts royalties based on gross sales of products, as defined in the agreement, ranging in the low single digits depending on the applicable field of use for such product sale. If the Company enters into a sublicense under the agreement, based on the applicable field of use for such product, the Company will be obligated to pay Tufts (i) a percentage, ranging from 10% to 14% (ten percent to fourteen percent) for compounds other than omadacycline, and a percentage in the single digits for the compound omadacycline, of that portion of any sublicense issue fees or maintenance fees received by the Company that are reasonably attributable to the sublicense of the rights granted to the Company under the Tufts License Agreement and (ii) the lesser of (a) a percentage, ranging from the low tens to the high twenties based on the applicable field of use for such product, of the royalty payments made to the Company by the sublicensee or (b) the amount of royalty payments that would have been paid by the Company to Tufts if it had sold the product. Unless terminated earlier, the Tufts License Agreement will expire at the same time as the last-to-expire patent in the patent rights licensed to the Company under the agreement and after any such expiration the Company will continue to have an exclusive, fully-paid-up license to such intellectual property licensed from Tufts. Tufts has the right to terminate the agreement upon 30 days’ notice should the Company fail to make a material payment under the Tufts License Agreement or commit a material breach of the agreement and not cure such failure or breach within such 30-day period, or if, after the Company has started to commercialize a product under the Tufts License Agreement, the Company ceases to carry on its business for a period of 90 consecutive days. The Company has the right to terminate the Tufts License Agreement at any time upon 180 days’ notice. Tufts has the right to convert the Company’s exclusive license to a non-exclusive license if the Company does not commercialize a product licensed under the agreement within a specified time period. The Company incurred $0.6 million of royalty expense for the year ended December 31, 2020 under the Tufts License Agreement. Past Collaborations Novartis Pharma AG In September 2009, the Company and Novartis International Pharmaceutical Ltd., or Novartis, which merged into Novartis Pharma AG, a wholly owned subsidiary of Novartis AG, entered into a Collaborative Development, Manufacture and Commercialization License Agreement, or the Novartis Agreement, which provided Novartis with a global, exclusive patent and technology license for the development, manufacturing and marketing of omadacycline. The Novartis Agreement was terminated by Novartis without cause in June 2011 and the termination was effective 60 days later. The Company and Novartis subsequently entered in a letter agreement in January 2012, or the Novartis Letter Agreement, as amended, pursuant to which we reconciled shared development costs and expenses and granted Novartis a right of first negotiation with respect to commercialization rights of omadacycline following approval of omadacycline from the FDA, European Medicines Agency, or EMA, or any regulatory agency, but only to the extent the Company had not previously granted such commercialization rights related to omadacycline to another third - party as of any such approval. The Company also agreed to pay Novartis a 0.25 % royalty, to be paid from net sales received by the Company in any country following the launch of omadacycline in that country and continuing until the later of expiration of the last active valid patent claim covering such product in the country of sale and 10 years from the date of first commercial sale in such country. The first royalty payment became payable as of March 31, 2019. The amended Novartis Letter Agreement resulted in a long-term liability in the amount of $ million and $ million as of December 31, 20 20 and December 31, 201 9 , respectively, included within “Other Long-Term Liabilities” on the Company’s consolidated balance sheet. In addition, short-term liabilities included within “Other Current Liabilities” on our consolidated balance sheet as of December 31, 2020 and December 31, 2019 represent the portion of royalty payments due to Novartis within twelve months of each balance sheet date. There are no other payment obligations to Novartis under the Novartis Agreement or the amended Novartis Letter Agreement.

Cash and Cash Equivalents and R

Cash and Cash Equivalents and Restricted Cash	12 Months Ended
	Dec. 31, 2020
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents [Abstract]
Cash and Cash Equivalents and Restricted Cash	7 . Cash and Cash Equivalents and Restricted Cash The following table provides a reconciliation of cash, cash equivalents, and restricted cash reported within the consolidated statement of cash flows that sum to the total of the same such amounts shown in the consolidated statement of cash flows (in thousands): December 31, 2020 2019 Cash and cash equivalents $ 105,157 $ 102,302 Short-term restricted cash 891 324 Long-term restricted cash — 3,007 Total cash, cash equivalents and restricted cash shown on the consolidated statement of cash flows $ 106,048 $ 105,633 Short-term restricted cash On May 1, 2019, the Company deposited $4.0 million into an interest reserve account in conjunction with the funding of a royalty-backed loan agreement, or the Royalty-Backed Loan Agreement, executed with Healthcare Royalty Partners III, L.P. Payments of interest under the Royalty-Backed Loan Agreement are made quarterly using royalty payments received since the immediately preceding payment date under the Almirall Collaboration Agreement. On each interest payment date, if the royalty payments received do not equal the total interest due for the respective quarter, the Company will cover the balance of the interest payment due from the interest reserve account. Refer to Note 16, Long-Term Debt, for further details. The Company leases its Boston, Massachusetts office space under a non-cancelable operating lease. Refer to Note 18, Commitments and Contingencies In accordance with the lease, the Company has a cash-collateralized irrevocable standby letter of credit in the amount of $0.3 million as of December 31, 2020 and 2019, naming the landlord as beneficiary. Long-term restricted cash As of December 31, 2019, long term restricted cash of $2.7 million represents the remaining balance in the interest reserve account described above as well as the $0.3 million cash-collateralized irrevocable standby letter of credit described above.

Marketable Securities

Marketable Securities	12 Months Ended
	Dec. 31, 2020
Marketable Securities [Abstract]
Marketable Securities	8 . Marketable Securities The following is a summary of available-for-sale securities as of December 31, 2020 and 2019 (in thousands): Amortized Cost Unrealized Gains Unrealized Losses Fair Value December 31, 2020 U.S. treasury securities $ 20,001 $ 4 $ — $ 20,005 Total $ 20,001 $ 4 $ $ 20,005 December 31, 2019 U.S. treasury securities $ 113,003 $ 89 $ (15 ) $ 113,077 Total $ 113,003 $ 89 $ (15 ) $ 113,077 No available-for-sale securities held as of December 31, 2020 and 2019 had remaining maturities greater than twelve months.

Fixed Assets, Net

Fixed Assets, Net	12 Months Ended
	Dec. 31, 2020
Property Plant And Equipment [Abstract]
Fixed Assets, Net	9 . Fixed Assets, Net Fixed assets consist of the following (in thousands): Estimated December 31, In Years 2020 2019 Office equipment 5 $ 866 $ 866 Machinery and equipment 5 567 567 Computer equipment 3 412 412 Computer software 3 798 798 Leasehold improvements 920 920 Construction in progress 188 — Gross fixed assets 3,751 3,563 Less: Accumulated depreciation and amortization (2,787 ) (2,336 ) Net fixed assets $ 964 $ 1,227 In addition, leasehold improvements are amortized over the shorter of the lease term or the estimated useful economic lives of the related assets. Depreciation expense for the years ended December 31, 2020 and 2019 was approximately $0.5 million and $0.5 million, respectively, which is included in selling, general and administrative and research and development expense on the accompanying consolidated statements of operations and comprehensive loss.

Inventories, Net

Inventories, Net	12 Months Ended
	Dec. 31, 2020
Inventory Disclosure [Abstract]
Inventories, Net	10 . The following table presents inventories (in thousands): December 31, 2020 2019 Raw materials $ 720 $ — Work in process 12,925 9,330 Finished goods 9,638 2,249 Total inventories $ 23,283 $ 11,579 When recorded, inventory reserves reduce the carrying value of inventories to their net realizable value. The Company reviews inventories on hand at least quarterly and records provisions for estimated excess, slow-moving and obsolete inventory, as well as inventory with a carrying value in excess of net realizable value. No inventory reserves existed as of December 31, 2020 and 2019. Long-term inventory, which consists of raw materials and work in process, is included in other long-term assets in the Company’s consolidated balance sheets. December 31, 2020 2019 Balance Sheet Classification: Inventories, net $ 14,555 $ 11,579 Other long-term assets 8,728 — Total inventories $ 23,283 $ 11,579

Accrued Expenses

Accrued Expenses	12 Months Ended
	Dec. 31, 2020
Payables And Accruals [Abstract]
Accrued Expenses	11 . Accrued Expenses Accrued expenses consist of the following (in thousands): December 31, 2020 2019 Accrued compensation $ 7,783 $ 7,580 Accrued sales allowances 3,429 1,492 Accrued commercial 2,254 1,445 Accrued inventory 2,023 125 Accrued interest 1,768 2,264 Accrued professional fees 1,209 876 Accrued manufacturing 972 1,026 Accrued contract research 591 1,612 Accrued legal costs 580 181 Accrued other 217 95 Total $ 20,826 $ 16,696

Common Stock

Common Stock	12 Months Ended
	Dec. 31, 2019
Equity [Abstract]
Common Stock	12 . Common Stock The authorized capital stock of the Company consists of 100,000,000 shares of common stock, par value $0.001 per share, and the preferred stock described in Note 13, Preferred Stock The holders of common stock are entitled to one vote per share on all matters to be voted upon by the stockholders and there are no cumulative rights. Subject to preferences that may be applicable to any outstanding preferred stock, the holders of common stock are entitled to receive ratably any dividends that may be declared from time to time by the board of directors out of funds legally available for that purpose. In the event of liquidation of the Company, dissolution or winding up, the holders of common stock are entitled to share ratably in all assets remaining after payment of liabilities, subject to prior distribution rights of preferred stock then outstanding. The common stock has no preemptive or conversion rights or other subscription rights. There are no redemption or sinking fund provisions applicable to the common stock. The outstanding shares of common stock are fully paid and non-assessable. In July 2019, the Company entered into an At the Market Sales Agreement, or the 2019 Sales Agreement, with Jefferies LLC, or Jefferies, and BTIG, LLC, or BTIG, under which it was permitted to offer and sell its common stock having aggregate sales proceeds of up to $50.0 million from time to time through Jefferies and BTIG as its sales agents. Sales of the Company’s common stock through Jefferies and BTIG were to be made by any method permitted by law deemed to be an “at the market offering” as defined in Rule 415(a)(4) under the Securities Act of 1933, as amended, including without limitation sales made directly on the Nasdaq Global Market or any other existing trading market for its common stock. Jefferies or BTIG, as applicable, were entitled to a commission of 3% of the gross sales proceeds of any common stock sold through Jefferies and BTIG under the 2019 Sales Agreement. The Company sold 5,176,000 shares of common stock pursuant to the 2019 Sales Agreement for $21.9 million in proceeds, after deducting commissions of $0.7 million during the year ended December 31, 2020, which fully utilized the 2019 Sales Agreement. Upon completion of the final sale of our shares of common stock available for sale under the 2019 Sales Agreement, that agreement was terminated. On May 11, 2020, the Company filed a registration statement on Form S-3 with the SEC, as amended on June 19, 2020 and declared effective on July 9, 2020, to sell certain of its securities in an aggregate amount of up to $250.0 million. As of December 31, 2020, $250.0 million remains available on this shelf registration statement. Warrants to Purchase Common Stock Warrants to purchase preferred stock with intrinsic value issued to HBM Healthcare Investments (Cayman) Ltd., Omega Fund III, L.P., and K/S Danish BioVenture, all beneficial owners of more than 5% of the Company’s common stock, were exchanged for 9,614 warrants to purchase common stock in connection with the Merger. 9,614 warrants to purchase common stock have an exercise price of $0.15 per share and will, if not exercised, expire in 2021. In connection with the Loan and Security Agreement, dated September 30, 2015, as subsequently amended, or the Original Hercules Loan Agreement, into which the Company entered with Hercules Technology II, L.P. and Hercules Technology III, L.P., together, Hercules, and certain other lenders and Hercules Technology Growth Capital, Inc. (as agent), the Company issued to each of Hercules Technology II, L.P. and Hercules Technology III, L.P. a warrant to purchase 16,346 shares of its common stock (32,692 shares of common stock in total) at an exercise price of $24.47 per share, or the Hercules Warrants, on September 30, 2015, which expire five years from issuance or at the consummation of a Public Acquisition, as defined in each of the Hercules Warrant agreements. The Hercules Warrants expired on September 30, 2020. In connection with the second amendment to the Original Hercules Loan Agreement on December 12, 2016, the Company issued to each of Hercules Technology II, L.P. and Hercules Technology III, L.P. a warrant to purchase 18,574 shares of its common stock (37,148 shares of common stock in total) at an exercise price of $13.46 per share, or the Second Amendment Warrants. In connection with the borrowing under the Original Hercules Loan Agreement on June 27, 2017, the Company issued an additional warrant to Hercules Capital, Inc. to purchase 5,374 shares of its common stock at an exercise price of $23.26 per share, or the Additional Warrant. In connection with the fifth amendment to the Original Hercules Loan Agreement, on August 1, 2018, the Company issued to Hercules Capital, Inc. a warrant to purchase up to 19,627 shares of its common stock at an exercise price of $10.19 per share, or the Fifth Amendment Warrant. In connection with the First Amendment (as defined below), on August 5, 2020, the Company issued to Hercules Capital, Inc. a warrant to purchase up to 407,239 shares of its common stock at an exercise price of $4.42 per share, or the First Amendment Warrant. The Second Amendment Warrants, Additional Warrant, Fifth Amendment Warrant, and the First Amendment Warrant, collectively referred to as the Warrants, may be exercised on a cashless basis. The Warrants are exercisable for a term beginning on the date of issuance and ending on the earlier to occur of five years (or seven years, in the case of the Fifth Amendment Warrant and the First Amendment Warrant) from the date of issuance or the consummation of certain acquisitions of the Company as set forth in the various agreements for the Warrants.

Preferred Stock

Preferred Stock	12 Months Ended
	Dec. 31, 2020
Equity [Abstract]
Preferred Stock	13 . Preferred Stock The authorized capital stock of the Company consists of 5,000,000 shares of undesignated preferred stock, par value $0.001 per share, and the common stock described in Note 12, Common Stock The Company’s Board of Directors has the authority, without further action by the stockholders, to issue up to 5,000,000 shares of preferred stock, in one or more series, and to fix the rights, preferences, privileges and restrictions granted to or imposed upon the preferred stock. Any or all of these rights may be greater than the rights of the common stock. There are no shares of preferred stock issued or outstanding as of December 31, 2020 and 2019.

Fair Value Measurements

Fair Value Measurements	12 Months Ended
	Dec. 31, 2020
Fair Value Disclosures [Abstract]
Fair Value Measurements	14 . Fair Value Measurements Financial instruments, including cash, cash equivalents, restricted cash, money market funds, U.S. treasury securities, accounts receivable, accounts payable, and accrued expenses are carried on the consolidated financial statements at amounts that approximate fair value. The fair value of the Company’s long-term debt is determined using current applicable rates for similar instruments as of the balance sheet date. The fair value of the Company’s debt (including the Notes as defined in Note 16, Long-Term Debt) The following tables present information about the Company’s financial assets and liabilities that have been measured at fair value as of December 31, 2020 and December 31, 2019 and indicate the fair value hierarchy of the valuation inputs utilized to determine such fair value. In general, fair values determined by Level 1 inputs utilize quoted prices (unadjusted) in active markets for identical assets or liabilities (in thousands): Description Quoted Prices in Active Markets (Level 1) Significant Other Observable Inputs (Level 2) Significant Unobservable Inputs (Level 3) December 31, 2020 Assets: U.S. treasury securities $ 20,005 $ — $ — $ 20,005 Total Assets $ 20,005 $ — $ — $ 20,005 Description Quoted Prices in Active Markets (Level 1) Significant Other Observable Inputs (Level 2) Significant Unobservable Inputs (Level 3) December 31, 2019 Assets: U.S. treasury securities $ 113,077 $ — $ — $ 113,077 Total Assets $ 113,077 $ — $ — $ 113,077

Stock-Based and Incentive Compe

Stock-Based and Incentive Compensation	12 Months Ended
	Dec. 31, 2020
Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]
Stock-Based and Incentive Compensation	15 . Stock-Based and Incentive Compensation Certain employees, officers, directors, and consultants have been granted options and other equity instruments to purchase common shares under plans adopted in 2006, 2014 and 2015, or the 2006 Plan, the 2014 Plan, the 2015 Plan, respectively, the 2015 Inducement Plan and the 2017 Inducement Plan. Upon effectiveness of the 2015 Plan no further awards will be granted under the 2006 Plan and 2014 Plan. Incentive stock and non-statutory stock options must be granted with exercise prices of not less than the fair market value of the common stock on the date of grant. Incentive stock options granted to a stockholder owning more than 10% of voting stock of the Company must have an exercise price of not less than 110% of the fair market value of the common stock on the date of grant. The Company determined the fair market value of common stock until the Company became publicly traded. Stock options are generally granted with terms of up to ten years and vest over a period of one to four years. 2006 Plan The 2006 Plan provided for the grant of incentive stock options, non-statutory stock options, restricted stock, performance share awards, performance stock units, dividend equivalents, restricted stock units, stock payments, deferred stock, performance-based awards and stock appreciation rights. The 2006 Plan terminated on June 2, 2020. As of December 31, 2020 and 2019, no additional shares remained available for issuance under the 2006 Plan. All shares cancelled or forfeited during the years ended December 31, 2020 and 2019 became available for grant under the 2015 Plan. 2014 Plan The 2014 Plan provided for the grant of incentive and non-statutory stock options, stock appreciation rights, restricted stock awards, restricted stock unit awards and other stock awards to employees, officers, directors, and consultants of the Company. During the year ended December 31, 2015, prior to the effectiveness of the 2015 Plan, the Company’s Board of Directors granted 24,000 stock options to directors, officers, employees and consultants to the 2014 Plan with time vesting provisions ranging from one to four years. As of December 31, 2020 and 2019, no additional shares remained available for issuance the 2014 Plan. All shares cancelled or forfeited during the years ended December 31, 2020 and 2019 became available for grant under the 2015 Plan. 2015 Plans The Company’s Board of Directors adopted a 2015 Inducement Plan in accordance with Nasdaq Rule 5635(c)(4), reserving 360,000 shares of common stock solely for the grant of inducement stock options to new employees, and granting 353,500 stock options under the plan to executives and employees of the Company under the 2015 Inducement Plan with time vesting provisions ranging from one to four years . The Company has not made any additional grants under the 2015 Inducement Plan since December 31, 2015. shares remain available for grant under that plan, as well as any shares underlying outstanding stock options that may become available for grant pursuant to the plan’s terms. It is therefore possible that the Company may, based on the business and recruiting needs of the Company, issue additional stock options under the 2015 Inducement Plan. The Company’s Board of Directors also adopted the 2015 Plan, which was approved by Company stockholders at the Annual Meeting held on June 9, 2015, reserving 1,200,000 shares of common stock for the grant of incentive stock options, non-statutory stock options, stock appreciation rights, restricted stock awards, restricted stock unit awards, performance stock awards, performance cash awards and other stock awards to directors, officers, employees and consultants. The 2015 Plan is intended to be the successor to and continuation of the 2006 Plan and the 2014 Plan, or collectively, the Prior Plans. When the 2015 Plan became effective, no additional stock awards were granted under the Prior Plans, although all outstanding stock awards granted under the Prior Plans will continue to be subject to the terms and conditions as set forth in the agreements evidencing such stock awards and the terms of the Prior Plans. The number of shares available for issuance under the 2015 Plan was initially 1,200,000 shares, plus the number of shares that again become available for grant as a result of forfeited or terminated awards or shares withheld in satisfaction of the exercise price of withholding obligations associated with awards under the Prior Plans, not to exceed 2,000,000 shares. 2,325,828, 1,991,387, and 1,612,969 shares of common stock were automatically added to the shares authorized for issuance under the 2015 Plan on January 1, 2021, January 1, 2020, and January 1, 2019, respectively, pursuant to a “Share Reserve” provision contained in the 2015 Plan. The Share Reserve will automatically increase on January 1 st During the year ended December 31, 2018, the Company’s Board of Directors granted performance-based restricted stock units, or PRSU, awards to certain executives and employees of the Company and have vested or will vest as follows: (a) 10/55 20/55 25/55 During the year ended December 31, 2019, the Company’s Board of Directors granted PRSU awards to certain executives and employees of the Company in February 2019 and July 2019 under the 2015 Plan that will vest as follows: (a) 25/60 25/60 10/60 During the year ended December 31, 2020, the Company’s Board of Directors granted 103,900 stock options and 2,553,250 restricted stock units, or RSU, awards to directors, executives, and employees of the Company under the 2015 Plan. The stock option awards are generally subject to time-based vesting over a period of one to four years. The RSU awards granted to executives in February 2020 are subject to time-based vesting, with 1/3 1/3 25/55 15/55 15/55 will be achieved. The Company recognized compensation cost for a total of $ 0.4 million for milestone (b) during the year ended December 31, 2020 using the accelerated attribution method. 200,565 RSUs and 1,123,643 stock options granted under the 2015 Plan were cancelled, forfeited or expired during the year ended December 31, 2020. 2017 Inducement Plan In June 2017, the Company’s Board of Directors adopted the 2017 Inducement Plan in accordance with Nasdaq Rule 5635(c)(4), reserving 550,000 shares of common stock solely for the grant of inducement stock options to employees entering into employment or returning to employment after a bona fide period of non-employment with the Company. In October 2018, the Company’s Board of Directors adopted an amendment in accordance with Nasdaq Listing Rule 5635(c)(4) to increase the aggregate number of shares of common stock that may be issued pursuant to awards under the 2017 Inducement Plan from 550,000 shares to 1,050,000 shares. During the year ended December 31, 2020, the Company’s Board of Directors granted 44,050 stock options and 34,300 RSU awards to employees of the Company under the 2017 Inducement Plan. The stock option awards are generally subject to time-based vesting over a period of one to four years. The RSU awards are generally subject to time-based vesting, with 100% of the shares of common stock subject to the RSU award vesting three years from the grant date. 17,000 RSUs and 87,068 stock options granted under the 2017 Inducement Plan were forfeited during the year ended December 31, 2020. Total shares available for future issuance under the 2015 Plan, 2015 Inducement Plan and 2017 Inducement Plan are 1,339,392, 306,500 and 428,733 shares, respectively, as of December 31, 2020. A summary of stock option activity and related information through December 31, 2020 follows: Number of Shares Weighted Average Exercise Price Weighted– Average Remaining Contractual Term (in Years) Aggregate Intrinsic Value (in thousands) Outstanding Balances at December 31, 2019 3,236,073 $ 15.54 6.30 $ 90 Granted 147,950 4.37 Exercised (39,479 ) 4.30 Cancelled or forfeited (1,213,102 ) 19.83 Expired (145,000 ) 20.85 Balances at December 31, 2020 1,986,442 $ 11.92 5.63 $ 1,748 Exercisable December 31, 2020 1,717,030 $ 12.61 5.19 $ 1,356 The aggregate intrinsic value is calculated as the difference between the exercise price of the underlying options and the fair market value of the common stock for the options that were in the money at December 31, 2020 and 2019. During the years ended December 31, 2020 and 2019, the Company granted stock options to purchase an aggregate of 147,950 shares and 196,560 shares of its common stock, under the equity plans described above, respectively, with weighted-average grant date fair values of options granted of $2.46 and $2.69 and respectively. The total intrinsic value of stock options exercised was insignificant for the year ended December 31, 2020. No stock options were exercised during the year ended December 31, 2019. Restricted Stock Units The following is a summary of restricted stock unit activity for the year ended December 31, 2020: Number of Shares Weighted Average Grant Date Fair Value per Share Unvested balance at December 31, 2019 2,305,408 $ 7.66 Granted 2,587,550 3.56 Released (1,281,968 ) 7.96 Forfeited (217,565 ) 7.90 Unvested balance at December 31, 2020 3,393,425 $ 4.41 During the year ended December 31, 2020 the Company granted 2,587,550 restricted stock units with a weighted-average grant date fair value per share of $3.56. During the year ended December 31, 2019 the Company granted 2,275,340 restricted stock units with a weighted-average grant date fair value per share of $6.01. The aggregate fair value of restricted shares that vested during the years ended December 31, 2020 and 2019 was $10.2 million and $12.1 million, respectively. Stock-Based Compensation Expense For stock options issued to employees and members of the Board of Directors, the Company estimates the grant date fair value of each option using the Black-Scholes option-pricing model. The use of the Black-Scholes option-pricing model requires management to make assumptions with respect to the expected term of the option, the expected volatility of the common stock consistent with the expected life of the option, risk-free interest rates and expected dividend yields of the common stock. The relevant data used to determine the value of the stock option grants is as follows: Year Ended December 31, 2020 2019 Volatility 63.1 % 63.4 % Weighted average risk-free interest rate 0.9 % 2.0 % Expected dividend yield 0.0 % 0.0 % Expected life of options (in years) 5.7 5.9 The following table presents stock-based compensation expense included in the Company’s consolidated statements of operations (in thousands): Year Ended December 31, 2020 2019 Research and development expense $ 2,130 $ 3,568 Selling, general and administrative expense 8,118 10,727 Total stock-based compensation expense $ 10,248 $ 14,295 Total unrecognized stock-based compensation expense for all stock-based awards was $7.9 million at December 31, 2020. This amount will be recognized over a weighted-average period of 1.61 years. 2009 Employee Stock Purchase Plan In June 2009, at the annual meeting of stockholders, the stockholders of the Company approved the 2009 Employee Stock Purchase Plan, or the 2009 ESPP. 2018 Employee Stock Purchase Plan The Company’s Board of Directors adopted, and in June 2018 Company’s stockholders approved, the Paratek Pharmaceuticals, Inc. 2018 Employee Stock Purchase Plan, or the 2018 ESPP. The 2018 ESPP was amended in October 2018 to change the commencement dates of the offering periods. The maximum aggregate number of shares of the Company’s common stock that may be purchased under the 2018 ESPP is 943,294 shares, or the ESPP Share Pool, subject to adjustment as provided for in the 2018 ESPP. The ESPP Share Pool represented 3% of the total number of shares of our common stock outstanding as of March 31, 2018. The 2018 ESPP allows eligible employees to purchase shares during certain offering periods, which will be six Reserved Shares At December 31, 2020, the Company has reserved shares of common stock for future issuance as follows: Number of Shares Equity plans: Shares subject to outstanding options and unvested restricted stock units 5,379,867 Shares available for future grants 2,074,625 Shares subject to warrants to purchase common stock 479,002 Shares issuable under employee stock purchase plan 606,816 Common stock issuable under outstanding convertible notes 10,377,361 Total 18,917,671 Revenue Performance Incentive Plan On October 4, 2018, the Company adopted the Revenue Performance Incentive Plan, or the Plan, to grant performance-based cash incentive awards to key employees and consultants of the Company. The Plan provides for an incentive pool of up to $50.0 million, plus accrued interest during the period between the awards’ vesting date and payment dates. Each participant will be allocated a percentage of the incentive pool. The incentive pool will be divided into two equal tranches with the first tranche vesting upon the Company’s achievement of cumulative net product revenues over $300.0 million by December 31, 2025, or Tranche 1, and the second tranche vesting upon the Company’s achievement of cumulative product revenues over $600.0 million by December 31, 2026, or Tranche 2. Awards under the plan will vest annually in each tranche of a participant’s award in four equal installments on December 31, 2019, December 31, 2020, December 31, 2021, and December 31, 2022, subject to their continued employment with the Company through the applicable vesting date. If a participant’s employment terminates prior to December 31, 2022 due to death or disability, the participant will automatically vest in an additional 25% of each tranche of his or her award. Upon the achievement of a Tranche 1 or Tranche 2 milestone (but not a deemed achievement in connection with a change of control), each participant who has remained in continuous employment with the Company through December 31, 2022 will be 100% vested in the applicable tranche. In the event of a change of control of the Company prior to December 31, 2026, participants whose employment has terminated prior to such date will be eligible for payouts under the Plan based on the then-vested portion of their awards, and participants who have remained employed through the change of control will be deemed to have time vested in full in each tranche of their awards. Upon the achievement of a Tranche 1 or Tranche 2 milestone (but not a deemed achievement in connection with a change of control), each participant’s payout in respect of the applicable tranche of his or her award will equal (a) the participant’s then-vested percentage, multiplied by (b) $25 million, multiplied by (c) the participant’s individual percentage allocation of the incentive pool. If a change of control occurs prior to December 31, 2026, and the Tranche 1 milestone was not achieved prior to the change of control, the Tranche 1 milestone will be deemed to be achieved at a percentage equal to the greater of (1) 50% and (2) the cumulative product revenues as of the change of control, divided by $300.0 million. If a change of control occurs prior to December 31, 2026, and the Tranche 2 milestone was not achieved prior to the change of control, the Tranche 2 milestone will be deemed to be achieved at a percentage equal to the greater of (1) 30% and (2) the cumulative product revenues as of the change of control, divided by $600.0 million. A participant’s payout in respect of each tranche of his or her award in a change of control will equal (1) the participant’s then-vested percentage of such tranche, multiplied by (2) the percentage of that tranche’s milestone that has been achieved or is deemed to have been achieved, multiplied by (3) $ 25.0 million, multiplied by (4) the participant’s individual percentage allocation of the incentive pool. Amounts that become payable upon achievement of the Tranche 1 milestone will be paid in a lump-sum in the first quarter of 2026 and amounts that become payable upon achievement of the Tranche 2 milestone will be paid in a lump-sum in the first quarter of 2027. In the event of a change of control, any portion of the incentive pool that is earned, but unpaid, or deemed earned in connection with the change of control will be paid at the time of the change of control. If a change of control occurs prior to the achievement of either or both of the Tranche 1 and Tranche 2 milestones, the awards will remain outstanding and the remaining unpaid portion of the incentive pool applicable to the Tranche 1 or Tranche 2 milestone, as applicable, will be paid following the achievement of either such milestone at the time or times the bonuses would otherwise be paid out. Any successor in interest to the Company upon or following a change of control will be required to assume all obligations under the Plan. Awards may be paid out in cash or in a combination of cash and registered securities of equal value (based on the Company’s 20-day trailing average closing common stock price), with the portion paid in registered securities not to exceed 50% of the aggregate payment amount with respect to each tranche; provided, however, that any amounts payable with respect to an award in connection with a change in control will be paid in cash. The Company will recognize the compensation cost over the requisite service period, to the extent achievement of the performance condition is deemed probable relative to targeted performance. The performance condition is not yet deemed probable; as such, no amounts were accrued under the Plan during the years ended December 31, 2020 and December 31, 2019.

Long-Term Debt

Long-Term Debt	12 Months Ended
	Dec. 31, 2020
Debt Disclosure [Abstract]
Long-Term Debt	16 . Long-Term Debt R-Bridge Loan Agreement On December 31, 2020, or the Closing Date, the Company, through its wholly-owned subsidiary PRTK SPV2 LLC, a Delaware limited liability company, or the Subsidiary, entered into a royalty and revenue interest-backed loan agreement, or the R-Bridge Loan Agreement, with an affiliate of R-Bridge Healthcare Investment Advisory, Ltd., or the R-Bridge Lender. Pursuant to the terms of the R-Bridge Loan Agreement, the Subsidiary borrowed a $60.0 million term loan, secured by, and repaid with proceeds from, (i) royalties from the Zai Collaboration Agreement, and such royalties, or the Royalty Interest, and (ii) a revenue interest based on the Company’s U.S. sales of NUZYRA in an initial amount of two and a half percent (2.5%), which amount may adjust under certain circumstances up to five percent (5%), of the Company’s net U.S. sales, subject to an annual cap of $10.0 million, which may adjust under certain circumstances to $12.0 million, or the Revenue Interest. Under the R-Bridge Loan Agreement, the outstanding principal balance will bear interest at an annual rate of 7.0%, increasing to an annual rate of 10% during the continuance of any event of default. Payments of the obligations outstanding under the R-Bridge Loan Agreement will be made quarterly, beginning with the payment due in respect of the quarter ending March 31, 2021, out of the Royalty Interest payments and Revenue Interest payments received by the Subsidiary during such quarter, or the Collection Amount. On each payment date, after payment of certain expenses, the Collection Amount shall be applied first to accrued interest, with any excess up to $15.0 million per annum applied to repay principal until the balance is fully repaid, and any shortfalls being capitalized and added to the principal balance of the loan. Amounts in excess of the $15.0 million annual cap shall be shared between the Company and the R-Bridge Lender based on a formula set out in the R-Bridge Loan Agreement. Following repayment in full of the loan, the first $15.0 million per annum in Collection Amount shall be paid to the Company and any amounts in excess shall be shared between the Company and the R-Bridge Lender based on a formula set out in the R-Bridge Loan Agreement. Prior to the eighth (8 th th The Company’s subsidiary, PRTK SPV1 LLC , a Delaware limited liability company and owner of the Subsidiary’s capital stock, has entered into a Pledge and Security Agreement in favor of the R-Bridge Lender, pursuant to which the Subsidiary’s obligations under the R-Bridge Loan Agreement are secured by PRTK SPV1 LLC’s pledge of all of the Subsidiary’s capital stock. The R-Bridge Loan Agreement contains certain customary affirmative covenants, including those relating to: use of proceeds; maintenance of books and records; financial reporting and notification; compliance with laws; and protection of Company intellectual property. The R-Bridge Loan Agreement also contains certain customary negative covenants, barring the Subsidiary from: certain fundamental transactions; issuing dividends and distributions; incurring additional indebtedness outside of the ordinary course of business; engaging in any business activity other than related to the Zai Collaboration Agreement; and permitting any additional liens on the collateral provided to the R-Bridge Lender under the R-Bridge Loan Agreement. As of December 31, 2020, the Company was in compliance with all covenants under the R-Bridge Loan Agreement. An ancillary agreement executed by the Company and the Subsidiary in respect of the Revenue Interest, contains negative covenants applicable to the Company, including restrictions on the sale or transfer of our assets related to NUZYRA and giving rise to the Revenue Interest, each subject to the exceptions set forth therein. The R-Bridge Loan Agreement contains customary defined events of default, upon which any outstanding principal, unpaid interest, and other obligations of the Subsidiary, shall be immediately due and payable by the Subsidiary. These include: failure to pay any principal or interest when due; failure to the Capped Amount as and when due following a non-qualified change of control of the Company, any uncured breach of a representation, warranty or covenant; any uncured failure to perform or observe covenants; any uncured breach of our representations, warranties or covenants under an ancillary agreement executed by the Company and the Subsidiary in respect of the Royalty Interest; any termination of the Zai Collaboration Agreement; and certain bankruptcy or insolvency events. No events of default had occurred under the R-Bridge Loan Agreement through December 31, 2020. The Company raised approximately $58.3 million in net proceeds in connection with the R-Bridge Loan Agreement, comprised of the $60.0 million term loan funded at execution, net of $1.1 million in lender fees accounted for as debt discount and $0.6 million in direct and incremental third-party expenses accounted for as debt issuance costs. The net proceeds of the term loan, together with cash on hand, was used to prepay in full all obligations outstanding under the A&R Loan and Security Agreement with Hercules (further defined below). The Company evaluated the R-Bridge Loan Agreement for embedded derivatives pursuant to ASC 815, Derivatives and Hedging The accounting for the R-Bridge Loan Agreement requires the Company to make certain estimates and assumptions, particularly about future royalties under the Zai Collaboration Agreement and sales of NUZYRA in the U.S. Such estimates and assumptions are utilized in determining the expected repayment term, amortization period of the debt discount and issuance costs, accretion of interest expense and classification between current and long-term portions of amounts outstanding. The Company amortizes the debt discount and issuance costs to interest expense over the expected term of the arrangement using the interest method based on projected cash flows. Similarly, the Company classifies as current debt for the R-Bridge Loan Agreement, amounts that are expected to be repaid during the succeeding twelve months after the reporting period end. However, the repayment of amounts due under the R-Bridge Loan Agreement is variable because the cash flows to be utilized for periodic payments is a function of amounts received by the Company with respect to the Royalty Interest and the Revenue Interest. Accordingly , the estimates of the magnitude and timing of amounts to be available for debt service are subject to significant variability and thus, subject to significant uncertainty. Therefore, these estimates and assumptions are likely to change, which may result in future adjustments to the portion of the debt that is classified as a current liability, the amortization of debt discount and issuance costs and the accretion of interest expense. The amount of principal to be repaid in each of the five succeeding years is not fixed and determinable. Other amounts that may become due and payable under the R-Bridge Loan Agreement, including amounts shared between the parties with respect to cash flows received in excess of pre-defined thresholds, are recognized as additional interest expense when they become probable and estimable. The following table summarizes the impact of the R-Bridge Loan Agreement on the Company’s consolidated balance sheets at December 31, 2020 (in thousands): Gross proceeds $ 60,000 Unamortized debt discount and issuance costs (1,680 ) Carrying Value $ 58,320 No interest expense was recognized during the year ended December 31, 2020 due to the timing of deal effectiveness. Hercules Loan Agreement On June 27, 2019, the Company entered into an Amended and Restated Loan and Security Agreement, or the A&R A&R A&R Hercules Loan Agreement A&R Hercules Loan Agreement Modification and Extinguishment A&R In connection with such loan agreements, the Company issued to each of Hercules Technology II, L.P. and Hercules Technology III, L.P., a warrant to purchase 16,346 shares of common stock (32,692 shares of common stock in total) at an exercise price of $24.47 per share and a warrant to purchase 18,574 shares of common stock (37,148 shares of common stock in total) at an exercise price of $13.46 per share. The Company also issued to Hercules Capital, Inc. a warrant to purchase up to 5,374 shares of common stock at an exercise price of $23.26 per share, as well as a warrant to purchase up to 19,627 shares of common stock at an exercise price of $10.19 per share. On August 5, 2020, the Company entered into the First Amendment to the A&R Hercules Loan Agreement, or the First Amendment. Concurrently with the closing of the First Amendment, we repaid a Term Loan Tranche of $10.0 million and paid the Lenders the existing end of term charges equal to $2.5 million. Following the closing of the First Amendment, $60.0 million of Term Loan Tranches remained outstanding and $30.0 million of additional Term Loan Tranches remained available to the Company, subject to approval by Hercules, in its sole discretion, whether to provide such tranches. The First Amendment provided for an additional end of term charge equal to 1.95% of the issued principal balance of the Term Loan Tranches on September 1, 2022 or upon prepayment in addition to the $0.7 million end of term charge from the A&R Hercules Loan agreement that is due on August 1, 2020 or upon prepayment. The First Amendment extended the date on which the Company was required to begin making monthly principal installments on the outstanding Term Loan Tranches from January 1, 2021 to January 1, 2022 (which could have been extended to July 1, 2022 or January 1, 2023, upon certain events set forth in the First Amendment), and extended the scheduled maturity of the Term Loan Tranches from August 1, 2022 to September 1, 2022 (which could have been extended to March 1, 2023 or September 1, 2023, upon certain events set forth in the First Amendment). The First Amendment increased the cash interest rate with respect to the Term Loan Tranches to a floating per annum rate equal to the greater of (i) 8.85% or (ii) the prime rate as reported from time to time in The Wall Street Journal plus 5.35%, and provided for the payment of additional “paid-in-kind” interest by the Company under the First Amendment at a fixed per annum rate equal to 1.55%, compounding monthly and payable at maturity or upon prepayment. The modified terms under the First Amendment A&R First Amendment Modification and Extinguishment A&R In connection with the First Amendment, the Company issued an additional warrant to Hercules Capital, Inc. that is exercisable for a minimum of up to 407,239 shares of common stock at an exercise price of $4.42 per share. On December 31, 2020, the Company used the proceeds from the sale of the Royalty Interest and Revenue Interest from the R-Bridge Loan, together with cash on hand, to prepay in full all obligations outstanding of $62.7 million under the A&R Hercules Loan Agreement. Repayment of all amounts outstanding under the A&R Hercules Loan Agreement qualified as an extinguishment of debt, under Modification and Extinguishment , on the date the payment was made in satisfaction of all amounts due and we were unconditionally relieved of our obligations therein. Extinguishment loss is calculated as the difference between the reacquisition price of $62.7 million and the carrying value of the extinguished debt of $60.3 million, net of unamortized debt discount and unamortized debt issuance costs. Accordingly, we recorded a $2.4 million loss on extinguishment of debt as a component of other income and expenses in our consolidated statements of operations and comprehensive loss during the year ended December 31, 2020. The loss on extinguishment of debt of $2.4 million consisted of the following: (i) $1.3 million related to end of term fees, (ii) $1.0 million related to the write-off of unamortized debt discount and (iii) an insignificant amount related to the write-off of unamortized debt issuance costs. Upon repayment, the A&R Hercules Loan Agreement was terminated pursuant to which the Company was unconditionally released from all obligations thereunder. The following table summarizes the impact of the A&R Gross proceeds $ 70,000 Unamortized debt discount costs (361 ) Carrying Value $ 69,639 Debt issuance costs are presented on the consolidated balance sheet as a direct deduction from the related debt liability rather than capitalized as an asset in accordance with ASU No. 2015-03, Interest - Imputation of Interest (Subtopic 835-30): Simplifying the Presentation of Debt Issuance Costs The Company recognized interest expense of $7.3 million and $6.8 million on the A&R Hercules Loan for the years ended December 31, 2020 and 2019, respectively. Convertible Senior Subordinated Notes On April 18, 2018, the Company entered into a Purchase Agreement, or the Purchase Agreement, with several initial purchasers, or the Initial Purchasers, for whom Merrill Lynch, Pierce, Fenner & Smith Incorporated The Purchase Agreement includes customary representations, warranties and covenants. Under the terms of the Purchase Agreement, the Company agreed to indemnify the Initial Purchasers against certain liabilities. In addition, J. Wood Capital Advisors LLC, the Company’s financial advisor, purchased $5.0 million aggregate principal amount of Notes in a separate, concurrent private placement on the same terms as other investors. The Notes were issued by the Company on April 23, 2018, pursuant to an Indenture, dated as of such date, or the Indenture, between the Company and U.S. Bank National Association, as trustee, or the Trustee. The Notes bear cash interest at the annual rate of 4.75%, payable on November 1 and May 1 of each year, beginning on November 1, 2018, and mature on May 1, 2024 unless earlier repurchased, redeemed or converted. The Company will settle conversions of the Notes through delivery of shares of common stock of the Company, in accordance with the terms of the Indenture. The initial conversion rate for the Notes is 62.8931 shares of common stock (subject to adjustment as provided for in the Indenture) per $1,000 principal amount of the Notes, which is equal to an initial conversion price of approximately $15.90 per share, representing a conversion premium of approximately 20% above the closing price of the common stock of $13.25 per share on April 18, 2018. Holders of the Notes may convert all or any portion of their Notes, in multiples of $1,000 principal amount, at their option at any time prior to the close of business on the second scheduled trading day immediately preceding the stated maturity date. The Company may not redeem the Notes prior to May 6, 2021. The Company may redeem for cash all or part of the Notes, at its option, on or after May 6, 2021 if the last reported sale price of the Company’s common stock has been at least 130% of the conversion price then in effect for at least 20 trading days (whether or not consecutive) during any 30 consecutive trading day period (including the last trading day of such period) ending on, and including, the trading day immediately preceding the date on which the Company provides notice of redemption at a redemption price equal to 100% of the principal amount of the Notes to be redeemed, plus accrued and unpaid interest to, but excluding, the redemption date. If the Company experiences a fundamental change, as described in the Indenture, prior to the maturity date of the Notes, holders of the Notes will, subject to specified conditions, have the right, at their option, to require the Company to repurchase for cash all or a portion of their Notes at a repurchase price equal to 100% of the principal amount of the Notes to be repurchased, plus accrued and unpaid interest, if any, to, but not including, the fundamental change repurchase date. In addition, following certain corporate events that occur prior to the maturity date of the Notes and following a notice of redemption of the notes, the Company will increase the conversion rate for a holder who elects to convert its Notes in connection with such corporate event or redemption. The Indenture provides for customary events of default. In the case of an event of default with respect to the Notes arising from specified events of bankruptcy or insolvency, all outstanding Notes will become due and payable immediately without further action or notice. If any other event of default with respect to the Notes under the Indenture occurs or is continuing, the Trustee or holders of at least 25% in aggregate principal amount of the then outstanding Notes may declare the principal amount of the Notes to be immediately due and payable. In certain circumstances if, at any time during the six-month period beginning on, and including, the date that is six months after the last date of original issuance of the Notes, the Company fails to timely file certain documents or reports required under the Securities Exchange Act of 1934, as amended, or the Notes are not otherwise freely tradable by holders of the Notes other than the Company’s affiliates or holders that were the Company’s affiliates at any time during the three months immediately preceding, additional interest will accrue on the Notes during the first 90-day period in which its failure to file has occurred and is continuing or such Notes are not otherwise freely tradable by holders other than the Company’s affiliates (or holders that were the Company’s affiliates at any time during the three months immediately preceding). After deducting costs incurred of $6.0 million, the Company raised net proceeds from the issuance of long-term convertible debt of $159.0 million in April 2018. All costs were deferred and are being amortized over the life of the Notes at an effective interest rate of 5.47% and recorded as additional interest expense. The Company has evaluated the Indenture for derivatives pursuant to ASC 815, Derivatives and Hedging , or ASC 815, and identified an embedded derivative that requires bifurcation as the feature is not clearly and closely related to the host instrument. The embedded derivative is a default provision, which could require additional interest payments. The Company has determined that the fair value of this embedded derivative was nominal during the year ended December 31, 20 20 . The Company evaluated the conversion feature and determined it was not within the scope of ASC 815 and therefore is not required to be accounted for separately. The Company concluded that the embedded conversion option is not subject to separate accounting pursuant to either the cash conversion guidance or the beneficial conversion feature guidance. Under the general conversion guidance in ASC 470, Debt The following table summarizes how the issuance of the Notes is reflected in the Company’s consolidated balance sheets at December 31, 2020 and 2019 (in thousands): Year Ended December 31, 2020 2019 Gross proceeds $ 165,000 $ 165,000 Unamortized debt discount costs (3,578 ) (4,531 ) Carrying Value $ 161,422 $ 160,469 Debt issuance costs are presented on the consolidated balance sheet as a direct deduction from the related debt liability rather than capitalized as an asset in accordance with ASU No. 2015-03, Interest - Imputation of Interest (Subtopic 835-30): Simplifying the Presentation of Debt Issuance Costs The Company recognized coupon interest expense of $7.8 million and amortization expense on the debt issuance costs of $1.0 million on the Notes for the year ended December 31, 2020. The Company recognized coupon interest expense of $7.8 million and amortization expense on the debt issuance costs of $0.9 million on the Notes for the year ended December 31, 2019. Royalty-Backed Loan Agreement On February 25, 2019, the Company, through its wholly-owned subsidiary Paratek Royalty Corporation, or the Subsidiary, entered into a royalty-backed loan agreement, or the Royalty-Backed Loan Agreement, with Healthcare Royalty Partners III, L.P., or the HCRP Lender. Pursuant to the terms of the Royalty-Backed Loan Agreement, the Subsidiary borrowed a $32.5 million loan, which was secured by, and is being repaid based upon, royalties from the Almirall Collaboration Agreement. On May 1, 2019, the Company received $27.8 million, net of $0.5 million lender discount, $0.2 million in lender expenses incurred, and $4.0 million that was deposited into an interest reserve account. The Company also paid $1.2 million in other lender fees related to the Royalty-Backed Loan Agreement. Under the Royalty-Backed Loan Agreement, the outstanding principal balance will bear interest at an annual rate of 12.0%. Payments of interest under the Royalty-Backed Loan Agreement will be made quarterly, beginning in August 2019, using the Almirall Collaboration Agreement royalty payments received since the immediately preceding payment date. On each interest payment date, any royalty payments in excess of accrued interest on the loan will be used to repay the principal of the loan until the balance is fully repaid. In addition, the Subsidiary will make up-front payments to the HCRP Lender of (i) a 1.5% fee and (ii) up to $300,000 for the HCRP Lender’s expenses. The Royalty-Backed Loan Agreement matures on May 1, 2029, at which time, if not earlier repaid in full, the outstanding principal amount of the loan, together with any accrued and unpaid interest, and all other obligations then outstanding, shall be due and payable in cash. The Company has entered into a Pledge and Security Agreement in favor of the HCRP Lender, pursuant to which the Subsidiary’s obligations under the Royalty-Backed Loan Agreement are secured by a pledge of all of the Company’s holdings of the Subsidiary’s capital stock. The Royalty-Backed Loan Agreement contains certain customary affirmative covenants, including those relating to: use of proceeds; maintenance of books and records; financial reporting and notification; compliance with laws; and protection of Company intellectual property. The Royalty-Backed Loan Agreement also contains certain customary negative covenants, barring the Subsidiary from: certain fundamental transactions; issuing dividends and distributions; incurring additional indebtedness outside of the ordinary course of business; engaging in any business activity other than related to the Almirall Collaboration Agreement; and permitting any additional liens on the collateral provided to HCRP Lender under the Royalty-Backed Loan Agreement. The Royalty-Backed Loan Agreement contains customary defined events of default, upon which any outstanding principal and unpaid interest shall be immediately due and payable. These include: failure to pay any principal or interest when due; any uncured breach of a representation, warranty or covenant; any uncured failure to perform or observe covenants; any uncured cross default under a material contract; any uncured breach of the Company’s representations, warranties or covenants under its Contribution and Servicing Agreement with the Subsidiary; any termination of the Almirall Collaboration Agreement ; and certain bankruptcy or insolvency events. The following table summarizes the impact of the Royalty-Backed Loan Agreement on the Company’s consolidated balance sheets for the years ended December 31, 2020 and December 31, 2019 (in thousands): Year Ended December 31, 2020 2019 Gross proceeds $ 32,500 $ 32,500 Unamortized debt discount costs (1,768 ) (1,880 ) Carrying Value $ 30,732 $ 30,620 Debt issuance costs are presented on the consolidated balance sheet as a direct deduction from the related debt liability rather than capitalized as an asset in accordance with ASU No. 2015-03, Interest - Imputation of Interest (Subtopic 835-30): Simplifying the Presentation of Debt Issuance Costs The Company recognized interest expense of $4.0 million and $2.7 million on the Royalty-Backed Loan for the years ended December 31, 2020 and 2019, respectively. Long-term debt on the Company’s consolidated balance sheets at December 31, 2020 includes the carrying value of the R-Bridge Loan Agreement, the Notes and the Royalty-Backed Loan Agreement. Long-term debt on the Company’s consolidated balance sheets at December 31, 2019 includes the carrying value of the A&R

Income Taxes

Income Taxes	12 Months Ended
	Dec. 31, 2020
Income Tax Disclosure [Abstract]
Income Taxes	17 . Income Taxes Loss before income taxes consists of the following: Year Ended December 31, (in thousands) 2020 2019 United States $ (96,541 ) $ (120,302 ) Foreign — (8,187 ) Total $ (96,541 ) $ (128,489 ) The components of income tax expense consist of the following: Year Ended December 31, (in thousands) 2020 2019 Foreign $ — $ 301 Total $ — $ 301 There is no provision for income taxes in the U.S. A reconciliation of the Company’s effective tax rate to the statutory federal income tax rate is as follows: Year Ended December 31, 2020 2019 Federal statutory rate 21.00 % 21.00 % Change in valuation allowance (14.95 ) (20.43 ) Non-deductible interest (1.91 ) (1.43 ) Stock compensation (2.72 ) (3.00 ) Permanent differences (1.20 ) (0.03 ) State taxes, net of federal benefits (0.86 ) 4.07 Withholding tax — (0.23 ) Foreign rate differential — (1.34 ) Federal R&D credits 0.64 1.06 Other — 0.10 0.00 % (0.23 )% Significant components of the Company’s net deferred tax assets at December 31, 2020 and 2019 are as follows: Year Ended December 31, (in thousands) 2020 2019 Non-current deferred tax assets Net operating losses $ 147,305 $ 125,341 Accrued expenses 2,480 2,869 Capitalized research and development 12,446 17,195 Tax credit carryforwards 13,968 13,413 Stock compensation and other 5,931 9,043 Total non-current deferred tax assets 182,130 167,861 Non-current deferred tax liabilities Right of use assets (486 ) (668 ) Total non-current deferred tax liabilities (486 ) (668 ) Net non-current deferred tax asset 181,644 167,193 Less: valuation allowance (181,644 ) (167,193 ) Net deferred tax asset $ — $ — As of December 31, 2020, the Company had federal and state net operating loss carryforwards of $574.7 million and $422.7 million, respectively, which begin to expire in 2024 and 2034, respectively. The Company's federal and state net operating losses include $294.9 million and $65.4 million, respectively, which can be carried forward indefinitely. As of December 31, 2020, the Company had federal and state research and development tax credits carryforwards of $12.4 million and $2.0 million, respectively, which begin to expire in 2020. Management of the Company has evaluated the positive and negative evidence bearing upon the realizability of its deferred tax assets, which are composed principally of net operating loss carryforwards and research and development credits. Under the applicable accounting standards, management has considered the Company's history of losses and concluded that it is more likely than not that the Company will not recognize the benefits of federal and state deferred tax assets. Accordingly, a full valuation allowance of $181.6 million and $167.2 million, respectively, was established as of December 31, 2020 and 2019. A change in the Company's valuation allowance was recorded in 2020, in the amount of $14.5 million due primarily to the generation of net operating losses. Utilization of the net operating loss and research and development credit carryforwards may be subject to a substantial annual limitation under Sections 382 and 383 of the Internal Revenue Code of 1986, as amended, due to ownership change limitations that have occurred previously or that could occur in the future. These ownership changes may limit the amount of net operating loss and research and development credit carryforwards that can be utilized annually to offset future taxable income and tax, respectively. The Company conducted an analysis under Section 382 and 383 of the Internal Revenue Code of 1986, as amended, to determine if historical changes in ownership through December 31, 2017 would limit or otherwise restrict its ability to utilize its net operating loss and research and development credit carryforwards. As a result of that study, the Company has identified certain net operating losses that might expire unused. The Company has established a full valuation allowance against these attributes. The Company follows the provisions of ASC 740-10, Accounting for Uncertainty in Income Taxes—an interpretation of ASC 740 , which requires it to determine whether a tax position of the Company is more likely than not to be sustained upon examination, including resolution of any related appeals of litigation processes, based on the technical merits of the position. For tax positions meeting the more likely than not threshold, the tax amount recognized in the financial statements is reduced by the largest benefit that has a greater than fifty percent likelihood of being realized upon the ultimate settlement with the relevant taxing authority. The Company completed a study of its research and development credits through December 31, 2017. As a result of this study the Company adjusted its deferred tax asset related to research and development credit carryforwards. The Company has not identified or recorded any uncertain tax positions related to this study. A full valuation allowance has been provided against the Company’s research and development credits, and if an adjustment is required, this adjustment would be offset by an adjustment to the valuation allowance. Thus, there would be no impact to the consolidated balance sheets or statements of operations if an adjustment were required. The Company files tax returns as prescribed by the tax laws of the jurisdictions in which it operates. In the normal course of business, the Company is subject to examination by federal and state jurisdictions, where applicable. The earliest tax years that remain subject to examination by jurisdiction is 2017 for both federal and Massachusetts. However, to the extent the Company utilizes net operating losses from years prior to 2017, the statute remains open to the extent of the net operating losses or other credits are utilized. The Company’s policy is to record interest and penalties related to income taxes as part of the tax provision. There was no interest or penalties pertaining to uncertain tax positions in 2020 or 2019.

Commitments and Contingencies

Commitments and Contingencies	12 Months Ended
	Dec. 31, 2020
Commitments And Contingencies Disclosure [Abstract]
Commitments and Contingencies	18 . Commitments and Contingencies Leases Boston, Massachusetts and King of Prussia, Pennsylvania The Company leases its Boston, Massachusetts and King of Prussia, Pennsylvania office spaces under non-cancelable operating leases expiring in August 2021 and 2024, respectively. The Company entered into the original King of Prussia and Boston leases in January 2015 and April 2015, respectively. The lease terms under the original agreements were for six and four years, respectively. Each agreement had one renewal option for an extended term. The King of Prussia and Boston lease terms under the original agreements began in June 2015 and July 2015, respectively. The Company executed an amended lease agreement on its Boston office space in July 2016. The amended lease agreement added 4,153 rentable square feet of office space and extended the original lease term by two years. In accordance with the amended lease agreement, the Company paid a security deposit of $0.1 million. Subsequent to the amended lease agreement, the Company records monthly lease expense of approximately $49,000 for the Boston office space. In applying the ASC 842 transition guidance, the Company retained the classification of this lease to be operating and recorded a lease liability and a right-of-use asset on the ASC 842 effective date. The Company executed an amended lease agreement on its King of Prussia office space in October 2016. The amended lease agreement is for 19,708 rentable square feet of office space and the Company took control of this office space during the first quarter of 2017 seven-year and seven-month CIPAN In November 2016, the Company entered into a manufacturing and services agreement, or MSA, with CIPAN – Companhia Industrial Produtora de Antibióticos, or CIPAN, which was later amended and restated in April of 2018, and further amended and restated in February 2019, December 2019, July 2020, and December 2020, collectively, the CIPAN Agreements. The CIPAN Agreements provide the terms and conditions under which CIPAN will manufacture and supply to the Company increased quantities of minocycline starting material and crude omadacycline, or the CIPAN Products, for purification into omadacycline and, subsequently, for use in the Company’s products that contain omadacycline tosylate as the active pharmaceutical ingredient. Additionally, the CIPAN Agreements included an investment by the Company in a new facility area to increase the manufacturing capacity for production of crude omadacycline. The Company was required to make advance payments to CIPAN upon completion of certain milestones within the CIPAN Agreements. The term of the CIPAN Agreements will continue throughout the term that the Company receives benefit from the new facility area. The Company may renew the CIPAN Agreements for additional periods and can terminate the CIPAN Agreements at any time by delivery, within a certain time period, of prior written notice to CIPAN. Following the first renewal term, CIPAN may terminate the MSA in its entirety by delivery, within a certain time period, of prior written notice to the Company. Under the CIPAN Agreements, the Company will purchase product in batches from CIPAN in quantities to be set forth on purchase orders submitted to CIPAN, within a certain time period, prior to the requested date of delivery. The Company will provide CIPAN with a rolling forecast with a best estimate of the quantities that will be ordered each month. The quantities of product forecasted for each forecast are binding obligations to purchase from CIPAN. execution of the CIPAN Agreements, the Company determined that the CIPAN Agreements contain an embedded lease because the Company has the right to direct the use of the facility and related equipment therein. Further, the Company determined that it did not control the facility or related equipment during construction and, thus, the lease did not fall in the scope of “build-to-suit” accounting. The lease commenced during the fourth quarter of 2020, the point at which the new facility area and the related equipment was available for use by the Company. Accordingly, during the year ended December 31, 2020, the Company recorded a right-of-use asset of $ For the year ended December 31, 2020, the Company recorded insignificant operating lease costs related CIPAN embedded lease. The operating lease costs of the embedded lease were included in inventories, net on the Company’s consolidated balance sheet. The following table contains a summary of the lease costs recognized under Topic 842 and other information pertaining to the Company’s operating leases for year ended December 31, 2020: Lease cost (in thousands) Operating lease cost $ 1,120 Variable lease cost 131 Total lease cost $ 1,251 Cash paid for amounts included in the measurement of lease liabilities: $ 1,178 Other information Weighted average remaining lease term (in years) 3.0 Weighted average discount rate 8.75 % Amounts above include an insignificant amount of lease costs associated with our CIPAN embedded lease arrangement for the year ended December 31, 2020, which have been capitalized into inventory as part of the cost of product being manufactured at the site. Future minimum operating lease obligations under non-cancelable operating leases with initial terms of more than one-year as of December 31 Maturity of lease liabilities (in thousands) 2021 $ 1,241 2022 508 2023 518 2024 and thereafter 396 Total lease payments $ 2,663 Less: imputed interest (292 ) Total operating lease liabilities $ 2,371 The total operating liability is presented on the Company’s consolidated balance sheet based on maturity dates. $0.8 million of the total operating liabilities is classified under “Other Current Liabilities” for the portion due within twelve months, and $1.5 million is classified under “Long-Term Lease Liability”. Commercial CIPAN In November 2016, the Company entered into a manufacturing and services agreement with CIPAN – Companhia Industrial Produtora de Antibióticos, or CIPAN. The agreement, as subsequently amended, provides the terms and conditions under which CIPAN will manufacture and supply to the Company increased quantities of minocycline starting material and crude omadacycline, or the CIPAN Products, for purification into omadacycline and, subsequently, for use in the Company’s products that contain omadacycline tosylate as the active pharmaceutical ingredient. Under this agreement, the Company is obligated to pay a CIPAN Product price in the four-digit U.S. dollar range per kilogram for minocycline starting material and in the four-digit or five-digit U.S. dollar range per kilogram for crude omadacycline, based on the annual volume of crude omadacycline that the Company orders, subject to adjustments as set forth in the agreement. In April 2018, the Company entered into an amended and restated manufacturing and services agreement with CIPAN, which included an investment by the Company in a new facility area to increase the manufacturing capacity for production of crude omadacycline. CIPAN will also perform certain services related to development, technology transfer and manufacturing of the CIPAN Products as provided in one or more statements of work, which shall set forth the fees payable by the Company to CIPAN for such services. The Company’s agreement with CIPAN will remain in effect for an initial term, as extended, after which the agreement will continue, with respect to each CIPAN Product, for successive renewal terms unless either the Company or CIPAN have given written notice of termination within a certain period prior to the expiration of either the initial or then-current renewal term. The agreement may also be terminated under certain other circumstances, including by either party due to a material uncured breach by the other party or the other party’s insolvency. Carbogen In December 2016, the Company entered into a manufacturing and services agreement with CARBOGEN AMCIS AG, or Carbogen. The agreement, as subsequently amended, provides for the terms and conditions under which Carbogen will manufacture and supply to the Company the active pharmaceutical ingredient for our omadacycline drug products in bulk quantities, or the Carbogen Product. Under this agreement, the Company is responsible for the cost and supply of crude omadacycline that Carbogen requires to manufacture the Carbogen Products and perform related services. The Company is obligated to pay Carbogen an amount in the seven-digit U.S. dollar range per campaign of Carbogen Product that the Company orders, depending on the number of batches in the campaign, and the price may be adjusted in accordance with the terms of the agreement. The Company may also request that Carbogen perform certain services related to the Carbogen Product, for which the Company will pay reasonable compensation to Carbogen. The Company’s agreement with Carbogen will remain in effect for a fixed initial term and subsequent renewal terms. Both parties, however, are required to use diligent efforts to replace the existing agreement with a subsequent long-term agreement. The Company may terminate this agreement by delivering notice of termination to Carbogen. The agreement may also be terminated under certain other circumstances, including by either party due to a material uncured breach by the other party or the other party’s insolvency. Almac In December 2016, the Company entered into a manufacturing and services agreement with Almac Pharma Services Limited, or Almac. The agreement, as subsequently amended, provides for the terms and conditions under which Almac will manufacture, package and supply to the Company omadacycline oral solid dosage tablets in bulk form, or the Almac Products. Under this agreement, the Company is required to use commercially reasonable efforts to timely provide Almac with the active pharmaceutical ingredient needed to manufacture the Almac Products and perform related services. The Company is obligated to pay a supply price in the five-digit range in Great Britain Pounds per batch of the Almac Products, subject to adjustments as provided in the agreement. The Company is also subject to an annual minimum revenue commitment in the six-digit GBP range. The Company will also negotiate with Almac, as part of each individual scope of work, the reasonable costs for the services to be performed for the Company by Almac. Each of the Company’s agreements with Almac will remain in effect for a fixed initial term, after which each agreement will continue for successive renewal terms unless either the Company or Almac have given written notice of termination within a certain period prior to the expiration of the initial or then-current renewal term. The manufacturing agreement may also be terminated under certain other circumstances, including by either party due to a material uncured breach of the other party or the other party’s insolvency. Patheon In July 2017, the Company entered into a master manufacturing services agreement and corresponding product agreement with Patheon UK Limited, or Patheon. The agreements, as subsequently amended, provide for the terms and conditions under which Patheon will manufacture, package and supply to the Company, omadacycline in injectable form, or the Patheon Products. Under these agreements, the Company is required to deliver to Patheon the active pharmaceutical ingredient needed to manufacture the Patheon Products. The Company is obligated to pay a supply price in the six-digit dollar range per batch of the Patheon Products, subject to adjustments as provided in the agreements. Now that the Company’s omadacycline product has been approved, the Company is also subject to an annual minimum purchase requirement in the six-digit U.S. dollar range. If the Company desires for Patheon to conduct additional services other than those expressly set forth in the agreements, those would be subject to additional fees. The Company’s agreements with Patheon will remain in effect for a fixed initial term, after which they will continue for successive renewal terms unless either the Company or Patheon have given written notice of termination within a certain period prior to the expiration of the applicable initial or then-current renewal term. The agreements may also be terminated under certain other circumstances, including by either party due to a material uncured breach of the other party or the other party’s insolvency. Litigation The following pending litigation was assumed through the Merger. Patent Term Adjustment Suit In January 2013, the Company filed suit in the Eastern District of Virginia against the U.S. Other Legal Proceedings From time to time the Company is involved in legal proceedings arising in the ordinary course of business. The Company believes there is no other litigation pending that could have, individually, or in the aggregate, a material adverse effect on its results of operations or financial condition. The Company does not believe that any of the above matters will result in a liability that is probable or estimable at December 31, 2020.

401(k) Savings Plan

401(k) Savings Plan	12 Months Ended
	Dec. 31, 2020
Compensation And Retirement Disclosure [Abstract]
401(k) Savings Plan	19 . 401(k) Savings Plan The Company maintains a defined-contribution savings plan under Section 401(k) of the Internal Revenue Code, or the 401(k) Plan. The 401(k) Plan covers all employees who meet defined minimum age and service requirements and allows participants to defer a portion of their annual compensation on a pretax basis. The Plan provides for matching contributions on a portion of participant contributions pursuant to the 401(k) Savings Plan’s matching formula. All matching contributions and participant contributions vest immediately. Contributions totaled $0.8 million and $0.9 million for the years ended December 31, 2020 and 2019, respectively and have been recorded in the consolidated statements of operations.

Quarterly Results (Unaudited)

Quarterly Results (Unaudited)	12 Months Ended
	Dec. 31, 2020
Quarterly Financial Information Disclosure [Abstract]
Quarterly Results (Unaudited)	20 . Quarterly Results (Unaudited) Three Months Ended March 31, 2020 June 30, 2020 September 30, 2020 December 31, 2020 (in thousands, except per share data) (unaudited) Revenue $ 7,920 $ 9,326 $ 13,659 $ 16,019 Operating expenses 31,498 27,772 29,606 33,552 Loss from operations (23,578 ) (18,446 ) (15,947 ) (17,533 ) Other expense, net (4,039 ) (4,613 ) (4,908 ) (7,477 ) Provision for income tax — — — — Net loss $ (27,617 ) $ (23,059 ) $ (20,855 ) $ (25,010 ) Net loss per share - basic and diluted $ (0.66 ) $ (0.53 ) $ (0.46 ) $ (0.54 ) Three Months Ended March 31, 2019 June 30, 2019 September 30, 2019 December 31, 2019 (in thousands, except per share data) (unaudited) Revenue $ 1,598 $ 2,045 $ 3,934 $ 8,967 Operating expenses 34,914 32,166 32,944 32,149 Loss from operations (33,316 ) (30,121 ) (29,010 ) (23,182 ) Other expense, net (2,294 ) (3,080 ) (3,604 ) (3,882 ) Provision for income tax — — — 301 Net loss $ (35,610 ) $ (33,201 ) $ (32,614 ) $ (27,365 ) Net loss per share - basic and diluted $ (1.10 ) $ (1.02 ) $ (1.00 ) $ (0.81 )

Summary of Significant Accoun_2

Summary of Significant Accounting Policies (Policies)	12 Months Ended
	Dec. 31, 2020
Accounting Policies [Abstract]
Basis of Presentation	Basis of Presentation The accompanying consolidated financial statements have been prepared in accordance with U.S. generally accepted accounting principles, or U.S. GAAP, as found in the Accounting Standards Codification, or ASC, and Accounting Standards Update, or ASU, of the Financial Accounting Standards Board, or FASB, and pursuant to the rules and regulations of the U.S. Securities and Exchange Commission, or the SEC. Beginning on January 1, 2020, purchase of prepaid interest - marketable securities, which totaled $0.2 million and was included as a line item in the December 31, 2019 consolidated statement of cash flows, has been reclassified into the accounts receivable, other receivables, prepaid, and other current assets line item to conform to the fiscal 2020 presentation.
Principles of Consolidation	Principles of Consolidation The accompanying audited consolidated financial statements include the results of operations of Paratek Pharmaceuticals, Inc. and its wholly-owned subsidiaries, Paratek Pharma, LLC, Paratek Securities Corporation, Transcept Pharma, Inc., Paratek UK Limited, Paratek Ireland Limited, Paratek Royalty Corporation, Paratek Royalty Corporation II, PRTK SPV1 LLC and PRTK SPV2 LLC. All significant intercompany accounts and transactions have been eliminated in consolidation.
Use of Estimates	Use of Estimates The preparation of consolidated financial statements in conformity with U.S. GAAP requires management of the Company to make certain estimates and assumptions that affect the reported amounts of assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. These estimates are based on management’s best knowledge of current events and actions the Company may undertake in the future. Management considers many factors in selecting appropriate financial accounting policies and controls, and in developing the estimates and assumptions that are used in the preparation of these financial statements. Management must apply significant judgment in this process. In addition, other factors may affect estimates, including expected business and operational changes, sensitivity and volatility associated with the assumptions used in developing estimates, and whether historical trends are expected to be representative of future trends. The estimation process often may yield a range of potentially reasonable estimates of the ultimate future outcomes and management must select an amount that falls within that range of reasonable estimates. This process may result in actual results differing materially from those estimated amounts used in the preparation of the financial statements. Estimates are used in accounting for, among other items, accounts receivable and related reserves, inventory and related reserves, goodwill, net product revenue, government contract service revenue, government contract grant revenue, collaboration and royalty revenue, leases, stock-based compensation arrangements, manufacturing and clinical accruals, useful lives for depreciation and valuation allowances on deferred tax assets. Actual results could differ from those estimates. The Company evaluates its estimates on an ongoing basis. Changes in estimates are reflected in reported results in the period in which they become known by the Company’s management.
Cash and Cash Equivalents and Marketable Securities	Cash and Cash Equivalents and Marketable Securities The Company considers all highly liquid investments purchased with original maturities of 90 days or less at acquisition to be cash equivalents. Cash and cash equivalents include cash held in banks and amounts held primarily in interest-bearing money market accounts. Cash equivalents are carried at cost, which approximates their fair market value. The Company determines the appropriate classification of marketable securities at the time of purchase and reevaluates such designation at each balance sheet date. The Company classified all of its marketable securities at December 31, 2020 as “available-for-sale” pursuant to ASC 320, Investments – Debt and Equity Securities. The Company reviews marketable securities for other-than-temporary impairment whenever the fair value of a marketable security is less than the amortized cost and evidence indicates that a marketable security’s carrying amount is not recoverable within a reasonable period of time. Other-than-temporary impairments of investments are recognized in the consolidated statements of operations and comprehensive loss if the Company has experienced a credit loss, has the intent to sell the marketable security, or if it is more likely than not that the Company will be required to sell the marketable security before recovery of the amortized cost basis. Evidence considered in this assessment includes reasons for the impairment, compliance with the Company’s investment policy, the severity and duration of the impairment and changes in value subsequent to the end of the period. There were no other-than-temporary impairments of investments recognized for the years ended December 31, 2020 and 2019.
Fair Value of Financial Instruments	Fair Value of Financial Instruments The Company is required to disclose information on all assets and liabilities reported at fair value that enables an assessment of the inputs used in determining the reported fair values. FASB ASC 820, Fair Value Measurements and Disclosures Level 1—Valuations based on unadjusted quoted prices in active markets for identical assets or liabilities that the Company has the ability to access at the measurement date. Level 2—Valuations based on quoted prices for similar assets or liabilities in markets that are not active or for which all significant inputs are observable, either directly or indirectly. Level 3—Valuations that require inputs that reflect the Company’s own assumptions that are both significant to the fair value measurement and unobservable. To the extent that valuation is based on models or inputs that are less observable or unobservable in the market, the determination of fair value requires more judgment. Accordingly, the degree of judgment exercised by the Company in determining fair value is greatest for instruments categorized in Level 3. A financial instrument’s level within the fair value hierarchy is based on the lowest level of any input that is significant to the fair value measurement.
Restricted Cash	Restricted Cash Cash accounts with any type of restriction are classified as restricted cash. If restrictions are expected to be lifted or to be used to pay a third party in the next twelve months, the restricted cash account is classified as current.
Accounts Receivable, Net	Accounts Receivable, Net Accounts receivable as of December 31, 2020 is primarily comprised of trade accounts receivable of $10.1 million due from customers for sales of NUZYRA, net of prompt payment discounts, chargebacks, rebates and certain fees. The balance of accounts receivable as of December 31, 2020 incudes $0.6 million of government contract service revenue earned under the BARDA contract, $0.6 million of government contract grant revenue earned under the BARDA contract, and $0.5 million in estimated revenue from royalties earned on U.S. sales of SEYSARA under the Almirall Collaboration Agreement and U.S. sales of XERAVA under the Tetraphase License Agreement Government Contract Revenue License and Collaboration Agreements
Concentration of Credit Risk	Concentration of Credit Risk Financial instruments that subject the Company to credit risk consist primarily of cash, restricted cash, and accounts receivable. The Company places its cash in an accredited financial institution and this balance is above federally insured amounts. The Company has no off-balance sheet concentrations of credit risk such as foreign currency exchange contracts, option contracts or other hedging arrangements.
Fixed Assets	Fixed Assets Fixed assets, including leasehold improvements, are recorded at cost and depreciated when placed into service using the straight-line method, based on their estimated useful lives as follows: Estimated Useful Life In Years Laboratory equipment 5 Office equipment 5 Machinery and equipment 5 Computer equipment 3 Computer software 3 In addition, leasehold improvements are depreciated over the shorter of their estimated useful lives or the term of the respective lease on a straight-line basis. Costs for capital assets not yet placed into service have been capitalized as construction-in-progress and will be depreciated in accordance with the above guidelines once placed into service. The Company reviews its long-lived assets for impairment whenever events or changes in business circumstances indicate that the carrying amount of assets may not be fully recoverable or that the useful lives of these assets are no longer appropriate. Each impairment test is based on a comparison of the undiscounted cash flow to the recorded value of the asset. If impairment is indicated, the asset will be written down to its estimated fair value on a discounted cash flow basis. Upon sale or retirement, the asset cost and related accumulated depreciation are removed from the respective accounts, and any related gain or loss is reflected in results of operations. Repair and maintenance costs are expensed as incurred.
Inventory	Inventory Inventories are stated at the lower of cost or estimated net realizable value, on a first-in, first-out basis. Prior to the regulatory approval of its product candidates, the Company incurs expenses for the manufacture of drug product that could potentially be available to support the commercial launch of its products. Until the first reporting period when regulatory approval has been received or is otherwise considered probable, the Company records all such costs as research and development expense. Inventory used in clinical trials is also expensed as research and development expense, when selected for such use. The Company classifies inventory costs as long-term when the Company expects to utilize the inventory beyond its normal operating cycle. The Company performs an assessment of the recoverability of capitalized inventory during each reporting period and writes down any excess and obsolete inventory to its net realizable value in the period in which the impairment is first identified. Such impairment charges, should they occur, are recorded as a component of cost of product sales in the consolidated statements of operations and comprehensive loss. The determination of whether inventory costs will be realizable requires the use of estimates by management. If actual market conditions are less favorable than projected by management, additional write-downs of inventory may be required.
Valuation of Goodwill	Valuation of Goodwill Goodwill is not amortized but is evaluated for impairment within the Company’s single reporting unit on an annual basis, during the fourth quarter, or more frequently if an event occurs or circumstances change that would more-likely-than-not reduce the fair value of the Company’s reporting unit below its carrying amount. As discussed below, on January 1, 2020, the Company adopted ASU No. 2017-04, Simplifying the Test for Goodwill Impairment , or ASU 2017-04, which eliminates the second step of the goodwill impairment test. Under this ASU 2017-04, the Company will now perform a one-step quantitative test and record the amount of goodwill impairment, if any, as the excess of a reporting unit's carrying amount over its fair value, not to exceed the total amount of goodwill allocated to the reporting unit. The Company did not record an impairment charge relating to goodwill for the years ended December 31, 2020 and 2019.
Accrued Expenses	Accrued Expenses The Company’s process of determining accrued expense for a financial period-end involves reviewing open contracts and purchase orders, communicating with personnel to identify services that have been performed for the Company and estimating the level of service performed and the associated cost incurred for the service when the Company has not yet been invoiced or otherwise notified of the actual cost. The majority of the Company’s service providers invoice periodically in arrears for services performed or when contractual milestones are met. The Company estimates accrued expenses at a financial period-end based on facts and circumstances known at that time and may periodically confirm the accuracy of estimates with its service providers and make adjustments if necessary.
Leases	Leases At the inception of an arrangement, the Company determines whether the arrangement is or contains a lease based on the unique facts and circumstances present in the arrangement including the use of a distinct identified asset(s) and the Company’s control over the use of that identified asset. Most leases are recognized on the balance sheet as right-of-use assets and lease liabilities, current and non-current, as applicable. The Company has elected not to recognize on the balance sheet leases with terms of 12 months or less. These lease costs will be expensed as incurred. The Company typically only includes an initial lease term in its assessment of a lease arrangement. Options to renew a lease are not included in the Company’s assessment unless there is reasonable certainty that the Company will renew. The Company monitors its plans to renew its material leases on a quarterly basis. Right-of-use assets and lease liabilities are recorded based on the present value of lease payments over the expected remaining lease term. Certain adjustments to the right-of-use asset may be required for items such as incentives received or initial direct costs. The interest rate implicit in lease contracts is typically not readily determinable. As a result, the Company utilizes its incremental borrowing rate, which reflects the fixed rate at which the Company could borrow on a collateralized basis the amount of the lease payments in the same currency, for a similar term, in a similar economic environment. In transition to ASU No. 2016-02, Leases In accordance with ASC 842, components of a lease should be split into three categories: lease components (e.g., land, building, etc.), non-lease components (e.g., common area maintenance, consumables, etc.), and non-components (e.g., property taxes, insurance, etc.). The fixed and in-substance fixed contract consideration (including any consideration related to non-components) must be allocated based on the respective relative fair values to the lease components and non-lease components. Although separation of lease and non-lease components is otherwise required, certain expedients are available. Entities may elect to not separate lease and non-lease components by class of underlying asset and account for each lease component and the related non-lease component together as a single component. For new and amended leases beginning in 2019 and after, the Company has elected to account for each lease component and related non-lease component as a single lease component and allocate all of the contract consideration to the lease component only. In contrast, the Company does not apply the practical expedient for embedded leases in manufacturing and supply agreements with certain of its contract manufacturing organizations and has instead allocated contract consideration between the lease and non-lease components based on their relative standalone price.
Revenue Recognition	Revenue Recognition Accounting Standards Codification, or ASC, Topic 606, Revenue from Contracts with Customers The Company enters into collaboration agreements for research, development, manufacturing and commercial services that are within the scope of ASC 606, under which it licenses certain rights to its product candidates to third parties. The terms of these arrangements typically include payment to the Company of one or more of the following: non-refundable, upfront license fees; reimbursement of certain costs; customer option exercise fees; development, regulatory and commercial milestone payments; and royalties on net sales of licensed products. The amount of variable consideration is constrained until it is probable that the revenue is not at a significant risk of reversal in a future period. The contracts into which the Company enters generally do not include significant financing components. As part of the accounting for these arrangements, the Company must use significant judgment to determine: (a) the transaction price under step (iii) above and (b) the timing of revenue recognition, including the appropriate measure of progress, in step (v) above. The Company uses judgment to determine whether milestones or other variable consideration, except for royalties, should be included in the transaction price, as described further below. The transaction price is allocated to each performance obligation on a relative stand-alone selling price basis, for which the Company recognizes revenue as or when the performance obligations under the contract are satisfied. If a milestone or other variable consideration relates specifically to the Company’s efforts to satisfy a single performance obligation or to a specific outcome from satisfying the performance obligation, the Company generally allocates the milestone amount entirely to that performance obligation once it is probable that a significant revenue reversal would not occur. Amounts received prior to revenue recognition are recorded as deferred revenue. Amounts expected to be recognized as revenue within the 12 months following the balance sheet date are classified as current portion of deferred revenue in the accompanying consolidated balance sheets. Amounts not expected to be recognized as revenue within the 12 months following the balance sheet date are classified as deferred revenue, net of current portion. Licenses of intellectual property In assessing whether a license is distinct from the other promises, the Company considers factors such as the research, development, manufacturing and commercialization capabilities of the collaboration partner and the availability of the associated expertise in the general marketplace. In addition, the Company considers whether the collaboration partner can benefit from a license for its intended purpose without the receipt of the remaining promise(s), whether the value of the license is dependent on the unsatisfied promise(s), whether there are other vendors that could provide the remaining promise(s), and whether it is separately identifiable from the remaining promise(s). For licenses that are combined with other promises, the Company utilizes judgment to assess the nature of the combined performance obligation to determine whether the combined performance obligation is satisfied over time or at a point in time and, if over time, the appropriate method of measuring progress for purposes of recognizing revenue. The Company evaluates the measure of progress each reporting period and, if necessary, adjusts the measure of performance and related revenue recognition. Customer options If an arrangement is determined to contain customer options that allow the customer to acquire additional goods or services, the goods and services underlying the customer options are not considered to be performance obligations at the outset of the arrangement, as they are contingent upon option exercise. The Company evaluates the customer options for material rights, or options to acquire additional goods or services for free or at a discount. If the customer options are determined to represent or include a material right, the material right is recognized as a separate performance obligation at the outset of the arrangement. The Company allocates the transaction price to material rights based on the relative standalone selling price, which is determined based on the identified discount and the probability that the customer will exercise. Amounts allocated to a material right are not recognized as revenue until, at the earliest, the option is exercised. Milestone payments At the inception of each arrangement that includes milestone payments, the Company evaluates whether the milestones are considered probable of being achieved and estimates the amount to be included in the transaction price using the most likely amount method. If it is probable that a significant reversal of cumulative revenue would not occur, the associated milestone value is included in the transaction price. Milestone payments that are not within the control of the Company or the licensee, such as regulatory approvals, are not considered probable of being achieved until those approvals are received. The Company evaluates factors such as the scientific, clinical, regulatory, commercial, and other risks that must be overcome to achieve the particular milestone in making this assessment. There is considerable judgment involved in determining whether it is probable that a significant reversal of cumulative revenue would not occur. At the end of each subsequent reporting period, the Company reevaluates the probability of achievement of all milestones subject to constraint and, if necessary, adjusts its estimate of the overall transaction price. Any such adjustments are recorded on a cumulative catch-up basis, which would affect revenues and earnings in the period of adjustment. Royalties For arrangements that include sales-based royalties, including milestone payments based on a level of sales, and the license is deemed to be the predominant item to which the royalties relate, the Company recognizes revenue at the later of (i) when the related sales occur, or (ii) when the performance obligation to which some or all the royalty has been allocated is satisfied (or partially satisfied). Contract costs The Company recognizes as an asset the incremental costs of obtaining a contract with a customer if the costs are expected to be recovered. As a practical expedient, the Company recognizes the incremental costs of obtaining a contract as an expense when incurred if the amortization period of the asset that the Company otherwise would have recognized is one year or less. To date, the Company has not incurred any incremental costs of obtaining a contract with a customer. The Company sells its product principally to a limited number of specialty distributors and specialty pharmacy providers in the U.S Revenues from product sales are recognized when the customer obtains control of the Company’s product, which typically occurs once the Company has transferred physical possession of the good to the customer. The transaction price that the Company recognizes as revenue reflects the amount it expects to be entitled to in connection with the sale and transfer of control of product to its customers. Variable consideration is only included in the transaction price to the extent that it is probable that a significant reversal in the amount of cumulative revenue recognized will not occur when the uncertainty associated with the variable consideration is subsequently resolved. At the time that the Company’s customers take control of the product, which is when the Company’s performance obligation under the sales contracts is complete, the Company records product revenues net of applicable reserves for various types of variable consideration based on the Company’s estimates of channel mix. The types of variable consideration in our product revenue are as follows: • Trade discounts and allowances • Product returns • Chargebacks and rebates • Government rebates • Commercial payer and other rebates • Voluntary patient assistance programs In determining the amounts of certain allowances and accruals, the Company must make significant judgments and estimates. For example, in determining these amounts, the Company estimates prescription demand from the specialty pharmacies, hospital demand, buying patterns by hospitals, hospital systems and/or group purchasing organizations and the levels of inventory held by specialty distributors and customers. Making these determinations involves analyzing third-party industry data to determine whether trends in historical channel distribution patterns will predict future product sales. The Company receives data periodically from its specialty distributors and customers on inventory levels and historical channel sales mix, and the Company considers this data when determining the amount of the allowances and accruals for variable consideration. The amount of variable consideration is estimated by using either of the following methods, depending on which method better predicts the amount of consideration to which the Company is entitled: a) The “expected value” is the sum of probability-weighted amounts in a range of possible consideration amounts. Under ASC 606, an expected value may be an appropriate estimate of the amount of variable consideration if the Company has many contracts with similar characteristics. b) The “most likely amount” is the single most likely amount in a range of possible consideration amounts (i.e., the single most likely outcome of the contract). Under ASC 606, the most likely amount may be an appropriate estimate of the amount of variable consideration if the contract has only two possible outcomes (i.e., either achieve or do not achieve a threshold specified in a contract). The method selected is applied consistently throughout the contract when estimating the effect of an uncertainty on an amount of variable consideration. In addition, the Company considers all the information (historical, current, and forecasted) that is reasonably available to the Company and shall identify a reasonable number of possible consideration amounts. The relevant factors used in this determination include, but are not limited to, current contractual and statutory requirements, specific known market events and trends, industry data, and forecasted customer buying and payment patterns. In assessing whether a constraint is necessary, the Company considers both the likelihood and the magnitude of the revenue reversal. Actual amounts of consideration ultimately received may differ from the Company’s estimates. If actual results in the future vary from the Company’s estimates, the Company adjusts these estimates, which would affect net product revenue and earnings in the period such variances become known. The specific considerations the Company uses in estimating these amounts related to variable consideration associated with the Company’s products are as follows: Trade Discounts and Allowances Product Returns At the end of each reporting period for any of our products, the Company may decide to constrain revenue for product returns based on information from various sources, including channel inventory levels and dating and sell-through data, the expiration dates of product currently being shipped, price changes of competitive products and introductions of generic products. Chargebacks U.S. Government Rebates – The Company is subject to discount obligations under state Medicaid programs and Medicare. The Company estimates our Medicaid and Medicare rebates based upon a range of possible outcomes that are probability-weighted for the estimated payer mix. These reserves are recorded in the same period the related product revenue is recognized, resulting in a reduction of product revenue and the establishment of a current liability that is included in accrued expenses on the consolidated balance sheet. For Medicare, the Company also estimate s the number of patients in the prescription drug coverage gap for whom it will owe an additional liability under the Medicare Part D program. The Company’s liability for these rebates consists of an estimate of claims for the current quarter and estimated future claims that will be made for product sales that have been recognized as revenue but remain in distribution channel inventory at period end. Commercial Payer and Other Rebates Patient Assistance At the end of each reporting period, the Company adjusts its allowances for cash discounts, product returns, chargebacks, and other rebates and discounts when the Company believes actual experience may differ from current estimates.
Revenue Earned Under Government Contracts	Revenue Earned Under Government Contracts If the Company concludes that some or all aspects of its government contracts represent a transaction with a customer to obtain services or goods that are an output of its ordinary activities in exchange for consideration, it accounts for those aspects of the arrangement in accordance with ASC 606. Arrangements that are entirely in the scope of other guidance are accounted for under that guidance. The Company recognizes sales of NUZYRA under its government contracts as product revenue when control of NUZYRA is transferred, in accordance with ASC 606. It also recognizes government contract service revenue and government contract grant revenue as defined below.
Government Contract Service Revenue	Government Contract Service Revenue Government contract service revenue is recognized as services are performed. Revenue and related reimbursable expenses are presented on a gross basis in the Company’s consolidated statements of operations. The related reimbursable expenses are expensed as incurred as research and development expense.
Government Contract Grant Revenue	Government Contract Grant Revenue The allocated consideration of government contract grant revenue is recognized as the related reimbursable expenses are incurred. The cost reimbursements that are reported as revenue is presented gross of the related reimbursable expenses in the Company’s consolidated statements of operations. The related reimbursable expenses are expensed as incurred as research and development expense.
Cost of Product Revenue	Cost of Product Revenue Cost of product revenue consists primarily of the manufacturing costs for NUZYRA and royalties owed on net sales of NUZYRA. All manufacturing costs incurred prior to NUZYRA’s approval in the U.S.
Research and Development Expenses	Research and Development Expenses Research and development expenses are charged to expense as incurred. Research and development expenses consist of the costs incurred in performing research and development activities, including personnel-related costs, stock-based compensation, facilities, research-related overhead, clinical trial costs, contracted services, manufacturing, license fees and other external costs. Research and development expenses also include gross reimbursable costs incurred through research and development services performed for the treatment of pulmonary anthrax, services performed for U.S. manufacturing onshoring and security requirements, and services performed for FDA PMRs under the BARDA contract. The Company accounts for nonrefundable advance payments for goods and services that will be used in future research and development activities as expenses when the service has been performed or when the goods have been received rather than when the payment is made.
Income Taxes	Income Taxes The Company accounts for income taxes under the asset and liability method, which requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of events that have been included in the financial statements. Under this method, the Company determines deferred tax assets and liabilities on the basis of the differences between the financial statement and tax bases of assets and liabilities by using enacted tax rates in effect for the year in which the differences are expected to reverse. The effect of a change in tax rates on deferred tax assets and liabilities is recognized in income in the period that includes the enactment date. The Company recognizes deferred tax assets to the extent that the Company believes that these assets are more likely than not to be realized. In making such a determination, the Company considers all available positive and negative evidence, including future reversals of existing taxable temporary differences, projected future taxable income, tax-planning strategies, and results of recent operations. If the Company determines that the Company would be able to realize our deferred tax assets in the future in excess of their net recorded amount, the Company would make an adjustment to the deferred tax asset valuation allowance, which would reduce the provision for income taxes. The Company records uncertain tax positions in accordance with ASC 740, Income Taxes The Company recognizes interest and penalties related to unrecognized tax benefits on the income tax expense line in the accompanying consolidated statement of operations. The Company has not recorded interest and penalties
Stock-Based Compensation	Stock-Based Compensation The Company accounts for its stock-based awards in accordance with ASC 718, Compensation—Stock Compensation The measurement date for non-employee awards is the later of the adoption date of ASU No. 2018-07, “ Compensation—Stock Compensation (Topic 718): Improvements to Nonemployee Share-Based Payment Accounting ”, or ASU No. 2018-07 , or the date of grant, without changes in the fair value of the award. Stock-based compensation costs for non-employees are recognized as expense over the vesting period on a straight-line basis. The Company estimates the fair value of its stock-based awards to employees and non-employees using the Black-Scholes option pricing model, which requires the input of assumptions, including (1) the expected volatility of stock, (2) the expected term of the award, (3) the risk-free interest rate and (4) expected dividends. The Company has estimated the expected volatility by comping its historical volatility data, using the daily closing price during the equivalent period as the calculated expected life, of its stock-based awards. The Company has estimated the expected life of its employee stock options as the average of the midpoints between vesting exercise date for each vesting-tranche and the contractual term of the options as the last available exercise date of the option. The risk-free interest rates for periods within the expected life of the option are based on the U.S. Treasury yield curve in effect during the period the options were granted.
Comprehensive Income (Loss)	Comprehensive Income (Loss) Comprehensive income (loss) is defined as the change in non-owner sources of equity of a business enterprise during a period from transactions, other events and circumstances and currently consists of net loss and changes in unrealized gains and losses on available-for-sale securities.
Segment and Geographic Information	Segment and Geographic Information Operating segments are defined as components of an enterprise engaging in business activities for which discrete financial information is available and regularly reviewed by the chief operating decision maker in deciding how to allocate resources and in assessing performance. The Company views its operations and manages its business in one operating segment, and the Company operates in only one geographic segment.
Subsequent Events	Subsequent Events The Company considers events or transactions that occur after the balance sheet date, but prior to the issuance of the financial statements to provide additional evidence relative to certain estimates or to identify matters that require additional disclosure. Refer to the Notes below for further details on subsequent events.
Recent Accounting Pronouncements	Recent Accounting Pronouncements From time to time, new accounting pronouncements are issued by the FASB or other standard setting bodies and adopted by the Company as of the specified effective date. Unless otherwise discussed, the Company believes that the impact of recently issued standards that are not yet effective will not have a material impact on its financial position or results of operations upon adoption. In January 2017, the FASB issued ASU No. 2017-04, Simplifying the Test for Goodwill Impairment In August 2018 the FASB issued ASU No. 2018-13, Fair Value Measurement (Topic 820): Disclosure Framework - Changes to the Disclosure Requirements for Fair Value Measurement In June 2016 the FASB issued ASU No. 2016-13, Financial Instruments - Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments . The FASB subsequently issued amendments to ASU 2016-13, which have the same effective date and transition date of January 1, 2023 . These standards require that credit losses be reported using an expected losses model rather than the incurred losses model that is currently used, and establishes additional disclosures related to credit risks. For available-for-sale debt securities with unrealized losses, these standards now require allowances to be recorded instead of reducing the amortized cost of the investment. These standards limit the amount of credit losses to be recognized for available-for-sale debt securities to the amount by which carrying value exceeds fair value and requires the reversal of previously recognized credit losses if fair value increases. Based on the composition of our investment portfolio, accounts receivable and other financial assets, current market conditions and historical credit loss activity, the adoption of this guidance is not expected to have a material effect on the Company’s consolidated balance sheet, consolidated statements of operation and comprehensive loss and related disclosures.

Summary of Significant Accoun_3

Summary of Significant Accounting Policies (Tables)	12 Months Ended
	Dec. 31, 2020
Accounting Policies [Abstract]
Schedule of Estimated Useful Lives of Fixed Assets	Fixed assets, including leasehold improvements, are recorded at cost and depreciated when placed into service using the straight-line method, based on their estimated useful lives as follows: Estimated Useful Life In Years Laboratory equipment 5 Office equipment 5 Machinery and equipment 5 Computer equipment 3 Computer software 3

Product Revenue (Tables)

Product Revenue (Tables)	12 Months Ended
	Dec. 31, 2020
Revenue From Contract With Customer [Abstract]
Schedule of Product Revenue Allowance and Reserve Categories	The following table summarizes balances and activity in each of the product revenue allowance and reserve categories (in thousands): Chargebacks, discounts and fees Government and other rebates Returns Patient assistance Total Balance at December 31, 2018 $ — $ — $ — $ — $ — Provision related to current period sales 926 1,424 369 174 2,893 Adjustment related to prior period sales — — — — — Credit or payments made during the period (627 ) (729 ) — (45 ) (1,401 ) Balance at December 31, 2019 $ 299 $ 695 $ 369 $ 129 $ 1,492 Provision related to current period sales 3,160 6,091 337 371 9,959 Adjustment related to prior period sales (8 ) 19 — — 11 Credit or payments made during the period (2,824 ) (4,603 ) (320 ) (286 ) (8,033 ) Balance at December 31, 2020 $ 627 $ 2,202 $ 386 $ 214 $ 3,429

Net Loss Per Share (Tables)

Net Loss Per Share (Tables)	12 Months Ended
	Dec. 31, 2020
Earnings Per Share [Abstract]
Antidilutive Shares Excluded from Computation of Diluted Net Income (Loss) Per Share	The following outstanding shares subject to stock options and restricted stock units, warrants to purchase shares of common stock, common stock issuable upon conversion of convertible debt and shares issuable under the employee stock purchase plan were antidilutive due to a net loss in the periods presented and, therefore, were excluded from the dilutive securities computation for the years ended December 31, 2020 and 2019 as indicated below: Year Ended December 31, 2020 2019 Excluded potentially dilutive securities (1) Common stock issuable under outstanding convertible notes 10,377,361 10,377,361 Shares subject to outstanding options to purchase common stock 1,986,442 3,236,073 Unvested restricted stock units 3,393,425 2,305,408 Shares subject to warrants to purchase common stock 479,002 104,455 Shares issuable under employee stock purchase plan 606,816 798,187 Totals 16,843,046 16,821,484 (1) The number of shares is based on the maximum number of shares issuable on exercise or conversion of the related securities as of the year end. Such amounts have not been adjusted for the treasury-stock method or weighted-average outstanding calculations as required if the securities were dilutive.

Cash and Cash Equivalents and_2

Cash and Cash Equivalents and Restricted Cash (Tables)	12 Months Ended
	Dec. 31, 2020
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents [Abstract]
Summary of Reconciliation of Cash, Cash Equivalents, and Restricted Cash Reported Within Consolidated Statement of Cash Flows	The following table provides a reconciliation of cash, cash equivalents, and restricted cash reported within the consolidated statement of cash flows that sum to the total of the same such amounts shown in the consolidated statement of cash flows (in thousands): December 31, 2020 2019 Cash and cash equivalents $ 105,157 $ 102,302 Short-term restricted cash 891 324 Long-term restricted cash — 3,007 Total cash, cash equivalents and restricted cash shown on the consolidated statement of cash flows $ 106,048 $ 105,633

Marketable Securities (Tables)

Marketable Securities (Tables)	12 Months Ended
	Dec. 31, 2020
Marketable Securities [Abstract]
Summary of Available for Sale Securities	The following is a summary of available-for-sale securities as of December 31, 2020 and 2019 (in thousands): Amortized Cost Unrealized Gains Unrealized Losses Fair Value December 31, 2020 U.S. treasury securities $ 20,001 $ 4 $ — $ 20,005 Total $ 20,001 $ 4 $ $ 20,005 December 31, 2019 U.S. treasury securities $ 113,003 $ 89 $ (15 ) $ 113,077 Total $ 113,003 $ 89 $ (15 ) $ 113,077

Fixed Assets, Net (Tables)

Fixed Assets, Net (Tables)	12 Months Ended
	Dec. 31, 2020
Property Plant And Equipment [Abstract]
Schedule of Fixed Assets	Fixed assets consist of the following (in thousands): Estimated December 31, In Years 2020 2019 Office equipment 5 $ 866 $ 866 Machinery and equipment 5 567 567 Computer equipment 3 412 412 Computer software 3 798 798 Leasehold improvements 920 920 Construction in progress 188 — Gross fixed assets 3,751 3,563 Less: Accumulated depreciation and amortization (2,787 ) (2,336 ) Net fixed assets $ 964 $ 1,227

Inventories, Net (Tables)

Inventories, Net (Tables)	12 Months Ended
	Dec. 31, 2020
Inventory Disclosure [Abstract]
Schedule of Inventories	The following table presents inventories (in thousands): December 31, 2020 2019 Raw materials $ 720 $ — Work in process 12,925 9,330 Finished goods 9,638 2,249 Total inventories $ 23,283 $ 11,579
Schedule of Balance Sheet Classification of Inventory	Long-term inventory, which consists of raw materials and work in process, is included in other long-term assets in the Company’s consolidated balance sheets. December 31, 2020 2019 Balance Sheet Classification: Inventories, net $ 14,555 $ 11,579 Other long-term assets 8,728 — Total inventories $ 23,283 $ 11,579

Accrued Expenses (Tables)

Accrued Expenses (Tables)	12 Months Ended
	Dec. 31, 2020
Payables And Accruals [Abstract]
Schedule of Accrued Expenses	Accrued expenses consist of the following (in thousands): December 31, 2020 2019 Accrued compensation $ 7,783 $ 7,580 Accrued sales allowances 3,429 1,492 Accrued commercial 2,254 1,445 Accrued inventory 2,023 125 Accrued interest 1,768 2,264 Accrued professional fees 1,209 876 Accrued manufacturing 972 1,026 Accrued contract research 591 1,612 Accrued legal costs 580 181 Accrued other 217 95 Total $ 20,826 $ 16,696

Fair Value Measurements (Tables

Fair Value Measurements (Tables)	12 Months Ended
	Dec. 31, 2020
Fair Value Disclosures [Abstract]
Schedule of Financial Assets and Liabilities Measured at Fair Value	The following tables present information about the Company’s financial assets and liabilities that have been measured at fair value as of December 31, 2020 and December 31, 2019 and indicate the fair value hierarchy of the valuation inputs utilized to determine such fair value. In general, fair values determined by Level 1 inputs utilize quoted prices (unadjusted) in active markets for identical assets or liabilities (in thousands): Description Quoted Prices in Active Markets (Level 1) Significant Other Observable Inputs (Level 2) Significant Unobservable Inputs (Level 3) December 31, 2020 Assets: U.S. treasury securities $ 20,005 $ — $ — $ 20,005 Total Assets $ 20,005 $ — $ — $ 20,005 Description Quoted Prices in Active Markets (Level 1) Significant Other Observable Inputs (Level 2) Significant Unobservable Inputs (Level 3) December 31, 2019 Assets: U.S. treasury securities $ 113,077 $ — $ — $ 113,077 Total Assets $ 113,077 $ — $ — $ 113,077

Stock-Based and Incentive Com_2

Stock-Based and Incentive Compensation (Tables)	12 Months Ended
	Dec. 31, 2020
Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]
Schedule of Share-based Compensation, Stock Options, Activity	A summary of stock option activity and related information through December 31, 2020 follows: Number of Shares Weighted Average Exercise Price Weighted– Average Remaining Contractual Term (in Years) Aggregate Intrinsic Value (in thousands) Outstanding Balances at December 31, 2019 3,236,073 $ 15.54 6.30 $ 90 Granted 147,950 4.37 Exercised (39,479 ) 4.30 Cancelled or forfeited (1,213,102 ) 19.83 Expired (145,000 ) 20.85 Balances at December 31, 2020 1,986,442 $ 11.92 5.63 $ 1,748 Exercisable December 31, 2020 1,717,030 $ 12.61 5.19 $ 1,356
Schedule of Share-based Compensation, Restricted Stock Unit, Activity	The following is a summary of restricted stock unit activity for the year ended December 31, 2020: Number of Shares Weighted Average Grant Date Fair Value per Share Unvested balance at December 31, 2019 2,305,408 $ 7.66 Granted 2,587,550 3.56 Released (1,281,968 ) 7.96 Forfeited (217,565 ) 7.90 Unvested balance at December 31, 2020 3,393,425 $ 4.41
Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions	The relevant data used to determine the value of the stock option grants is as follows: Year Ended December 31, 2020 2019 Volatility 63.1 % 63.4 % Weighted average risk-free interest rate 0.9 % 2.0 % Expected dividend yield 0.0 % 0.0 % Expected life of options (in years) 5.7 5.9
Summary of Stock-Based Compensation Expense Included in Company's Consolidated Statements of Operations	The following table presents stock-based compensation expense included in the Company’s consolidated statements of operations (in thousands): Year Ended December 31, 2020 2019 Research and development expense $ 2,130 $ 3,568 Selling, general and administrative expense 8,118 10,727 Total stock-based compensation expense $ 10,248 $ 14,295
Schedule of Share-based Compensation, Common Stock, Shares Reserved for Future Issuance	At December 31, 2020, the Company has reserved shares of common stock for future issuance as follows: Number of Shares Equity plans: Shares subject to outstanding options and unvested restricted stock units 5,379,867 Shares available for future grants 2,074,625 Shares subject to warrants to purchase common stock 479,002 Shares issuable under employee stock purchase plan 606,816 Common stock issuable under outstanding convertible notes 10,377,361 Total 18,917,671

Long-Term Debt (Tables)

Long-Term Debt (Tables)	12 Months Ended
	Dec. 31, 2020
4.75% Convertible Senior Subordinated Notes due 2024 [Member]
Summary of Debt	The following table summarizes how the issuance of the Notes is reflected in the Company’s consolidated balance sheets at December 31, 2020 and 2019 (in thousands): Year Ended December 31, 2020 2019 Gross proceeds $ 165,000 $ 165,000 Unamortized debt discount costs (3,578 ) (4,531 ) Carrying Value $ 161,422 $ 160,469
Hercules Term Loan [Member]
Summary of Debt	The following table summarizes the impact of the A&R Gross proceeds $ 70,000 Unamortized debt discount costs (361 ) Carrying Value $ 69,639
R-Bridge Loan Agreement [Member]
Summary of Debt	The following table summarizes the impact of the R-Bridge Loan Agreement on the Company’s consolidated balance sheets at December 31, 2020 (in thousands): Gross proceeds $ 60,000 Unamortized debt discount and issuance costs (1,680 ) Carrying Value $ 58,320
Royalty Backed Loan Agreement [Member]
Summary of Debt	The following table summarizes the impact of the Royalty-Backed Loan Agreement on the Company’s consolidated balance sheets for the years ended December 31, 2020 and December 31, 2019 (in thousands): Year Ended December 31, 2020 2019 Gross proceeds $ 32,500 $ 32,500 Unamortized debt discount costs (1,768 ) (1,880 ) Carrying Value $ 30,732 $ 30,620

Income Taxes (Tables)

Income Taxes (Tables)	12 Months Ended
	Dec. 31, 2020
Income Tax Disclosure [Abstract]
Schedule of Loss before Income Taxes	Loss before income taxes consists of the following: Year Ended December 31, (in thousands) 2020 2019 United States $ (96,541 ) $ (120,302 ) Foreign — (8,187 ) Total $ (96,541 ) $ (128,489 )
Schedule of Components of Income Tax Expense	The components of income tax expense consist of the following: Year Ended December 31, (in thousands) 2020 2019 Foreign $ — $ 301 Total $ — $ 301
Schedule of Effective Income Tax Rate Reconciliation	A reconciliation of the Company’s effective tax rate to the statutory federal income tax rate is as follows: Year Ended December 31, 2020 2019 Federal statutory rate 21.00 % 21.00 % Change in valuation allowance (14.95 ) (20.43 ) Non-deductible interest (1.91 ) (1.43 ) Stock compensation (2.72 ) (3.00 ) Permanent differences (1.20 ) (0.03 ) State taxes, net of federal benefits (0.86 ) 4.07 Withholding tax — (0.23 ) Foreign rate differential — (1.34 ) Federal R&D credits 0.64 1.06 Other — 0.10 0.00 % (0.23 )%
Schedule of Deferred Tax Assets and Liabilities	Significant components of the Company’s net deferred tax assets at December 31, 2020 and 2019 are as follows: Year Ended December 31, (in thousands) 2020 2019 Non-current deferred tax assets Net operating losses $ 147,305 $ 125,341 Accrued expenses 2,480 2,869 Capitalized research and development 12,446 17,195 Tax credit carryforwards 13,968 13,413 Stock compensation and other 5,931 9,043 Total non-current deferred tax assets 182,130 167,861 Non-current deferred tax liabilities Right of use assets (486 ) (668 ) Total non-current deferred tax liabilities (486 ) (668 ) Net non-current deferred tax asset 181,644 167,193 Less: valuation allowance (181,644 ) (167,193 ) Net deferred tax asset $ — $ —

Commitments and Contingencies (

Commitments and Contingencies (Tables)	12 Months Ended
	Dec. 31, 2020
Commitments And Contingencies Disclosure [Abstract]
Summary of Lease Costs Recognized Under Topic 842 and Other Information	The following table contains a summary of the lease costs recognized under Topic 842 and other information pertaining to the Company’s operating leases for year ended December 31, 2020: Lease cost (in thousands) Operating lease cost $ 1,120 Variable lease cost 131 Total lease cost $ 1,251 Cash paid for amounts included in the measurement of lease liabilities: $ 1,178 Other information Weighted average remaining lease term (in years) 3.0 Weighted average discount rate 8.75 %
Summary of Future Minimum Operating Lease Obligations under Non-cancelable Operating Leases	Future minimum operating lease obligations under non-cancelable operating leases with initial terms of more than one-year as of December 31 Maturity of lease liabilities (in thousands) 2021 $ 1,241 2022 508 2023 518 2024 and thereafter 396 Total lease payments $ 2,663 Less: imputed interest (292 ) Total operating lease liabilities $ 2,371

Quarterly Results (Unaudited) (

Quarterly Results (Unaudited) (Tables)	12 Months Ended
	Dec. 31, 2020
Quarterly Financial Information Disclosure [Abstract]
Schedule of Quarterly Results	Three Months Ended March 31, 2020 June 30, 2020 September 30, 2020 December 31, 2020 (in thousands, except per share data) (unaudited) Revenue $ 7,920 $ 9,326 $ 13,659 $ 16,019 Operating expenses 31,498 27,772 29,606 33,552 Loss from operations (23,578 ) (18,446 ) (15,947 ) (17,533 ) Other expense, net (4,039 ) (4,613 ) (4,908 ) (7,477 ) Provision for income tax — — — — Net loss $ (27,617 ) $ (23,059 ) $ (20,855 ) $ (25,010 ) Net loss per share - basic and diluted $ (0.66 ) $ (0.53 ) $ (0.46 ) $ (0.54 ) Three Months Ended March 31, 2019 June 30, 2019 September 30, 2019 December 31, 2019 (in thousands, except per share data) (unaudited) Revenue $ 1,598 $ 2,045 $ 3,934 $ 8,967 Operating expenses 34,914 32,166 32,944 32,149 Loss from operations (33,316 ) (30,121 ) (29,010 ) (23,182 ) Other expense, net (2,294 ) (3,080 ) (3,604 ) (3,882 ) Provision for income tax — — — 301 Net loss $ (35,610 ) $ (33,201 ) $ (32,614 ) $ (27,365 ) Net loss per share - basic and diluted $ (1.10 ) $ (1.02 ) $ (1.00 ) $ (0.81 )

Organization - Additional Infor

Organization - Additional Information (Detail) - USD ($) $ in Thousands	Dec. 31, 2020	Dec. 31, 2019
Organization Consolidation And Presentation Of Financial Statements [Abstract]
Accumulated deficit	$ (807,799)	$ (711,258)
Cash, cash equivalents and available for sale marketable securities current	$ 125,200

Summary of Significant Accoun_4

Summary of Significant Accounting Policies - Additional Information (Detail)	Jan. 01, 2020USD ($)	Dec. 31, 2020USD ($)Segment	Dec. 31, 2019USD ($)
Accounting Policies [Line Items]
Accounts receivable, other receivables, prepaid, and other current assets		$ 7,459,000	$ 11,467,000
Realized gains or losses on marketable securities		0	0
Other-than-temporary impairments of investments		0	0
Accounts receivable, net		11,878,000	8,475,000
Off-balance sheet concentration of credit risk		0
Impairment charge related to goodwill		$ 0	$ 0
Revenue, practical expedient, incremental cost of obtaining contract		true
Number of operating segments | Segment		1
Number of geographical segments | Segment		1
ASC 606 [Member]
Accounting Policies [Line Items]
Revenue recognition description		Amounts received prior to revenue recognition are recorded as deferred revenue. Amounts expected to be recognized as revenue within the 12 months following the balance sheet date are classified as current portion of deferred revenue in the accompanying consolidated balance sheets. Amounts not expected to be recognized as revenue within the 12 months following the balance sheet date are classified as deferred revenue, net of current portion.
ASU No. 2017-04 [Member]
Accounting Policies [Line Items]
Change In Accounting Principle Accounting Standards Update Adopted		true
Change In Accounting Principle Accounting Standards Update Adoption Date		Jan. 1, 2020
Change In Accounting Principle Accounting Standards Update Immaterial Effect		true
ASU No. 2018-13 [Member]
Accounting Policies [Line Items]
Change In Accounting Principle Accounting Standards Update Adopted		true
Change In Accounting Principle Accounting Standards Update Adoption Date		Jan. 1, 2020
Change In Accounting Principle Accounting Standards Update Immaterial Effect		true
Almirall [Member]
Accounting Policies [Line Items]
Accounts receivable, net		$ 500,000
Tetraphase License Agreement [Member]
Accounting Policies [Line Items]
Accounts receivable, net		500,000
Government Contract Service Revenue [Member] | BARDA Contract [Member]
Accounting Policies [Line Items]
Accounts receivable, net		600,000
Government Contract Grant Revenue [Member] | BARDA Contract [Member]
Accounting Policies [Line Items]
Accounts receivable, net		600,000
Trade Accounts Receivable [Member] | NUZYRA [Member]
Accounting Policies [Line Items]
Accounts receivable, net		$ 10,100,000
Revision of Prior Period, Reclassification, Adjustment [Member]
Accounting Policies [Line Items]
Purchase of prepaid interest - marketable securities	$ (200,000)
Accounts receivable, other receivables, prepaid, and other current assets	$ 200,000

Summary of Significant Accoun_5

Summary of Significant Accounting Policies - Schedule of Estimated Useful Lives of Fixed Assets (Detail)	12 Months Ended
	Dec. 31, 2020
Laboratory Equipment [Member]
Property Plant And Equipment [Line Items]
Estimated Useful Life In Years	5 years
Office Equipment [Member]
Property Plant And Equipment [Line Items]
Estimated Useful Life In Years	5 years
Machinery and Equipment [Member]
Property Plant And Equipment [Line Items]
Estimated Useful Life In Years	5 years
Computer Equipment [Member]
Property Plant And Equipment [Line Items]
Estimated Useful Life In Years	3 years
Computer Software [Member]
Property Plant And Equipment [Line Items]
Estimated Useful Life In Years	3 years

Product Revenue - Summary of Pr

Product Revenue - Summary of Product Revenue Allowance and Reserve Categories (Detail) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019
Disaggregation Of Revenue [Line Items]
Beginning Balance	$ 1,492
Provision related to current period sales	9,959	$ 2,893
Adjustment related to prior period sales	11
Credit or payments made during the period	(8,033)	(1,401)
Ending Balance	3,429	1,492
Chargebacks, Discounts and Fees [Member]
Disaggregation Of Revenue [Line Items]
Beginning Balance	299
Provision related to current period sales	3,160	926
Adjustment related to prior period sales	(8)
Credit or payments made during the period	(2,824)	(627)
Ending Balance	627	299
Government and Other Rebates [Member]
Disaggregation Of Revenue [Line Items]
Beginning Balance	695
Provision related to current period sales	6,091	1,424
Adjustment related to prior period sales	19
Credit or payments made during the period	(4,603)	(729)
Ending Balance	2,202	695
Returns [Member]
Disaggregation Of Revenue [Line Items]
Beginning Balance	369
Provision related to current period sales	337	369
Credit or payments made during the period	(320)
Ending Balance	386	369
Patient Assistance [Member]
Disaggregation Of Revenue [Line Items]
Beginning Balance	129
Provision related to current period sales	371	174
Credit or payments made during the period	(286)	(45)
Ending Balance	$ 214	$ 129

Net Loss Per Share - Antidiluti

Net Loss Per Share - Antidilutive Shares Excluded from Computation of Diluted Net Income (Loss) Per Share (Detail) - shares	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]
Excluded potentially dilutive securities	16,843,046	16,821,484
Outstanding Convertible Notes [Member]
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]
Excluded potentially dilutive securities	10,377,361	10,377,361
Stock Option [Member]
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]
Excluded potentially dilutive securities	1,986,442	3,236,073
Unvested Restricted Stock Units [Member]
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]
Excluded potentially dilutive securities	3,393,425	2,305,408
Warrants [Member]
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]
Excluded potentially dilutive securities	479,002	104,455
Employee Stock Purchase Plan [Member]
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]
Excluded potentially dilutive securities	606,816	798,187

Government Contract Revenue - A

Government Contract Revenue - Additional Information (Detail)	3 Months Ended								12 Months Ended
	Dec. 31, 2020USD ($)TreatmentCourse	Sep. 30, 2020USD ($)	Jun. 30, 2020USD ($)	Mar. 31, 2020USD ($)	Dec. 31, 2019USD ($)	Sep. 30, 2019USD ($)	Jun. 30, 2019USD ($)	Mar. 31, 2019USD ($)	Dec. 31, 2020USD ($)TreatmentCourse	Dec. 31, 2019USD ($)	Apr. 30, 2020USD ($)
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Milestone payment recognized as revenue	$ 16,019,000	$ 13,659,000	$ 9,326,000	$ 7,920,000	$ 8,967,000	$ 3,934,000	$ 2,045,000	$ 1,598,000	$ 46,924,000	$ 16,544,000
Government Contract Service Revenue [Member]
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Milestone payment recognized as revenue									3,299,000
Product Revenue, Net [Member]
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Milestone payment recognized as revenue									38,753,000	11,517,000
Government Contract Grant Revenue [Member]
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Milestone payment recognized as revenue									$ 3,407,000
BARDA Contract [Member]
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Contract term									5 years
Option to extend term									10 years
Maximum payment receivable in contract	$ 284,700,000								$ 284,700,000
Term of base period of performance									5 years
Maximum number of years in contract period of performance									10 years
Maximum number of treatment courses of drug product | TreatmentCourse	2,500								2,500
Potential additional staged funding for existing FDA PMR commitments	$ 76,800,000								$ 76,800,000
Potential additional staged funding for manufacturing-related requirements	20,400,000								20,400,000
Revenue performance obligations allocated transaction price									63,600,000
Product revenue recognized									0
Manufacturing-related requirements exercised											$ 20,400,000
BARDA Contract [Member] | Accounts Receivable, Net [Member]
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Unbilled accounts receivable	600,000								600,000
BARDA Contract [Member] | Other Current Liabilities [Member]
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Deferred revenue	200,000								$ 200,000
BARDA Contract [Member] | NUZYRA [Member]
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Maximum number of treatment courses procured | TreatmentCourse									10,000
Initial funding for development of NUZYRA	59,400,000								$ 59,400,000
Funding to support drug development.	12,700,000								12,700,000
Funding for three additional purchases	$ 115,400,000								$ 115,400,000
Maximum number of treatment courses procure options | TreatmentCourse									2,500
Revenue performance obligations allocated transaction price									$ 4,200,000
BARDA Contract [Member] | Government Contract Service Revenue [Member]
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Revenue performance obligations allocated transaction price									21,500,000
Milestone payment recognized as revenue									3,300,000	0
BARDA Contract [Member] | Product Revenue, Net [Member]
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Revenue performance obligations allocated transaction price									37,900,000
BARDA Contract [Member] | Government Contract Grant Revenue [Member]
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Milestone payment recognized as revenue									3,400,000	$ 0
Allocated consideration for reimbursement of existing FDA PMR requirements related to reimbursable expenses									$ 72,600,000

Government Contract Revenue -_2

Government Contract Revenue - Additional Information (Detail1) - Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date: 2021-01-01 $ in Millions	Dec. 31, 2020USD ($)
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Remaining performance obligations	$ 80.7
Minimum [Member]
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Remaining performance obligations, expected recognize period	3 years
Maximum [Member]
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Remaining performance obligations, expected recognize period	6 years

License and Collaboration Agr_2

License and Collaboration Agreements - Additional Information (Detail)	1 Months Ended			3 Months Ended								12 Months Ended
	Oct. 31, 2018USD ($)	Apr. 30, 2017USD ($)	Feb. 28, 1997shares	Dec. 31, 2020USD ($)	Sep. 30, 2020USD ($)	Jun. 30, 2020USD ($)	Mar. 31, 2020USD ($)	Dec. 31, 2019USD ($)	Sep. 30, 2019USD ($)	Jun. 30, 2019USD ($)	Mar. 31, 2019USD ($)	Dec. 31, 2020USD ($)Obligation	Dec. 31, 2019USD ($)
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Milestone payment recognized as revenue				$ 16,019,000	$ 13,659,000	$ 9,326,000	$ 7,920,000	$ 8,967,000	$ 3,934,000	$ 2,045,000	$ 1,598,000	$ 46,924,000	$ 16,544,000
Almirall [Member]
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Milestone payment recognized as revenue												$ 1,300,000
Number of performance obligations | Obligation												2
Tufts [Member]
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Shares issued | shares			1,024
Milestone payments, maximum												$ 300,000
Milestone payments, paid												50,000
Second milestone payment												100,000
Third and final milestone payment due on acceptance of an NDA submission	$ 150,000
Royalty, payable				25,000								25,000
Royalty expense												$ 600,000
Maximum [Member] | Tufts [Member]
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
License agreement, sublicensing Fees percent												14.00%
Minimum [Member] | Tufts [Member]
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
License agreement, sublicensing Fees percent												10.00%
Tetraphase License Agreement [Member]
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
License agreement expiration date												2023-10
Milestone payment recognized as revenue												$ 200,000
Zai Lab (Shanghai) Co., Ltd. [Member]
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Milestone payment recognized as revenue								3,000,000				$ 0
Period of anniversary for first commercial sale of licensed product												11 years
Number of performance obligations | Obligation												2
Recognized milestone revenue												$ 12,500,000
Deferred revenue				0				0				0	0
Zai Lab (Shanghai) Co., Ltd. [Member] | Paratek Bermuda Ltd [Member]
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Upfront license fee payment received and recognized as revenue		$ 7,500,000
Eligible to receive potential regulatory milestone payments				6,000,000								6,000,000
Milestone payments on acceptance of an NDA submission	$ 5,000,000
Milestone payments upon submission of the first regulatory approval application for a licensed product								3,000,000					3,000,000
Milestone payments upon regulatory approval for a licensed product				6,000,000								6,000,000
Zai Lab (Shanghai) Co., Ltd. [Member] | Paratek Bermuda Ltd [Member] | Maximum [Member]
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Eligible to receive potential commercial milestone payments				40,500,000								$ 40,500,000
Novartis [Member]
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Advance notice to terminate collaboration agreement												60 days
Royalty based on annual net sales												0.25%
Period of patent claim												10 years
Novartis [Member] | Other Long Term Liabilities [Member]
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Liability under collaboration agreement				$ 3,100,000				$ 3,400,000				$ 3,100,000	$ 3,400,000

Cash and Cash Equivalents and_3

Cash and Cash Equivalents and Restricted Cash - Summary of Reconciliation of Cash, Cash Equivalents, and Restricted Cash Reported Within Consolidated Statement of Cash Flows (Detail) - USD ($) $ in Thousands	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2018
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents [Abstract]
Cash and cash equivalents	$ 105,157	$ 102,302
Short-term restricted cash	891	324
Long-term restricted cash		3,007
Total cash, cash equivalents and restricted cash shown on the consolidated statement of cash flows	$ 106,048	$ 105,633	$ 47,502

Cash and Cash Equivalents and_4

Cash and Cash Equivalents and Restricted Cash - Additional Information (Detail) - USD ($) $ in Thousands	May 01, 2019	Dec. 31, 2020	Dec. 31, 2019
Cash And Cash Equivalents [Line Items]
Remaining balance in interest reserve account expected to be paid held as long term restricted cash			$ 2,700
Long-term restricted cash			3,007
Royalty Backed Loan Agreement [Member] | Healthcare Royalty Partners III, L.P [Member]
Cash And Cash Equivalents [Line Items]
Line of credit deposits into interest reserve account	$ 4,000
Estimated interest amount expected to be paid out of interest reserve account held as restricted cash		$ 600
Letters of Credit [Member]
Cash And Cash Equivalents [Line Items]
Letters of credit amount collateralized		$ 300	300
Long-term restricted cash			$ 300

Marketable Securities - Summary

Marketable Securities - Summary of Available for Sale Securities (Detail) - USD ($) $ in Thousands	Dec. 31, 2020	Dec. 31, 2019
Schedule Of Available For Sale Securities [Line Items]
Amortized Cost	$ 20,001	$ 113,003
Unrealized Gains	4	89
Unrealized Losses		(15)
Fair Value	20,005	113,077
U.S. Treasury Securities [Member]
Schedule Of Available For Sale Securities [Line Items]
Amortized Cost	20,001	113,003
Unrealized Gains	4	89
Unrealized Losses		(15)
Fair Value	$ 20,005	$ 113,077

Marketable Securities - Additio

Marketable Securities - Additional Information (Detail) - USD ($)	Dec. 31, 2020	Dec. 31, 2019
Marketable Securities [Abstract]
Available for sale securities have remaining maturities greater than twelve months	$ 0	$ 0

Fixed Assets, Net - Schedule of

Fixed Assets, Net - Schedule of Fixed Assets (Detail) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019
Property, Plant and Equipment [Line Items]
Gross fixed assets	$ 3,751	$ 3,563
Less: Accumulated depreciation and amortization	(2,787)	(2,336)
Net fixed assets	964	1,227
Office Equipment [Member]
Property, Plant and Equipment [Line Items]
Gross fixed assets	$ 866	866
Estimated Useful Life In Years	5 years
Machinery and Equipment [Member]
Property, Plant and Equipment [Line Items]
Gross fixed assets	$ 567	567
Estimated Useful Life In Years	5 years
Computer Equipment [Member]
Property, Plant and Equipment [Line Items]
Gross fixed assets	$ 412	412
Estimated Useful Life In Years	3 years
Computer Software [Member]
Property, Plant and Equipment [Line Items]
Gross fixed assets	$ 798	798
Estimated Useful Life In Years	3 years
Leasehold Improvements [Member]
Property, Plant and Equipment [Line Items]
Gross fixed assets	$ 920	$ 920
Construction in Progress [Member]
Property, Plant and Equipment [Line Items]
Gross fixed assets	$ 188

Fixed Assets, Net - Additional

Fixed Assets, Net - Additional Information (Detail) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019
Selling, General and Administrative and Research and Development Expense [Member]
Property, Plant and Equipment [Line Items]
Depreciation expense	$ 0.5	$ 0.5
Leasehold Improvements [Member]
Property, Plant and Equipment [Line Items]
Estimated useful life	shorter of the lease term or the estimated useful economic lives of the related assets.

Inventories, Net - Schedule of

Inventories, Net - Schedule of Inventories (Detail) - USD ($) $ in Thousands	Dec. 31, 2020	Dec. 31, 2019
Inventory Disclosure [Abstract]
Raw materials	$ 720
Work in process	12,925	$ 9,330
Finished goods	9,638	2,249
Total inventories	$ 23,283	$ 11,579

Inventories, Net - Additional I

Inventories, Net - Additional Information (Detail) - USD ($)	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019
Inventory Disclosure [Abstract]
Inventory reserves	$ 0	$ 0

Inventories, Net - Schedule o_2

Inventories, Net - Schedule of Balance Sheet Classification of Inventory (Detail) - USD ($) $ in Thousands	Dec. 31, 2020	Dec. 31, 2019
Balance Sheet Classification:
Inventories, net	$ 14,555	$ 11,579
Other long-term assets	8,728
Total inventories	$ 23,283	$ 11,579

Accrued Expenses - Schedule of

Accrued Expenses - Schedule of Accrued Expenses (Detail) - USD ($) $ in Thousands	Dec. 31, 2020	Dec. 31, 2019
Payables And Accruals [Abstract]
Accrued compensation	$ 7,783	$ 7,580
Accrued sales allowances	3,429	1,492
Accrued commercial	2,254	1,445
Accrued inventory	2,023	125
Accrued interest	1,768	2,264
Accrued professional fees	1,209	876
Accrued manufacturing	972	1,026
Accrued contract research	591	1,612
Accrued legal costs	580	181
Accrued other	217	95
Total	$ 20,826	$ 16,696

Common Stock - Additional Infor

Common Stock - Additional Information (Detail) - USD ($)	Aug. 05, 2020	Jul. 02, 2019	Aug. 01, 2018	Jun. 27, 2017	Dec. 12, 2016	Sep. 30, 2015	Dec. 31, 2020	Dec. 31, 2019	Jul. 09, 2020
Class Of Stock [Line Items]
Common stock, shares authorized							100,000,000	100,000,000
Common stock, par value							$ 0.001	$ 0.001
Common stock, conversion rights							0
Common stock, redemption rights							There are no redemption or sinking fund provisions applicable to the common stock.
Common stock, voting rights							The holders of common stock are entitled to one vote per share on all matters to be voted upon by the stockholders
Proceeds from issuance of common stock							$ 21,891,000	$ 26,559,000
Beneficial owners minimum required percentage of common stock exchanged for warrant							5.00%
Warrants exercisable description							The Warrants are exercisable for a term beginning on the date of issuance and ending on the earlier to occur of five years (or seven years, in the case of the Fifth Amendment Warrant and the First Amendment Warrant) from the date of issuance or the consummation of certain acquisitions of the Company as set forth in the various agreements for the Warrants.
Term of warrants							5 years
Fifth Amendment [Member]
Class Of Stock [Line Items]
Term of warrants			7 years
Hercules Term Loan [Member]
Class Of Stock [Line Items]
Exercise price of warrants						$ 24.47
Warrants issued to purchase common stock						32,692
Hercules Term Loan [Member] | Second Tranche [Member]
Class Of Stock [Line Items]
Exercise price of warrants	$ 4.42
Hercules Term Loan [Member] | Second Amendment [Member]
Class Of Stock [Line Items]
Exercise price of warrants					$ 13.46
Warrants issued to purchase common stock					37,148
Hercules Term Loan [Member] | Fifth Amendment [Member]
Class Of Stock [Line Items]
Exercise price of warrants			$ 10.19
Hercules Term Loan [Member] | Hercules Technology II, L.P. [Member]
Class Of Stock [Line Items]
Exercise price of warrants						$ 24.47
Warrants issued to purchase common stock						16,346
Expected life of options (in years)						5 years
Hercules Term Loan [Member] | Hercules Technology II, L.P. [Member] | Second Amendment [Member]
Class Of Stock [Line Items]
Warrants issued to purchase common stock					18,574
Hercules Term Loan [Member] | Hercules Technology III, L.P. [Member]
Class Of Stock [Line Items]
Warrants issued to purchase common stock						16,346
Expected life of options (in years)						5 years
Hercules Term Loan [Member] | Hercules Technology III, L.P. [Member] | Second Amendment [Member]
Class Of Stock [Line Items]
Exercise price of warrants					$ 13.46
Warrants issued to purchase common stock					18,574
Hercules Term Loan [Member] | Hercules Capital Inc [Member]
Class Of Stock [Line Items]
Exercise price of warrants				$ 23.26
Warrants issued to purchase common stock				5,374
Hercules Term Loan [Member] | Hercules Capital Inc [Member] | Fifth Amendment [Member]
Class Of Stock [Line Items]
Exercise price of warrants			$ 10.19
Warrants issued to purchase common stock			19,627
Warrants Expires in 2021 [Member]
Class Of Stock [Line Items]
Warrants outstanding							9,614
Exercise price of warrants							$ 0.15
Warrants expiration year							2021
Shelf Registration [Member]
Class Of Stock [Line Items]
Common stock value, available for future issuance							$ 250,000,000
2019 Sales Agreement [Member] | Jefferies and BTIG [Member]
Class Of Stock [Line Items]
Percentage of proceeds payable as compensation to underwriter		3.00%
Common stock issued on public offering							5,176,000
Proceeds from issuance of common stock							$ 21,900,000
Proceeds payable as commission to underwriter							$ 700,000
Maximum [Member] | Hercules Term Loan [Member] | Second Tranche [Member]
Class Of Stock [Line Items]
Warrants issued to purchase common stock	407,239
Maximum [Member] | 2019 Sales Agreement [Member] | Jefferies and BTIG [Member]
Class Of Stock [Line Items]
Common stock for sale		$ 50,000,000
Maximum [Member] | Initial Public Offering [Member] | Shelf Registration [Member]
Class Of Stock [Line Items]
Common stock, aggregate amount authorized									$ 250,000,000

Preferred Stock - Additional In

Preferred Stock - Additional Information (Detail) - $ / shares	Dec. 31, 2020	Dec. 31, 2019
Class Of Stock [Line Items]
Preferred stock, shares authorized	5,000,000	5,000,000
Preferred stock, par value	$ 0.001	$ 0.001
Preferred stock, shares outstanding	0	0
Preferred stock, shares issued	0	0
Maximum [Member]
Class Of Stock [Line Items]
Preferred stock, shares authorized	5,000,000

Fair Value Measurements - Addit

Fair Value Measurements - Additional Information (Detail) - USD ($) $ in Millions	Dec. 31, 2020	Dec. 31, 2019
Fair Value Disclosures [Abstract]
Carrying value of debt	$ 223.5	$ 191.3

Fair Value Measurements - Sched

Fair Value Measurements - Schedule of Financial Assets and Liabilities Measured at Fair Value (Detail) - USD ($) $ in Thousands	Dec. 31, 2020	Dec. 31, 2019
Assets
Total Assets	$ 20,005	$ 113,077
Total Assets	20,005	113,077
U.S. Treasury Securities [Member]
Assets
Total Assets	20,005	113,077
Quoted Prices in Active Markets (Level 1) [Member]
Assets
Total Assets	20,005	113,077
Quoted Prices in Active Markets (Level 1) [Member] | U.S. Treasury Securities [Member]
Assets
Total Assets	$ 20,005	$ 113,077

Stock-Based and Incentive Com_3

Stock-Based and Incentive Compensation - Additional Information (Detail)	12 Months Ended
	Dec. 31, 2020USD ($)TrancheInstallment	Dec. 31, 2019USD ($)	Oct. 04, 2018USD ($)
Revenue Performance Incentive Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of tranches | Tranche	2
Employment termination description	If a participant’s employment terminates prior to December 31, 2022 due to death or disability, the participant will automatically vest in an additional 25% of each tranche of his or her award.
Percentage of additional performance-based cash incentive awards	25.00%
Revenue incentive plan, vesting percentage	100.00%
Revenue incentive plan upon achievement of milestone description	Upon the achievement of a Tranche 1 or Tranche 2 milestone (but not a deemed achievement in connection with a change of control), each participant’s payout in respect of the applicable tranche of his or her award will equal (a) the participant’s then-vested percentage, multiplied by (b) $25 million, multiplied by (c) the participant’s individual percentage allocation of the incentive pool.
Payout of revenues to participants	$ 25,000,000
Percentage of cash and registered securities of aggregate payment	50.00%
Accrued compensation cost	$ 0	$ 0
Revenue Performance Incentive Plan [Member] | Tranche 1 Milestone [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of equal installments | Installment	4
Payout of revenues to participants	$ 25,000,000
Percentage of milestone deemed to be achieved if milestone not achieved prior to change of control	50.00%
Base amount for dividing cumulative product revenue if milestone not achieved prior to change of control	$ 300,000,000
Revenue Performance Incentive Plan [Member] | Tranche 2 Milestone [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of equal installments | Installment	4
Payout of revenues to participants	$ 25,000,000
Percentage of milestone deemed to be achieved if milestone not achieved prior to change of control	30.00%
Base amount for dividing cumulative product revenue if milestone not achieved prior to change of control	$ 600,000,000
Employee Stock Option [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Exercise price as percentage of fair market value of common stock on grant date for holders of more than ten percent of voting stock	110.00%
Maximum [Member] | Revenue Performance Incentive Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Incentive pool amount plus accrued interest			$ 50,000,000
Maximum [Member] | Employee Stock Option [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Award expiration period	10 years
Award vesting period	4 years
Minimum [Member] | Revenue Performance Incentive Plan [Member] | Tranche 1 Milestone [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Cumulative net product revenues	$ 300,000,000
Minimum [Member] | Revenue Performance Incentive Plan [Member] | Tranche 2 Milestone [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Cumulative net product revenues	$ 600,000,000
Minimum [Member] | Employee Stock Option [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Award vesting period	1 year

Stock-Based and Incentive Com_4

Stock-Based and Incentive Compensation - 2006 Plan - Additional Information (Detail) - 2006 Plan [Member] - shares	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock option termination date	Jun. 2, 2020
Shares remained available for issuance	0	0

Stock-Based and Incentive Com_5

Stock-Based and Incentive Compensation - 2014 Plan - Additional Information (Detail) - shares	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2015	Dec. 31, 2019
Minimum [Member] | Employee Stock Option [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Time-based vesting period	1 year
Maximum [Member] | Employee Stock Option [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Time-based vesting period	4 years
2014 Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Shares remained available for issuance	0		0
2014 Plan [Member] | Employee Stock Option [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Options granted under plan		24,000
2014 Plan [Member] | Minimum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Time-based vesting period		1 year
2014 Plan [Member] | Maximum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Time-based vesting period		4 years

Stock-Based and Incentive Com_6

Stock-Based and Incentive Compensation - 2015 Plan - Additional Information (Detail) $ in Thousands	Dec. 10, 2020	Jan. 02, 2020shares	Jan. 02, 2019shares	Jan. 02, 2018shares	Feb. 29, 2020	Dec. 31, 2020USD ($)shares	Dec. 31, 2019USD ($)shares	Dec. 31, 2018USD ($)	Dec. 31, 2015shares	Jun. 09, 2015shares
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Options granted under plan						147,950	196,560
Compensation cost recognized | $						$ 10,248	$ 14,295
PRSUs [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Time-based vesting period								15 months
RSU [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Options granted under plan						2,587,550	2,275,340
Minimum [Member] | Employee Stock Option [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Time-based vesting period						1 year
Maximum [Member] | Employee Stock Option [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Time-based vesting period						4 years
2015 Inducement Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Options granted under plan						0
Common stock shares, authorized						306,500
2015 Inducement Plan [Member] | Minimum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Time-based vesting period						1 year
2015 Inducement Plan [Member] | Maximum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Time-based vesting period						4 years
2015 Inducement Plan [Member] | New Employee [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock options reserved for future issuance						360,000
2015 Inducement Plan [Member] | Executives and Employees [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock options reserved for future issuance						353,500
2015 Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share based compensation, increase in shares issued		2,325,828	1,991,387	1,612,969
Percentage of shares		5.00%	5.00%	5.00%
Description of annual increase in percentage of share reserved for issuance						The Share Reserve will automatically increase on January 1st of each year, for the period commencing on (and including) January 1, 2016 and ending on (and including) January 1, 2025, in an amount equal to 5% of the total number of shares of common stock outstanding on December 31st of the preceding calendar year.
2015 Plan [Member] | PRSUs [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vested shares						155,000
Compensation cost | $								$ 100
Compensation cost recognized | $						$ 200	$ 1,400
2015 Plan [Member] | PRSUs [Member] | Tranche One [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting ratio							0.417	0.182
2015 Plan [Member] | PRSUs [Member] | Tranche Two [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting ratio							0.417	0.364
2015 Plan [Member] | PRSUs [Member] | Tranche Three [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting ratio							0.167	0.454
2015 Plan [Member] | RSU [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting ratio					0.333
Options granted under plan						2,553,250
Additional Vesting ratio	0.333
Options cancelled under plan						200,565
2015 Plan [Member] | PRSUs [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Compensation cost recognized | $						$ 400
2015 Plan [Member] | PRSUs [Member] | Tranche One [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting ratio					0.454
2015 Plan [Member] | PRSUs [Member] | Tranche Two [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting ratio					0.272
2015 Plan [Member] | PRSUs [Member] | Tranche Three [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting ratio					0.272
2015 Plan [Member] | Employee Stock Option [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Options granted under plan						103,900
Options forfeited or expired under plan						1,123,643
2015 Plan [Member] | Minimum [Member] | Employee Stock Option [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Time-based vesting period						1 year
2015 Plan [Member] | Maximum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock options reserved for future issuance						2,000,000
2015 Plan [Member] | Maximum [Member] | Employee Stock Option [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Time-based vesting period						4 years
2015 Plan [Member] | Directors, Officers, Employees and Consultants [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock options reserved for future issuance										1,200,000
2006 Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Options granted under plan						0
2014 Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Options granted under plan						0
2014 Plan [Member] | Employee Stock Option [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Options granted under plan									24,000
2014 Plan [Member] | Minimum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Time-based vesting period									1 year
2014 Plan [Member] | Maximum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Time-based vesting period									4 years

Stock-Based and Incentive Com_7

Stock-Based and Incentive Compensation - 2017 Inducement Plan - Additional Information (Detail) - $ / shares	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019	Oct. 31, 2018	Jun. 30, 2017
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Options granted under plan	147,950	196,560
Options forfeited under plan	1,213,102
Total shares available for future issuance	18,917,671
Weighted-average grant date fair value of options granted to employees	$ 2.46	$ 2.69
Stock option exercised	39,479	0
Employee Stock Option [Member] | Minimum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Time-based vesting period	1 year
Employee Stock Option [Member] | Maximum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Time-based vesting period	4 years
Restricted Stock Units [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Options granted under plan	2,587,550	2,275,340
2017 Inducement Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Total shares available for future issuance	428,733
2017 Inducement Plan [Member] | Employee Stock Option [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Options granted under plan	44,050
Options forfeited under plan	87,068
2017 Inducement Plan [Member] | Employee Stock Option [Member] | Minimum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Time-based vesting period	1 year
2017 Inducement Plan [Member] | Employee Stock Option [Member] | Maximum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Time-based vesting period	4 years
2017 Inducement Plan [Member] | Restricted Stock Units [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Options granted under plan	34,300
Time-based vesting period	3 years
Vesting percentage	100.00%
Options forfeited under plan	17,000
2017 Inducement Plan [Member] | Employees Entering into Employment Or Returning to Employment [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock options reserved for future issuance			1,050,000	550,000
2015 Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Total shares available for future issuance	1,339,392
2015 Plan [Member] | Maximum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock options reserved for future issuance	2,000,000
2015 Plan [Member] | Employee Stock Option [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Options granted under plan	103,900
2015 Plan [Member] | Employee Stock Option [Member] | Minimum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Time-based vesting period	1 year
2015 Plan [Member] | Employee Stock Option [Member] | Maximum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Time-based vesting period	4 years
2015 Plan [Member] | Restricted Stock Units [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Options granted under plan	2,553,250
Options forfeited under plan	200,565
2015 Inducement Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Total shares available for future issuance	306,500
2015 Inducement Plan [Member] | Minimum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Time-based vesting period	1 year
2015 Inducement Plan [Member] | Maximum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Time-based vesting period	4 years

Stock-Based and Incentive Com_8

Stock-Based and Incentive Compensation - Schedule of Share-based Compensation, Stock Options, Activity (Detail) - USD ($) $ / shares in Units, $ in Thousands	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]
Number of Shares Outstanding, Beginning Balances	3,236,073
Number of Shares Outstanding, Granted	147,950	196,560
Number of Shares Outstanding, Exercised	(39,479)	0
Number of Shares Outstanding, Cancelled or forfeited	(1,213,102)
Number of Shares Outstanding, Expired	(145,000)
Number of Shares Outstanding, Ending Balances	1,986,442	3,236,073
Number of Shares Outstanding, Exercisable	1,717,030
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest [Abstract]
Weighted Average Exercise Price, Beginning Balances	$ 15.54
Weighted Average Exercise Price, Granted	4.37
Weighted Average Exercise Price, Exercised	4.30
Weighted Average Exercise Price, Cancelled or forfeited	19.83
Weighted Average Exercise Price, Expired	20.85
Weighted Average Exercise Price, Ending Balances	11.92	$ 15.54
Weighted Average Exercise Price, Exercisable	$ 12.61
Share-based Compensation Arrangement by Share-based Payment Award, Options, Weighted-Average Remaining Contractual Term (in Years)
Options Outstanding, Weighted-Average Remaining Contractual Term (in Years)	5 years 7 months 17 days	6 years 3 months 18 days
Options Exercisable, Weighted-Average Remaining Contractual Term (in Years)	5 years 2 months 8 days
Share-based Compensation Arrangement by Share-based Payment Award, Options, Aggregate Intrinsic Value
Options Outstanding, Aggregate Intrinsic Value	$ 1,748	$ 90
Options Exercisable, Aggregate Intrinsic Value	$ 1,356

Stock-Based and Incentive Com_9

Stock-Based and Incentive Compensation - Schedule of Share-based Compensation, Restricted Stock Unit, Activity (Detail) - Restricted Stock Units [Member]	12 Months Ended
	Dec. 31, 2020$ / sharesshares
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]
Unvested Number of Shares, Beginning Balance | shares	2,305,408
Number of Shares, Granted | shares	2,587,550
Number of Shares, Released | shares	(1,281,968)
Number of Shares, Forfeited | shares	(217,565)
Unvested Number of Shares, Ending Balance | shares	3,393,425
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]
Unvested Weighted Average Grant Date Fair Value, Beginning Balance | $ / shares	$ 7.66
Weighted Average Grant Date Fair Value, Granted | $ / shares	3.56
Weighted Average Grant Date Fair Value, Released | $ / shares	7.96
Weighted Average Grant Date Fair Value, Forfeited | $ / shares	7.90
Unvested Weighted Average Grant Date Fair Value, Ending Balance | $ / shares	$ 4.41

Stock-Based and Incentive Co_10

Stock-Based and Incentive Compensation - Restricted Stock - Additional Information (Detail) - Restricted Stock Units [Member] - USD ($) $ / shares in Units, $ in Millions	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of Shares, Granted	2,587,550	2,275,340
Weighted Average Grant Date Fair Value, Granted	$ 3.56	$ 6.01
Aggregate fair value, vested	$ 10.2	$ 12.1

Stock-Based and Incentive Co_11

Stock-Based and Incentive Compensation - Schedule of Share-based Payment Award, Stock Options, Weighted-Average Valuation Assumptions (Detail) - Employee Stock Option [Member]	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Volatility	63.10%	63.40%
Weighted average risk-free interest rate	0.90%	2.00%
Expected dividend yield	0.00%	0.00%
Expected life of options (in years)	5 years 8 months 12 days	5 years 10 months 24 days

Stock-Based and Incentive Co_12

Stock-Based and Incentive Compensation - Summary of Stock-Based Compensation Expense Included in Company's Consolidated Statements of Operations (Detail) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Total stock-based compensation expense	$ 10,248	$ 14,295
Research and Development Expense [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Total stock-based compensation expense	2,130	3,568
Selling, General and Administrative Expense [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Total stock-based compensation expense	$ 8,118	$ 10,727

Stock-Based and Incentive Co_13

Stock-Based and Incentive Compensation - Stock Based Compensation Expense - Additional Information (Detail) - Employee Stock Option [Member] $ in Millions	12 Months Ended
	Dec. 31, 2020USD ($)
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Unrecognized compensation cost related to unvested share-based arrangements	$ 7.9
Weighted average compensation cost recognition period	1 year 7 months 9 days

Stock-Based and Incentive Co_14

Stock-Based and Incentive Compensation - Employee Stock Purchase Plan - Additional Information (Detail) - USD ($) $ in Thousands	Mar. 31, 2018	Jun. 30, 2018	Dec. 31, 2020	Dec. 31, 2019
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Proceeds from issuance of common stock			$ 21,891	$ 26,559
2009 Employee Stock Purchase Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Percent of fair value			85.00%
Number of shares available for grant			36,539	36,539
2018 Employee Stock Purchase Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of shares available for grant			570,277
Maximum aggregate number of shares of common stock that may be purchased under ESPP		943,294
ESPP share pool percentage of total number of shares of common stock outstanding	3.00%
ESPP, eligible employees to purchase shares, offering periods		6 months
ESPP, eligible employees to purchase shares, offering periods, description			The 2018 ESPP allows eligible employees to purchase shares during certain offering periods, which will be six -month periods commencing June 1 and ending November 30 and commencing December 1 and ending May 31 of each year
First offering under the 2018 ESPP, date			Dec. 1, 2018
Shares issued			191,371
Proceeds from issuance of common stock			$ 600

Stock-Based and Incentive Co_15

Stock-Based and Incentive Compensation - Schedule of Share-based Compensation, Common Stock, Shares Reserved for Future Issuance (Detail)	Dec. 31, 2020shares
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Common stock reserved for future issuance	18,917,671
Outstanding Convertible Notes [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Common stock reserved for future issuance	10,377,361
Shares Subject to Warrants to Purchase Common Stock [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Common stock reserved for future issuance	479,002
Equity Plans [Member] | Shares Subject to Outstanding Options and Unvested Restricted Stock Units [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Common stock reserved for future issuance	5,379,867
Equity Plans [Member] | Shares Available for Future Grants [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Common stock reserved for future issuance	2,074,625
Shares Issuable under Employee Stock Purchase Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Common stock reserved for future issuance	606,816

Long-Term Debt - Additional Inf

Long-Term Debt - Additional Information (Detail)

Aug. 05, 2020USD ($)$ / sharesshares

May 01, 2019USD ($)

Feb. 25, 2019USD ($)

Aug. 01, 2018$ / sharesshares

Apr. 23, 2018USD ($)$ / shares

Apr. 18, 2018USD ($)d$ / shares

Jun. 27, 2017$ / sharesshares

Dec. 12, 2016$ / sharesshares

Sep. 30, 2015$ / sharesshares

Apr. 30, 2018USD ($)

Dec. 31, 2020USD ($)

Dec. 31, 2019USD ($)

Aug. 01, 2020USD ($)

Jun. 27, 2019USD ($)

Debt Instrument [Line Items]

Loss on extinguishment of debt

$ (2,368,000)

4.75% Convertible Senior Subordinated Notes due 2024 [Member]

Debt Instrument [Line Items]

Debt instrument maturity date

May 1, 2024

Net proceeds

161,422,000

$ 160,469,000

Term loan funded at execution

$ 165,000,000

165,000,000

Loan interest rate

5.47%

Loan agreement payment terms

payable on November 1 and May 1 of each year, beginning on November 1, 2018

Debt instrument interest payable beginning date

Nov. 1, 2018

Debt instrument initial conversion rate

62.8931

Debt instrument conversion, principal amount of each note converted

$ 1,000

Debt instrument conversion, conversion price per share | $ / shares

$ 15.90

Debt instrument conversion premium

20.00%

Closing price of the common stock | $ / shares

$ 13.25

Percentage of common stock price

130.00%

Debt instrument, convertible, threshold trading days | d

20

Debt instrument, convertible, threshold consecutive trading days | d

30

Percentage of debt instrument redemption price

100.00%

Debt instrument, debt default, minimum percentage of aggregate principal amount due

25.00%

Net proceeds from issuance of long-term convertible debt

$ 159,000,000

Costs incurred on issuance of debt

$ 6,000,000

$ 3,578,000

4,531,000

Coupon interest expense

7,800,000

7,800,000

Amortization expense on debt issuance costs

1,000,000

900,000

4.75% Convertible Senior Subordinated Notes due 2024 [Member] | J. Wood Capital Advisors LLC [Member]

Debt Instrument [Line Items]

Principal amount outstanding

$ 5,000,000

4.75% Convertible Senior Subordinated Notes due 2024 [Member] | Purchase Agreement [Member]

Debt Instrument [Line Items]

Principal amount outstanding

$ 135,000,000

Debt instrument, interest rate

4.75%

Additional principal amount outstanding

$ 25,000,000

Hercules Term Loan [Member]

Debt Instrument [Line Items]

Net proceeds

69,639,000

Term loan funded at execution

70,000,000

Interest expense

7,300,000

6,800,000

Principal amount outstanding

$ 100,000,000

Warrants issued to purchase common stock | shares

32,692

Exercise price of warrants | $ / shares

$ 24.47

Costs incurred on issuance of debt

361,000

Hercules Term Loan [Member] | Second Tranche [Member]

Debt Instrument [Line Items]

Debt instrument maturity date

Sep. 1, 2022

Exercise price of warrants | $ / shares

$ 4.42

Repayments of loan

$ 10,000,000

Repayment of other lender fees

2,500,000

Additional borrowing capacity subject to sole discretion of Hercules

$ 30,000,000

30,000,000

End of term charge

1.95%

End of term charge payable

$ 700,000

Loan interest rate

8.85%

Basis spread on prime rate

5.35%

Additional paid in kind interest rate

1.55%

Loan agreement payment terms

The First Amendment extended the date on which the Company was required to begin making monthly principal installments on the outstanding Term Loan Tranches from January 1, 2021 to January 1, 2022 (which could have been extended to July 1, 2022 or January 1, 2023, upon certain events set forth in the First Amendment), and extended the scheduled maturity of the Term Loan Tranches from August 1, 2022 to September 1, 2022 (which could have been extended to March 1, 2023 or September 1, 2023, upon certain events set forth in the First Amendment).

Reacquisition price

62,700,000

Carrying value of the extinguished debt

60,300,000

Hercules Term Loan [Member] | Second Tranche [Member] | Other Income and Expenses [Member]

Debt Instrument [Line Items]

Loss on extinguishment of debt

(2,400,000)

Loss on extinguishment of debt related to end of term fees

(1,300,000)

Write-off of unamortized debt discount

1,000,000

Hercules Term Loan [Member] | Second Tranche [Member] | Maximum [Member]

Debt Instrument [Line Items]

Warrants issued to purchase common stock | shares

407,239

Hercules Term Loan [Member] | First Tranche

Debt Instrument [Line Items]

Term loan funded at execution

62,700

Principal amount outstanding

$ 60,000,000

Hercules Term Loan [Member] | Hercules Technology II, L.P. [Member]

Debt Instrument [Line Items]

Warrants issued to purchase common stock | shares

16,346

Exercise price of warrants | $ / shares

$ 24.47

Hercules Term Loan [Member] | Hercules Technology III, L.P. [Member]

Debt Instrument [Line Items]

Warrants issued to purchase common stock | shares

16,346

Hercules Term Loan [Member] | Hercules Capital Inc [Member]

Debt Instrument [Line Items]

Warrants issued to purchase common stock | shares

5,374

Exercise price of warrants | $ / shares

$ 23.26

R-Bridge Loan Agreement [Member]

Debt Instrument [Line Items]

Line of credit facility, borrowing capacity

$ 60,000,000

Percentage of Initial sale on NUZYRA

2.50%

Maximum percentage of net sales adjust under certain circumstances

5.00%

Sales annual cap

$ 10,000,000

Sales annual cap adjust under certain circumstances

$ 12,000,000

Interest rate of annual rate

7.00%

Annual interest rate on event of default

10.00%

Accrued interest up to excess of principal payment

$ 15,000,000

Collection amount in excess of annual cap shared between parties

15,000,000

Excess of initial collection amount shared between parties

15,000,000

Loan capped amount

$ 114,000,000

Debt instrument maturity date

Dec. 31, 2032

Covenants compliance description

As of December 31, 2020, the Company was in compliance with all covenants under the R-Bridge Loan Agreement.

Event of default occurred amount

$ 0

Net proceeds

58,320,000

Term loan funded at execution

60,000,000

Lender fees accounted for as debt discount

1,100,000

Direct and incremental third-party expenses accounted for as debt issuance costs

600,000

Interest expense

0

Costs incurred on issuance of debt

1,680,000

Second Amendment [Member] | Hercules Term Loan [Member]

Debt Instrument [Line Items]

Warrants issued to purchase common stock | shares

37,148

Exercise price of warrants | $ / shares

$ 13.46

Second Amendment [Member] | Hercules Term Loan [Member] | Hercules Technology II, L.P. [Member]

Debt Instrument [Line Items]

Warrants issued to purchase common stock | shares

18,574

Second Amendment [Member] | Hercules Term Loan [Member] | Hercules Technology III, L.P. [Member]

Debt Instrument [Line Items]

Warrants issued to purchase common stock | shares

18,574

Exercise price of warrants | $ / shares

$ 13.46

Fifth Amendment [Member] | Hercules Term Loan [Member]

Debt Instrument [Line Items]

Exercise price of warrants | $ / shares

$ 10.19

Fifth Amendment [Member] | Hercules Term Loan [Member] | Hercules Capital Inc [Member]

Debt Instrument [Line Items]

Warrants issued to purchase common stock | shares

19,627

Exercise price of warrants | $ / shares

$ 10.19

Royalty Backed Loan Agreement [Member]

Debt Instrument [Line Items]

Net proceeds

30,732,000

30,620,000

Term loan funded at execution

32,500,000

32,500,000

Costs incurred on issuance of debt

1,768,000

1,880,000

Royalty Backed Loan Agreement [Member] | Healthcare Royalty Partners III, L.P [Member]

Debt Instrument [Line Items]

Line of credit facility, borrowing capacity

$ 32,500,000

Interest rate of annual rate

12.00%

Interest expense

$ 4,000,000

$ 2,700,000

Repayment of other lender fees

$ 1,200,000

Proceeds from lines of credit

27,800,000

Line of credit net of lender discount

500,000

Line of credit lender expenses

200,000

Line of credit deposits into interest reserve account

$ 4,000,000

Line of credit facility, fee

1.50%

Line of credit maturity period

May 1, 2029

Royalty Backed Loan Agreement [Member] | Healthcare Royalty Partners III, L.P [Member] | Maximum [Member]

Debt Instrument [Line Items]

Line of credit facility, periodic payment

$ 300,000

Long-Term Debt - Summary of Deb

Long-Term Debt - Summary of Debt (Detail) - USD ($) $ in Thousands	Dec. 31, 2020	Dec. 31, 2019	Apr. 30, 2018
4.75% Convertible Senior Subordinated Notes due 2024 [Member]
Debt Instrument [Line Items]
Gross proceeds	$ 165,000	$ 165,000
Unamortized debt discount and issuance costs	(3,578)	(4,531)	$ (6,000)
Carrying Value	161,422	160,469
Hercules Term Loan [Member]
Debt Instrument [Line Items]
Gross proceeds		70,000
Unamortized debt discount and issuance costs		(361)
Carrying Value		69,639
R-Bridge Loan Agreement [Member]
Debt Instrument [Line Items]
Gross proceeds	60,000
Unamortized debt discount and issuance costs	(1,680)
Carrying Value	58,320
Royalty Backed Loan Agreement [Member]
Debt Instrument [Line Items]
Gross proceeds	32,500	32,500
Unamortized debt discount and issuance costs	(1,768)	(1,880)
Carrying Value	$ 30,732	$ 30,620

Income Taxes - Schedule of Loss

Income Taxes - Schedule of Loss before Income Taxes (Detail) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019
Income Tax Disclosure [Abstract]
United States	$ (96,541)	$ (120,302)
Foreign		(8,187)
Net loss before provision for income taxes	$ (96,541)	$ (128,489)

Income Taxes - Schedule of Comp

Income Taxes - Schedule of Components of Income Tax Expense (Detail) - USD ($) $ in Thousands	3 Months Ended	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2019
Income Tax Disclosure [Abstract]
Foreign		$ 301
Total	$ 301	$ 301

Income Taxes - Additional Infor

Income Taxes - Additional Information (Detail) - USD ($)	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019
Income Taxes [Line Items]
Provision for income taxes in United States	$ 0
Valuation allowance	181,644,000	$ 167,193,000
Change in valuation allowance	14,500,000
Interest or penalties pertaining to uncertain tax positions	0	$ 0
Federal Tax Authority [Member]
Income Taxes [Line Items]
Operating loss carryforwards	574,700,000
Operating loss carryforwards, indefinite period	$ 294,900,000
Operating loss carryforwards, expiration period	2024
Federal Tax Authority [Member] | Research Tax Credit Carryforward [Member]
Income Taxes [Line Items]
Research and development credits	$ 12,400,000
State and Local Jurisdiction [Member]
Income Taxes [Line Items]
Operating loss carryforwards	422,700,000
Operating loss carryforwards, indefinite period	$ 65,400,000
Operating loss carryforwards, expiration period	2034
State and Local Jurisdiction [Member] | Research Tax Credit Carryforward [Member]
Income Taxes [Line Items]
Research and development credits	$ 2,000,000
Federal and State Tax Authority [Member] | Research Tax Credit Carryforward [Member]
Income Taxes [Line Items]
Tax credit carryforwards, expiration beginning period	2020

Income Taxes - Schedule of Effe

Income Taxes - Schedule of Effective Income Tax Rate Reconciliation (Detail)	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019
Income Tax Disclosure [Abstract]
Federal statutory rate	21.00%	21.00%
Change in valuation allowance	(14.95%)	(20.43%)
Non-deductible interest	(1.91%)	(1.43%)
Stock compensation	(2.72%)	(3.00%)
Permanent differences	(1.20%)	(0.03%)
State taxes, net of federal benefits	(0.86%)	4.07%
Withholding tax		(0.23%)
Foreign rate differential		(1.34%)
Federal R&D credits	0.64%	1.06%
Other		0.10%
Total tax expense	0.00%	(0.23%)

Income Taxes - Schedule of Defe

Income Taxes - Schedule of Deferred Tax Assets and Liabilities (Detail) - USD ($) $ in Thousands	Dec. 31, 2020	Dec. 31, 2019
Non-current deferred tax assets
Net operating losses	$ 147,305	$ 125,341
Accrued expenses	2,480	2,869
Capitalized research and development	12,446	17,195
Tax credit carryforwards	13,968	13,413
Stock compensation and other	5,931	9,043
Total non-current deferred tax assets	182,130	167,861
Non-current deferred tax liabilities
Right of use assets	(486)	(668)
Total non-current deferred tax liabilities	(486)	(668)
Net non-current deferred tax asset	181,644	167,193
Less: valuation allowance	$ (181,644)	$ (167,193)

Commitments and Contingencies -

Commitments and Contingencies - Additional Information (Detail)	Sep. 28, 2016	Apr. 30, 2015	Jan. 31, 2015	Dec. 31, 2020USD ($)	Dec. 31, 2019USD ($)	Oct. 30, 2016ft²	Jul. 31, 2016USD ($)ft²
Operating Leased Assets [Line Items]
Right-of-use asset				$ 2,010,000	$ 2,514,000
Lease liability				2,371,000
Long-term lease liabilities				1,544,000	$ 2,095,000
131 Patent [Member]
Operating Leased Assets [Line Items]
Patent term adjustment	1038 days
Patent expiration period	Mar. 26, 2029
Other Current Liabilities [Member]
Operating Leased Assets [Line Items]
Operating lease, liability, current				800,000
Long-Term Lease Liability [Member]
Operating Leased Assets [Line Items]
Long-term lease liabilities				1,500,000
CIPAN [Member]
Operating Leased Assets [Line Items]
Right-of-use asset				400,000
Lease liability				$ 300,000
Boston [Member]
Operating Leased Assets [Line Items]
Lease expiration period				2021-08
Lease terms		4 years
Operating leases beginning date		2015-07		2016-07
Lease agreement rentable of office space | ft²							4,153
Option to extend, operating lease, term							2 years
Lessee operating lease agreement security deposit paid							$ 100,000
Lease expense				$ 49,000
King of Prussia [Member]
Operating Leased Assets [Line Items]
Lease expiration period				2024-08
Lease terms			6 years			7 years 7 months
Operating leases beginning date			2015-06	2016-10
Lease agreement rentable of office space | ft²						19,708

Commitments and Contingencies_2

Commitments and Contingencies - Summary of Lease Costs Recognized Under Topic 842 and Other Information (Detail) $ in Thousands	12 Months Ended
	Dec. 31, 2020USD ($)
Commitments And Contingencies Disclosure [Abstract]
Operating lease cost	$ 1,120
Variable lease cost	131
Total lease cost	1,251
Cash paid for amounts included in the measurement of lease liabilities:	$ 1,178
Weighted average remaining lease term (in years)	3 years
Weighted average discount rate	8.75%

Commitments and Contingencies_3

Commitments and Contingencies - Summary of Future Minimum Operating Lease Obligations under Non-cancelable Operating Leases (Detail) $ in Thousands	Dec. 31, 2020USD ($)
Commitments And Contingencies Disclosure [Abstract]
2021	$ 1,241
2022	508
2023	518
2024 and thereafter	396
Total lease payments	2,663
Less: imputed interest	(292)
Total operating lease liabilities	$ 2,371

401(k) Savings Plan - Additiona

401(k) Savings Plan - Additional Information (Detail) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019
Compensation And Retirement Disclosure [Abstract]
Contributions by 401(k) plan participants	$ 0.8	$ 0.9

Quarterly Results (Unaudited) -

Quarterly Results (Unaudited) - Schedule of Quarterly Results (Details) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended								12 Months Ended
	Dec. 31, 2020	Sep. 30, 2020	Jun. 30, 2020	Mar. 31, 2020	Dec. 31, 2019	Sep. 30, 2019	Jun. 30, 2019	Mar. 31, 2019	Dec. 31, 2020	Dec. 31, 2019
Quarterly Financial Information Disclosure [Abstract]
Net revenue	$ 16,019	$ 13,659	$ 9,326	$ 7,920	$ 8,967	$ 3,934	$ 2,045	$ 1,598	$ 46,924	$ 16,544
Operating expenses	33,552	29,606	27,772	31,498	32,149	32,944	32,166	34,914	122,428	132,173
Loss from operations	(17,533)	(15,947)	(18,446)	(23,578)	(23,182)	(29,010)	(30,121)	(33,316)	(75,504)	(115,629)
Other expense, net	(7,477)	(4,908)	(4,613)	(4,039)	(3,882)	(3,604)	(3,080)	(2,294)
Provision for income tax					301					301
Net loss	$ (25,010)	$ (20,855)	$ (23,059)	$ (27,617)	$ (27,365)	$ (32,614)	$ (33,201)	$ (35,610)	$ (96,541)	$ (128,790)
Net loss per share - basic and diluted	$ (0.54)	$ (0.46)	$ (0.53)	$ (0.66)	$ (0.81)	$ (1)	$ (1.02)	$ (1.10)	$ (2.19)	$ (3.93)